Via Email: petesorenson@gmail.com

October 28, 2022

C. Pete Sorenson
Sorenson Law Office
PO Box 10836
Eugene, Oregon, 97440

Re: NIH FOIA Case No.: 54696; US Right to Know v. NIH, Case No. 20cv3196

Dear Mr. Sorenson:

This is a partial response to the Freedom of Information Act (FOIA) request that is the subject of the complaint filed in US Right to Know v. NIH, Case No. 20cv3196, now pending in the U.S. District Court for the District of Columbia. Your FOIA request, dated July 10, 2020, was received by the National Institutes of Allergy and Infectious Diseases (NIAID) on the same day.

You requested three parts pertaining to the following employees:

1. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases (NIAID)
2. Hugh Auchincloss, NIAID Principal Deputy Director
3. Paula Bryant, Director, Office of Biodefense, Research Resources and Translational Research, NIAID
4. F. Gray Handley, Associate Director for International Research Affairs
5. Gayle Bernabe, Regional Program Officer, East Asia-Pacific, NIAID
6. Heinz Ulrich Feldmann, Senior Investigator, Disease Modeling and Transmission Section, NIAID

“For this FOIA request we are seeking copies of records created, received and/or in the possession of NIH, including cross-references. Specifically, we are seeking records that reflect communications – whether in writing or verbal communications that were later reduced to writing (including any emails and their attachments, non-email correspondence, or other forms of communication) – to, from, or in the possession of the above-named individuals -- containing any of the following keywords or domains:

Part I of this request pertains to communications containing any of the following keywords or domains:

- East China Normal University
- Wuhan Institute of Virology OR WIV OR @wh.iov.cn
- Wuhan Center for Disease Control and Prevention
• Wuhan University Institute of Medical Virology
• EcoHealth Alliance OR EcoHealth OR @ecohealthalliance.org
• Christophe Mérieux Laboratory located in Beijing

Part II of this request pertains to communications containing any of the following combinations of keywords:

• “China” within 25 “biothreat”
• “China” within 25 “bioincident”
• “China” within 25 “Dual Use Research of Concern” OR “China” AND “DURC” OR “China” within 25 “GOF”
• “China” within 25 “biodefense”
• “China” within 25 “US Army Medical Research Institute of Infectious Diseases” OR “China” within 25 “USAMRIID”

For Part III, please search for all email correspondence to or from above listed employees—including attachments, CC and BCC—and the following person(s):

• Fang Li OR lifang@umn.edu
• George Gao OR gaof@im.ac.cn
• Linfa Wang OR linfa.wang@duke-nus.edu.sg
• Christian Bréchot OR cbrechot@usf.edu
• Ralph Baric OR rbaric@email.unc.edu
• Ian Lipkin OR wil2001@columbia.edu
• James Le Duc OR jwleduc@utmb.edu
• Thomas Ingelsby OR tinglesby@jhu.edu

In accordance with the Court’s order dated September 30, 2021, we have processed 300 pages of responsive records this month. The information being withheld is protected from release pursuant to Exemptions 4, 5, and 6 of the FOIA, 5 U.S.C. § 552 (b)(4), (b)(5) and (b)(6); and sections 5.31(d), (e) and (f) of the HHS FOIA Regulations, 45 CFR Part 5. Exemption 4 protects from disclosure trade secrets and commercial or financial information that is privileged and confidential. Exemption 5 permits the withholding of internal government records which are predecisional and contain staff advice, opinion, and recommendations. This exemption is intended to preserve free and candid internal dialogue leading to decision-making. Exemption 6 exempts from disclosure records the release of which would cause a clearly unwarranted invasion of personal privacy.
Please direct any questions regarding this response to Dedra Curteman of the Department of Justice, who can be reached at Dedra.Curteman@usdoj.gov, or (202) 252-2550.

Sincerely,

for Gorka Garcia-Malene  
Freedom of Information Act Officer, NIH
Dear Dr Fauci,

Cases since Valentine’s Day; Boycott.

From: kenn
To: Fauci, Anthony (NIH/NAID) [E] /o=ExchangeLabs/ou=Exchange Administrative Group
   (FYDIBOHF23SPDLT)/cn=Recipients/cn=d38103d75134f658ae2d356f0396b94-afauci; olx1
   Bill.gates [b (6) Billg [b (6) mmakary1 [b (6) ecci [b (6) juliana [b (6) jon [b (6) fhu [b (6) wingsuntam [b (6) gregory.re [b (6) swatlas [b (6) jared [b (6) stephen [b (6) djijr [b (6) larry.ellison [b (6) dducey [b (6) dougducey [b (6) bkemp [b (6) peternavarroii [b (6) governoron.desantis [b (6) info [b (6) m.alvarez [b (6) cruz_press [b (6) mmakary1 [b (6) Murphy, Robert /o=ExchangeLabs/ou=Exchange Administrative Group
   (FYDIBOHF23SPDLT)/cn=Recipients/cn=85c58566af5934cd0b2e9c169a17d3cb-cri-murphy-no]; dmilton
   [b (6) aneesh.mehta [b (6) jbl [b (6) seri [b (6) danielleallen [b (6) media [b (6) Frazier
   [b (6) Bilder [b (6) kotlikoff [b (6) limaye [b (6) rasmus_nielsen [b (6) Secretary [b (6) r.henry22
   [b (6) noymer [b (6) Pope, Kristin (CDC/DDID/NCIRD/OD)
   /o=ExchangeLabs/ou=Exchange Administrative Group
   (FYDIBOHF23SPDLT)/cn=Recipients/cn=f24f221e6314dedbb1a87c91d0f2a6-KFP7]; Posner, Sam
   (CDC/DDID/NCIRD/OD) /o=ExchangeLabs/ou=Exchange Administrative Group
   (FYDIBOHF23SPDLT)/cn=Recipients/cn=4f97785778c47e9bfo490384799be96-SHP5; Messonnier, Nancy
   (CDC/DDID/NCIRD/OD) /o=ExchangeLabs/ou=Exchange Administrative Group
   (FYDIBOHF23SPDLT)/cn=Recipients/cn=441f65db836c4a89a42ae9b96-c-NARS]; barcelo
   [b (6) jwhyte [b (6) jeff.arker [b (6) andy.pavla [b (6) ibouro [b (6) vicente.diaz [b (6) ayodola.adigun
   [b (6) joseph.vinetz [b (6) sachs [b (6) erin.bromage [b (6) derekchu [b (6) colleen.kraft [b (6) wme1
   [b (6) Carlos del Rio /o=ExchangeLabs/ou=Exchange Administrative Group
   (FYDIBOHF23SPDLT)/cn=Recipients/cn=272a97e9a0e847a7a99e888dcd083c9-cdelrio emo]; president
   [b (6) lichen [b (6) allegranizb [b (6) joshua.sharfeinstein
   [b (6) tingleby [b (6) william.schaffer [b (6) hyder.22 [b (6) yshin [b (6) barbour [b (6) mto [b (6) Collins,
   Francis (NIH/OD) [E] /o=ExchangeLabs/ou=Exchange Administrative Group
   (FYDIBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2ff0b6c2-collinsf]; sten.vermund
   [b (6) joshack [b (6) Sinha, Rajita /o=ExchangeLabs/ou=Exchange Administrative Group
   (FYDIBOHF23SPDLT)/cn=Recipients/cn=61abd5dad255450fa514ed61c1bf0df5-rajita.sinha]; ajha
   [b (6) edu]; bneuman [b (6) hamer, David (NIH) /o=ExchangeLabs/ou=Exchange Administrative Group
   (FYDIBOHF23SPDLT)/cn=Recipients/cn=3a33a643a95d444f9b42fe9a617bb271-dhamer.bu.e];
   cjlm [b (6) lipstch, marc /o=ExchangeLabs/ou=Exchange Administrative Group
   (FYDIBOHF23SPDLT)/cn=Recipients/cn=user9bbx2624]; john.brownstein
   [b (6) sshasig [b (6) etonere1 [b (6) hotex [b (6) ledcruz
   [b (6) afleischer [b (6) rredfield
   [b (6) nsaphier [b (6) saphier [b (6) tfrieden
   [b (6) deborah.birx [b (6) birzd [b (6) scott.gottlieb
   [b (6) gottlieb [b (6) gottlieb

Subject: Cases since Valentine’s Day; Boycott.
Attachments: us-cases.png; calculus.png; vote-fraud-vote-abuse-5-biden-graham.png; vote-fraud-vote-abuse-6-biden-paul.png; vote-fraud-vote-abuse-7-biden-roe.png; vote-fraud-vote-abuse-8-biden-carlson.png
(1) Valentine's Day

US data looks very very bad! The curve isn't going down since Valentine's Day. Are vaccines working???

(2) Boycott

Americans ought to beef up & boycott woke organizations & corporations. But here are 2 cents:

(2.1) The principle of "divide & conquer"
Simultaneously boycotting a range of corporations & organizations isn't optimal. First, this violates the principle of "divide & conquer". Second, this dilutes the sin of bellwethers. Third, this makes boycott less doable since People can't immediately exit from the economic & social ecological system largely controlled by Left Sticks (as in 'carrot & stick'). Instead, Coca-Cola and MLB could be singled out first.

(a) Coke contributes obesity & diabetes. Light tea (not strong tea) is healthier, except that a time gap between tea intake and protein intake should abide. By the way, breakfasts are more important than luncheons & dinners, but Americans got unhealthy & anti-nutritious breakfasts. A big corporation serving Americans with good breakfasts should be patriotic & profitable.

(b) MLB watching isn't a necessity. It could be replaced by more sleep, more sports & outdoor activities, and more book reading. A book is recommended as attached, to empower Americans.

(2.2) The principle of "carrot & stick"
On one hand, woke corporations & organizations should be boycotted; on the other hand, conservative activists should contact them, and convince them about vote fraud & vote abuse. Conservatives must emulate Left Sticks.

God bless America
Besides calculus: set & logic, linear algebra, calculus-based probability, elementary numerical analysis -- an excellent combination!

Good?

The only two volumes mysteriously disappeared, among 300 technical books owned by a Ph.D. student.

American brainpower booster

Difficult?

These two self-contained volumes were so well written that a talented ninth-grade girl ever went through at ease.
Graham: 'Sick' for Biden to 'play the race card' on Georgia election law, filibuster
Rand Paul blasts Democrats' 'racist' implication voters of color cannot follow rules
AMERICA REPORTS
Karl Rove: Biden criticism of new Georgia voting law is 'malarkey'

Democratic vote fraud & vote abuse
TUCKER CARLSON TONIGHT

Tucker: Everything Biden has said about Georgia election law is false

Left-stick vote fraud & vote abuse
Dear Dr Fauci,

OMG!!! Almost 80,000 cases!!! Where is Joe???

Attachments: us-cases.png; pedophile.png; fake-hair.png; vote-fraud-vote-abuse-9-biden-washingtonPost.png; vote-fraud-vote-abuse-10-biden-wh.png
(1)
OMG!!!
Almost 80,000 cases!!!

Please check out attached screenshots.
Are vaccines working???
Where is Joe???

Now, Party Republican should be starting to bang bang bang knock Joe's fishwood head, to call him back & solve the corona!
And before doing so, make sure to remove Joe's fake hair!

(2)
Anti-democracy vote abuse

People in China -- not talking about the CCP in China -- show great contempt for the one-person-one-vote democracy cherished by Americans. Why is that? Because they are stupid?

Their argument is: Politics is rather professional; How can you allow ignorant mob to decide the fate of the nation?

That makes a lot of sense to me, a computational physicist who is pretty good at logic. People in China ain't stupid.

Allowing ignorant mob to vote, is like allowing a manic to brandish a machete.

Thus, a strict election law preserves democracy not only via abstaining vote fraud, but also via discouraging ignorant voters.

Discouraging ignorant voters isn't about vote suppression -- they still can vote if they want. Discouraging ignorant voters is about protection of election integrity and protection of democracy.

I am a deep believer of the one-person-one-vote democracy. But I also believe the vote abuse must be averted. Otherwise I am afraid US would be defeated by China soon.

God bless America
Left-stick vote fraud & vote abuse

Media

Biden labeled ‘recidivist’ by Washington Post fact checker for repeating trio of false claims
Left-stick vote fraud & vote abuse

POLITICS
White House doubles down on Biden’s false Ga. voting claim after fact check
Subject: 61000 cases!! Black! Black! Black! Black!
Attachments: us-cases.png; corona-vaccine-trump-fauci-birx.png; violence-on-asians-by-Democratic-blacks.png; violence-on-asians-by-Democratic-blacks-2.png; violence-on-asians-by-Democratic-blacks-3.png; trump-biden-dc.png
Dear Dr Fauci,

US data looks very very bad!
61000 cases!
More than 4 weeks ago!
Two entire Chinas in one day, per capita!

Are vaccines working???

Two bugs were pointed out in the previous email regarding the CDC experiment:
(1) Did they wear masks?
(2) Was it a double blind experiment?
If they donned masks, why are we supposed to believe the 90% drop was not a merit of masking?

Now, some people are fighting for the vaccinal credit, as shown in the attached screenshot. But it seems completely unnecessary. As mentioned in "Trump2020-analysis" last October, the vaccine matter will turn out to be a political bale. Because the vaccination has little functionality, has induced 25,000,000 cases thus far, and still can't be ruled out for possible long-term catastrophic genetic consequences.

Besides the corona crisis and the border crisis, another crisis is surging too. After Biden's inauguration all the sudden Asians are subjected to rampant rabid attack by DemocRatic Blacks. Please check out the following two links to get a basic idea:

https://twitter.com/i/status/1376406876921810946

President Biden should order his supporters to stand back and stand by. Democratic Blacks made America the most dangerous place to live. The president should stop framing Trump's Black supporters and stop playing an ostrich. Face the reality and address the issue.

God bless America
Unnecessary to fight for the vaccinal credit

DOCTORING HISTORY

Trump fires back at 'self-promoters' Fauci, Birx after their comments on CNN COVID special
NYPD says 65-year-old Asian American woman was walking to church this morning when suspect assaulted her and said "f*** you, you don't belong here." Happened in front of 360 W. 43rd St. 11:40am. Source say building security guard not only failed to render her aid... 1/2
SUSPECT NABBED

Hate crime on Asians by Democratic Blacks

Man wanted in brutal beating of Asian woman in custody: NYPD
A person violently beats up and punches an Asian male in the head repeatedly in a Manhattan Bound (J) train at Kosciuszko Street Station, chokes him afterwards until he is unconscious. Be on the lookout for this person!

Hate crime on Asians by Democratic Blacks
District Of Columbia

Electoral Votes 3  Population 705,749

Joe Biden 92.9%  307,265
Donald Trump 5.5%  18,172

Blacks account for 50% DC population. Thus, this factor makes a Black in NYC a Biden's supporter at an extremely high probability.

Closed  Polls are closed  Reporting 99% in
From: kenn | (b) (6)
Sent: 4/2/2021 11:30:38 AM
To: Fauci, Anthony (NIH/NAID) [E] /o=ExchangeLabs/ou=Exchange Administrative Group (FYDBOHF23SPDLT)/cn=Recipients/cn=d38103d75134f658ae2d35f6039b94-4faucil; olx1 | (b) (6);
Bill.gates | (b) (6) Billg | (b) (6) mmakary1 | (b) (6) ecci
| (b) (6) juliana | (b) (6) jon | (b) (6) fh | (b) (6) wingsuntam
| (b) (6) gregory.re | (b) (6) swatlas
| (b) (6) laura | (b) (6) jared | (b) (6) stephen | (b) (6) djjr
| (b) (6) larry.elison | (b) (6) dducey | (b) (6) dougdcey
| (b) (6) bkemp | (b) (6) peternavarroii | (b) (6) peter.navarro
| (b) (6) press | (b) (6) governor.on.desantis
| (b) (6) info | (b) (6) press
| (b) (6) kevin.mccarthy | (b) (6) m.alvarez
| (b) (6) cruz_press | (b) (6) mmakary1 | (b) (6) gostin
| (b) (6) Murphy, Robert /o=ExchangeLabs/ou=Exchange Administrative Group (FYDBOHF23SPDLT)/cn=Recipients/cn=85c58566af59934cd0b2e9c167a7d3ca-r-murphy.no]; dmilton | (b) (6) aneesh.mehta | (b) (6); jbl | (b) (6) serip
| (b) (6) danielleaileen | (b) (6) media | (b) (6) Frazier
| (b) (6) bilder | (b) (6) kotlikoff | (b) (6) rimaye
| (b) (6) rasmus.nielsen | (b) (6) Secretary
| (b) (6) noymer | (b) (6) Pope, Kristin (CDC/NCID/NCRD/OD)
| (b) (6) r.henry22 /o=ExchangeLabs/ou=Exchange Administrative Group (FYDBOHF23SPDLT)/cn=Recipients/cn=441f65db836c4a89a424eab9a0d9b9b6-c-NARS]; barcelo | (b) (6) jwhyte | (b) (6) jeff.sarker | (b) (6) andy.pavla
| (b) (6) lbourou | (b) (6) vicente.diaz | (b) (6) ayodola.adigun
| (b) (6) josepb.nietz | (b) (6) sach | (b) (6) erin.bromage
| (b) (6) derekhu | (b) (6) colleen.kraft | (b) (6) wme1 | (b) (6) Carlos
del Rio /o=ExchangeLabs/ou=Exchange Administrative Group (FYDBOHF23SPDLT)/cn=Recipients/cn=272a695aa9e84a799e8888dc30d83c9-cdelrio.emo); president | (b) (6) lchen | (b) (6) allegranziib | (b) (6) joshua.sharfeinstein
| (b) (6) tingleby | (b) (6) william.schaffer | (b) (6)
=?ISO-8859-1?B?8anVsawFfWFyY3Vz?=? | (b) (6) hyder.22 | (b) (6) yshin
| (b) (6) barbour | (b) (6) vr1 | (b) (6) mto | (b) (6) Collins,
Francis (NIH/OD) [E] /o=ExchangeLabs/ou=Exchange Administrative Group (FYDBOHF23SPDLT)/cn=Recipients/cn=410e1ca313f44ced9938e50d2f0b062c3-collinsf]; sten.vernund | (b) (6) shassig | (b) (6) joshack | (b) (6) Sinha, Rajita /o=ExchangeLabs/ou=Exchange Administrative Group (FYDBOHF23SPDLT)/cn=Recipients/cn=61abd5dad255450f454ed6c1bf6d6f5-rajita.sinh); ajha | (b) (6) edu]; bneuman | (b) (6) Hamer, David (NIH) /o=ExchangeLabs/ou=Exchange Administrative Group (FYDBOHF23SPDLT)/cn=Recipients/cn=3a39ab395d44bf42f8e9a617b271-dhamer.bu.e]; cjlm | (b) (6) Lipstch, Marc /o=ExchangeLabs/ou=Exchange Administrative Group (FYDBOHF23SPDLT)/cn=Recipients/cn=user9bbx2624]; john.brownstein | (b) (6) shassig | (b) (6) etoner1 | (b) (6) hotez | (b) (6) ledcruz
| (b) (6) atifleischer | (b) (6) redfield
| (b) (6) nbsaphier | (b) (6) saphier | (b) (6) tfrieden
| (b) (6) deborah.birx | (b) (6) birxd | (b) (6) scott.gottlieb
| (b) (6) scott.gottlieb | (b) (6)
Subject: OMG!!! 79,000 cases!!! President Biden, please wake up & take the phone call!!
Attachments: us-cases.png; corona-vaccine-passport.png; mrcorrect.png; vaccine-fauci.png; corona-vaccine-trump-fauci-birx.png; corona-redfield-vaccine-mask.png

Dear Dr Fauci,
OMG!!!
79,000 cases!!!
Are vaccines working???

Com on, sleepy Joe!
US is on a wrong path!
Wake up & take the phone call!

Regarding the ongoing trial, all those witnesses in the court have one thing in common: They all emit slew of tears. Why is that?

Because they are all actors playing under the same DemocRatic cue! Now, we should be starting to seriously doubt about the jury mechanism. Recall the OJ Simpson.

By the way, in the OJ Simpson the proof unlawfully procured could have been handled this way: the proof can be taken in, but the officer must be punished for his unlawful breach.

God bless America
Are vaccines working?

So confident?

Biden administration working on vaccine passports to pave way for travel
Don't listen to the other side. Mr Correct, are you sure you are more logical? 'FAIRNESS IS OVERRATED'

NBC's Lester Holt shares views on 'truth' in a story
Claim the biggest lifetime decision? Before seeing any good sign?

Fauci credits himself for early move on vaccines. called out online
Unnecessary to fight for the vaccinal credit

It may turn out to be a political bale!

DOCTORING HISTORY

Trump fires back at 'self-promoters' Fauci, Birx after their comments on CNN COVID special
Dr Redfield, the doctor who claimed in September 2020 that masks may work better than vaccines.
Dear Dr Fauci,

OMGosh!!! 75,000 cases!!! Vaccines can reduce fatality ratio, really?? Senatorial filibuster

Attachments: us-cases.png; corona-vaccine-1-ivanka.png; corona-vaccine-2-tucker.png; corona-vaccine-3-tucker.png; corona-vaccine-4-tucker.png; corona-vaccine-5-tucker.png; corona-vaccine-6-tucker.png; corona-vaccine-7-masks.png
OMGosh!!
75,000 cases!!
10,000 cases more than that on Saint Valentine's Day!

So, are vaccines working???

(2) Vaccines can reduce fatality ratio, really???

When some medical/health scientists started to admit vaccines may not be able to stop transmission of corona, they claimed vaccines can lessen illness & reduce fatality ratio. Really?

First of all, I saw for a couple of times that medical/health scientists said the time lag between death & infection is something like 40 days. Just 1 hour ago, I checked the graphs. The second peak, which is more reliable than the first one, on the graph of daily new cases is 295215 on January 8th. The corresponding peak on the graph of daily new fatalities seems to be 4408 on January 20th.

Thus, the 40-day time lag isn't correct. It should be something like 12+8=20 days, if the time lag between tested-positiveness & infection is estimated as 8 days. Now, let's calculate the change of fatality ratio.

956 deaths were reported on April 14. Correspondingly, 69831 people were tested positive on April 2. Thus, the fatality ratio for January 8 = 4408/295215 = 1.49%
The fatality ratio for April 2 = 956/69831 = 1.37%

This level of diminishment should be well covered by the young-ization of patients, letting alone other factors such as people may see a doctor earlier as the pandemic proceeds. Of course, if smoothed data, not raw data, is adopted in the aforementioned estimation, it would be more accurate. But that doesn't seem to be able to alter the overall picture.

Thus, that vaccines can lessen illness & reduce fatality ratio sounds like a hearsay.

(3) Scientific corruption

As obvious & to be more obvious in upcoming months, a rampant scientific corruption has been growing in American soil for decades. Meanwhile, we have been witnessing a rampant DemocRatic corruption. Seemingly these two phenomenon highly correlate to each other.

(4) Senatorial filibuster

The senatorial filibuster is a brilliant design.

(a) Convergent series
Suppose we have three alternating series as follows:
Series A = 1 - 1.1 + 1.2 - 1.3 + 1.4 - 1.5 +...
Series B = 1 - 1 + 1 - 1 + 1 -1 +...
Series C = 1 - 0.9 + 0.8 - 0.7 + 0.6 - 0.5 +...
Obviously, series A diverges and series C converges, and in fact series B also diverges.

(b) Two-parameter systems

In the universe there are 4 fundamental forces, the binary electromagnetic force, the binary strong interaction inside nucleus, the binary gravitational force, and the unitary weak interaction. Why are they either binary or unitary, but not ternary?

Because a three-party system can be divided & conquered into two-party systems or one-party systems.

Thus for a system filled up with a bunch of parameters, we may always group some parameters together and group the remaining together to form a two-party system, as worst dynamically, which means for the next time we may have to regroup. Of course, if it happens to only have one parameter, it would remain as a one-party system.

A one-parameter system is corresponded by a linear curve. It's optimal value is at ends. And, it features transience.

A two-parameter system is corresponded by a quadratic curve. It's optimal value is not at ends, but somewhere in between. And, it features stability. Here is an example for a two-parameter system: the Laffer curve in tax.

(c) Why is filibuster a great design?

Equipped with the above two analogies, we may feel the filibuster embodies a convergent series, optimality, and stability. So it sounds good.

(d) More reason behind

The gap between simple majority of 50+% and super majority of 66.6666+% is practically too large. The filibuster of 60% well fits in between.

(e) Recommendation

We may further renormalize these numbers as the following:
Simple majority: 50+%
Filibuster: 60+%(one more vote than the concurrent filibuster)
Super majority: 70+% (It is understood the 66.6666+% has been widely used in business/corporations)

Alternatively,
Simple majoritiy: 6/12+ (51 votes to get a bill passed)
Filibuster: 7/12+ (59 votes to get a bill passed)
Super majority: 8/12+ (67 votes to get a bill passed)

God bless America
OMGosh!!! 75,000 cases!!!
10,000 cases more than Valentine's Day!
Are vaccines working???
Fortunately Ivanka got three kids already, thus the genetic ramification isn't a concern.
PhysicistForTrump

Just Now

"We do know that the way this country keeps track of Americans who are hurt by vaccines — something called the "Vaccine Adverse Event Reporting System" — is notoriously inaccurate. (Ask any physician.) But, no one seems in a hurry to improve it. Our public health bureaucracy doesn’t seem that anxious to know all the details."

these DemocRats are just too lazy & too irresponsible & not able to think properly. Simply record contact numbers of patients & make phone calls later to track the process.
PhysicistForTrump
Just Now

quote:

comments:
whitney robinson, a black+woman associate professor at university of north carolina at chapel hill.

so, probably incompetent, even though the school is excellent.
& black+woman, that's why so rude?
when can americans overthrow these oppressors?

btw,
(1) i visited the campus long long ago.
(2) my cousin's daughter attended this school, simply because she was a fan of the university rugby (so-called football) team.
Tucker is a man with integrity & brilliance. His analysis on vaccines is factual & logical. And he articulates so well on subtleties.

Tucker responds to Fauci's calling his vaccine questions a 'conspiracy theory': What are you telling us?
Come on, Joementia!
These vaccines even never got into in vivo trials!
Let alone double-blind trials!

What trialed was:
After vaccinated, if subjects could develop antibodies;
And the efficacy was 95%.

But have vaccinated subjects been tested against corona???

What was the efficacy for the second part??
What was the overall efficacy??!!!
america is filled up with DemocRatic fools.

the so-called 95% vaccinal efficacy refers to the probability of generating antibodies by vaccines. but what is the probability of antibodies to prevent/cancel corona?

they never said about it, which is obviously not 100%. they even never did the second part of the experiment. the real efficacy equals the product of the multiplication of these two quantities.

america needs more Republican mathematicians & physicists to operate the country.
but masks work, & work powerfully. without masking, the entire US population would have been contaminated by last summer.

the thing is, 60,000,000 of President Trump's supporters have been windmill tilting & mask-defying. if everyone wears a mask, this pandemic could be put under control within 4 cycles of transmission, which is 20 days, irrelevant to status in quo.

masking is the necessary & sufficient condition to impede, fully-stop, & completely eradicate this corona monster -- concluded by a computational physicist by january 31, 2020, ten days after the wuhan outbreak.
Dear Dr Fauci,

Oh my Gosh!!! 75,000 cases!!! corona arrogance, wokeness, & border crisis
(1)

Oh my Gosh!!!
75,000 cases!!
Each day America creates 2.5 entire Chinas!!
Are vaccines working???

Does Joe Biden understand the so-called vaccinal efficacy merely refers to the efficacy of inducing antibodies by vaccines? Does he understand big pharmaceutical corporations just have been playing a word game?

Look, when Americans ask for the efficacy of vaccines, they of course mean the efficacy of vaccines in preventing them from corona. But those bastards just played the word and gave the efficacy of vaccines in turning on antibodies.

Look, vaccines can induce antibodies with 95% efficacy, but what is the efficacy of antibodies in preventing corona from people? As we know, the (overall) efficacy of vaccines equals the product of the multiplication of these two quantities. Can antibodies attain 100% efficacy???

Of course not. This is not a computer science, either 0 or 1. This is about a biological or physical world, in which we virtually will always see a distribution between 0 and 1. Thus, antibodies only can achieve partial efficacy. How partial?

Suppose we use word 'severity' to rate an infectious virus. Viruses with very low fatality ratio of course can't be rated as severe. Viruses with very very high fatality ratio can't be rated as severe either, in that people surrounding a carrier will quickly die out thus automatically cut off the transmission. We don't have an exact definition of severity but we do know corona is very severe. Now, for non-severe viruses, vaccines could help. But for a very severe virus like corona, the vaccinal approach won't work. Because, we simply can't find a common ground that both the safety and the (overall) efficacy are satisfied. Look, as we know, the philosophy of the vaccinal approach is just to incite enough antibodies but to avoid enough side effects.

The aforementioned was the reasoning I used by January 31, 2020, to conclude that vaccines won't work, and masking is the necessary & sufficient condition to eradicate the corona.

Alternatively, one may take a factual approach. One may catch a number of rats and infect them with corona. After they recover, an additional infectious rate can be brought to contact them closely, to see what to happen. In this manner, we will see the efficacy of antibodies. Such an experiment should have been done by April 2020, before the gigantic corona vaccinal fever being launched.

(2) Rampant arrogance

(a) Corona arrogance
Why US has been so far so terrible in corona response? There are a string of reasons behind, with the illogicality as the bellwether. However, arrogance is a part of the game. Why Australia did so well in corona? One possible reason is, they listened to a computational physicist, indirectly. But American arrogance precluded similar advice.

(b) Wokeness
Why has US been a woke nation? There are a bunch of reasons behind, but arrogance should be one of them. America has been declining monotonically for dozens of years actually, but DemocRatic Americans are living in arrogance and believing they are qualified to continue to be woke. No. Americans have been disqualified to be woke. Look, for instance how much money America owes???
30,000,000,000,000 bucks. That's $100,000 per person. Is Joe Biden an idiotic moron, still foolishly talking about spending this money & that money???

(c) Border crisis
There are an array of reasons behind of the border crisis, including the wokeness. Will such a crisis happen if China operates? No, the ruling party in China is not woke. Will such a crisis happen if Australia operates? No, the ruling party in Australia is not woke. This type of ridiculous thing takes place in a woke nation only, and one of reasons behind wokeness is arrogance.

Here is a reminder, that every admission of an illegal causes US to approximately lose $1,000,000, as estimated in a previous email.

Please check out attached screenshots, and God bless America
2.5 entire Chinas per day per capita since Valentine's Day
Vaccines can induce antibodies with 95% efficacy.

WHO spokeswoman Margaret Harris said the world health agency does not back the use of these passports — proof that one has been vaccinated against COVID-19 — because it is not yet known if those who have been vaccinated against the virus can still transmit it. She cited equity concerns as another reason the WHO does not endorse the use of them at this time.

"We as WHO are saying at this stage we would not like to see the vaccination passport as a requirement for entry or exit because we are not certain at this stage that the vaccine prevents transmission," Harris said during a United Nations news briefing, per Reuters.

but what is the efficacy of antibodies???
STILL NO CRISIS, JOE?

Biden admin begs for government volunteers at border amid surge

One of fundamental reasons behind border crisis is wokeness, and one of fundamental reasons behind wokeness is arrogance.
Why are you laughing foolishly?

Am I wrong?

A LAUGHING MATTER
Subject: corona plateauing! biden lying about election law!

Dear Dr Fauci,

(1) corona

The corona has been plateauing for 2 months! Please check out the attached screenshot. Doesn't Joe Biden sense something wrong?? Are vaccines working???

(2) vote abuse

Contrary to the wide known vote fraud, the notion of vote abuse is quite new. However, many shortcomings of the one-person-one-vote democracy at the end of the day can be traced back to vote abuse. For instance, why Party DemocRat has deteriorated into a lying donkey? Because most Americans are unfortunately politically indifferent or ignorant, and they vote. Thus for many faithless, immoral, and greedy DemocRats, an efficient path to grab power, enrich cartels, and stay in power eternally is to lie, in collusion with corrupted media mob. For another instance, the endless political fighting in US is to woo ignorant mobs.

To lessen the problem, the election system ought to be designed in such way that ignorant mob are discouraged to vote, though they still possess the fundamental right of voting. Let judicious voters determine the direction and fate of the country.

As a matter of fact, the Georgia election law is still way way too loose:
(a) The early in-person voting ought to be banned completely. For voters who can't make the Election Day, they may vote in mail. The early in-person voting is completely redundant.
(b) The privilege of mail-in voting ought to be granted based on a compelling excuse.

Like or not, Chinese autocracy has been outperforming American democracy in the past dozen of years. This is a fact, and just admit it, so that a remedy could be possibly figured out. But as a deep believer of one-person-one-vote democracy, I deem that by stemming vote abuse alone the American democracy should be able to outperform Chinese autocracy.

God bless America
Each day two entire Chinas (per capita), since February 14
This 1987 Japanese newspaper says: As a first year graduate student at Syracuse in 1965, Biden plagiarized thesis and got caught.

He kneep in front of the committee and implored for pardon. He swore he would never do again and got forgiven. But as we know, he did again.
Hannity: Biden 'fueling vicious, divisive, racial rhetoric' with lies about Georgia election law
POLITICS

After Biden compares Georgia voting law with Jim Crow, ex-WH press sec knocks POTUS for past racially charged rhetoric
POLITICS

Georgia's GOP governor responds to Biden's smear of state's new voting law
Gov. Kemp slams left's 'outrageous' claims on Georgia election law: 'Hypocrisy running rampant'
Washington Post fact checker for repeating trio of false claims

The president has already been awarded ‘Four Pinocchios’ but continues to repeat debunked info

By Brian Flood | Fox News

Biden gets '4 Pinocchios' for election law claims

Former Georgia Congressman Doug Collins weighs in on backlash by Democrats against the Peach State’s election laws.

President Biden could wind up with the "Bottomless Pinocchio" moniker after the Washington Post noted he's repeated a trio of
CNN anchor stuns critics by defending Biden's widely condemned falsehood
A career liar, and a career disinfomer

THE INGRAHAM ANGLE
Newt Gingrich: Biden lied about Georgia voter law
Joe Biden, the #1 most divisive president in US history

HANNITY
Hannity: Every Georgian should be 'furious' with Biden, MLB
Biden has message for Georgia on MLB All-Star controversy as biz owners brace for worst

Biden told Georgians to cave in democracy for money
Dear Dr Fauci,

From: kenn
Sent: 4/1/2021 11:43:47 AM
To: Fauci, Anthony (NIH/NAID) [E] /o=ExchangeLabs/ou=Exchange Administrative Group [FYDIBOH23SPDLT]/cn=Recipients/cn=f38103d751346f58ae2d356f0396b94-afauci]; olx1 [b6]; Bill.gates [b6]; Billg [b6]; mmakary1 [b6]; ecci [b6]; juliana [b6]; jon [b6]; fhu [b6]; wingsuntam [b6]; gregory.re [b6]; swatlas [b6]; laura [b6]; jared [b6]; stephen [b6]; djjr [b6]; larry.eilson [b6]; dducey [b6]; dougdcey [b6]; bkemp [b6]; peternavarro [b6]; peter.navarro [b6]; press [b6]; governoron.desantis [b6]; info [b6]; press [b6]; kevin.mccarthy [b6]; m.alvarez [b6]; cruz_press [b6]; mmakary1 [b6]; goslin [b6]; Murphy, Robert [/o=ExchangeLabs/ou=Exchange Administrative Group [FYDIBOH23SPDLT]/cn=Recipients/cn=8558566af5934cd02e9c5e7717d3cb-a-r-murphy-no]; dmilton [b6]; aneesh.mehta [b6]; jbl [b6]; seri [b6]; danielleallen [b6]; media [b6]; Frazier [b6]; bilder [b6]; kotlikoff [b6]; rimaye [b6]; rasmus_nielsen [b6]; Secretary [b6]; r.henry22 [b6]; noymer [b6]; Pope, Kristin (CDC/DDID/NCIRD/OD) [/o=ExchangeLabs/ou=Exchange Administrative Group [FYDIBOH23SPDLT]/cn=Recipients/cn=fb2f4231e6314dedbb1a87c9f1d0f2a6-KF7P]; Posner, Sam (CDC/DDID/NCIRD/OD) [/o=ExchangeLabs/ou=Exchange Administrative Group [FYDIBOH23SPDLT]/cn=Recipients/cn=4f97785778c479ebf0490384799eb96-SHP5]; Messonnier, Nancy (CDC/DDID/NCIRD/OD) [/o=ExchangeLabs/ou=Exchange Administrative Group [FYDIBOH23SPDLT]/cn=Recipients/cn=441f65db83b4a59a42e8b9a0d9b96c-NARS]; barcelo [b6]; jwhyte [b6]; jeff.sarker [b6]; andy.pavla [b6]; lbourou [b6]; vicente.diaz [b6]; ayodola.adigun [b6]; joseph.vinetz [b6]; sachs [b6]; erin.bromage [b6]; derekchu [b6]; colleen.kraft [b6]; wme1 [b6]; Carlos del Rio [/o=ExchangeLabs/ou=Exchange Administrative Group [FYDIBOH23SPDLT]/cn=Recipients/cn=6c7da6954a9e842a7b998881dcd00d3c6-cdelrio.emo]; president [b6]; lichen [b6]; allegranzi [b6]; joshua.sharfestein [b6]; tingleby [b6]; william.schaffer [b6]; =gSO-88 59-1?BanVsaWfFbWFYy9v2=? [b6]; hyder.22 [b6]; yshin [b6]; barbour [b6]; vr1 [b6]; mto [b6]; Collins, Francis (NIH/OD) [/o=ExchangeLabs/ou=Exchange Administrative Group [FYDIBOH23SPDLT]/cn=Recipients/cn=410e1ca331344ced9938e502df0b62c-collinsf]; sten.vermund [b6]; joshack [b6]; Sinha, Rajita [/o=ExchangeLabs/ou=Exchange Administrative Group [FYDIBOH23SPDLT]/cn=Recipients/cn=61ad5dad255450fa514edcb6c1bfdf5-rajita.sinh]; agha [b6]; bneuman [b6]; hamer, David (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group [FYDIBOH23SPDLT]/cn=Recipients/cn=3a3aabe3a95d44bbf42fee9a617bb271-dhamer.bu.e]; cjlm [b6]; Lipstch, Marc [/o=ExchangeLabs/ou=Exchange Administrative Group [FYDIBOH23SPDLT]/cn=Recipients/cn=user9b2c624]; john.brownstein [b6]; shassig [b6]; eton1 [b6]; hotez [b6]; ledcruz [b6]; afleischer [b6]; redfield [b6]; nsbaphier [b6]; saphier [b6]; saphire [b6]; tfrieden [b6]; deborah.birx [b6]; birx [b6]; birxd [b6]; scott.gottlieb [b6]; scott.gottlieb [b6];

Subject: 66.6k new cases!!! violence by Democratic Blacks; Biden's infrastructure
Attachments: us-cases.png; black-violence-1.png; black-violence-2.png; black-violence-3-hate-crime.png; black-violence-4.png; black-violence-5.png; black-violence-6.png
66.6k new cases!!!
Are vaccines working???

US has been trapped in a sequence of crises:
(1) corona crisis,
(2) border crisis,
(3) safety crisis: violence by DemocRatic Blacks,
(4) culture crisis: wokeness & cancel culture,
(5) constitutional crisis,
(6) financial crisis: the $30,000,000,000,000 debts -- $100,000 per American!

But Biden is solving none, and actually busy with making it worse!

The infrastructure plan is wrong again! It is very wrong from 10 perspectives. Wrong timing, wrong ordering, wrong... One question alone should be able to debunk it: What is Biden's plan for the $30,000,000,000,000 debts?

Now, after a responsible officer is lynched by mob court, living in America would be an even more life-threatened experience!

God bless America
Vigil planned for spring breaker who died after being raped in Miami Beach
State trooper fighting for his life after being shot, police searching for suspect
Teen boy charged with murder after shooting innocent girl multiple times
Black women on white girl

U.S.

Tennessee women attacked, robbed 14-year-old trampoline park employee
13-year-old Black girl

'THEY'RE THIEVES!'

More DC teens arrested as graphic video of deadly carjacking surfaces, Dem mayor ignites outrage
EXCLUSIVE: JonBenet Ramsey’s half brother still wants to find her killer, says ‘this case can be solved’
Dear Dr Fauci,

Oh my Gosh!!! 80,000 cases!!! numerical simulation of global warming; boycott BLM & MLB!

us-cases.png; corona-1-vaccine.png; global-warming-simulation.png; global-warming-simulation-2.png; global-warming-simulation-3.png; mlb-blm-boycott.png
(1) Oh my Gosh!!!
80,000 cases!!!
Are vaccines working???
Where is Joe???

(2) Numerical simulation of global warming

Discrimination actually permeates everywhere, including the technical world. An engineer might be discriminated by a chemist, who in turn is discriminated by a physicist. Why is that? In scientific history, in every time period mankind usually can advance one major technical breakthrough only. Why was that? Because of limited brain power. That's why in an era that internet, medicine, and finance attract so many young talents, the advance in nanotechnology, and in green energy which failed badly in Europe & China years ago, often come out below expectation. Global warming is real and is a serious threat to mankind civilization, however, the concurrent scientists in the field may not possess sufficient brain power and powerful enough tools to work out something really significant. Please check out the attached screenshots. People may have to be patient, and wait until some other scientific fields get bored.

(3) Boycott BLM & MLB

Baseball indeed could be boycotted:
(a) It's a game that gains little popularity beyond America. Why is that?
(b) Players don't sweat, and sweating is a vital criterion to judge sports.
(c) The rules are so complicated. Ideally, the rules should be as simple as possible, but outcomes should be as complex as possible, like in the intellectual game Siege (so-called Go, as in AlphaGo).
(d) Some might praise the intellectual joy of the baseball, but Siege and Bridge contain way more intellectual joys.
(e) Football (so-called soccer) is a much better option.

Thus, boycott BLM & MLB!

God bless America
Since Valentine's Day
Fox Sports' Jeff Gordon tested positive for COVID-19 after getting vaccine

WHO just admitted they had no idea if vaccines could prevent transmission. What about the vaccinal contribution in fatality reduction?
Bill Gates was duped by arrogant & ignorant Democratic scientists.

Bill Gates support for 'bonkers' study of dimming the sun is 'grossly irresponsible:' Author
Always try a numerical simulation first before an actual experiment. Check out world's simulation bellwether at https://www.ansys.com/

Bill Gates support for 'bonkers study of dimming the sun is 'grossly irresponsible:' Author
Engineer What’s Ahead

Ansys engineering simulation software is the must-have superpower for solving the world’s most complex design and mission-level challenges.
'I DON'T WATCH'

Baseball great David Wells speaks out on MLB All-Star Game move from Ga.

MLB commissioner decided to move All-Star Game after pressure from Stacey Abrams: sources
Subject: corona crisis & border crisis
Attachments: us-cases.png; vaccine-fauci.png; border-crisis-1-scout.png; border-crisis-2-influx.png; border-crisis-3-terrorism.png; border-crisis-4-spin.png; border-crisis-5-spin.png; border-crisis-6-kneel-bow.png; border-crisis-7-democrats.png; border-crisis-8-night-raid.png; border-crisis-9-night-waterway.png; border-crisis-10-cruz.png; border-crisis-11-refugees.png; border-crisis-12-cover-up.png; border-crisis-13-cover-up.png; border-crisis-14-trump-fault.png; border-
Dear Dr Fauci,

US data looks very very bad!! There are more daily new cases now than 3 weeks ago! Obviously, vaccines are not working at all, and I have been yelling here over one month. I concluded by January 31, 2020, that NATIONAL mask mandate is the necessary & sufficient condition to end the corona crisis, and I have been yelling on internet over one year. If the current trajectory is followed, US corona pandemic could endure for 3 more years, accumulatively infect 60,000,000 Americans, and accumulatively kill 1,000,000 people. President Biden is stumbling badly. He must stop killing Americans & stop pushing hard for his damn destructive radical agenda!

Another crisis has been developing over two months — the southern border crisis. Attached screenshots give a rough picture of what has been going on.

The crisis of illegal immigrants isn't a complicated one. I guess China could handle it like blowing dusts. So, here is a downside for democracy, the one person one vote democracy, that in such a political system a vote-hungry party will always come into being and work very hard to destroy the country, inadvertently or even intentionally.

While legal immigrants make America stronger, illegal immigrants make America weaker. Currently US actually has approximately 30,000,000 illegals within two borders. Legalization of these illegals would bring down US average demographic strength, and bring down US average economic strength.

The 30,000,000 is certainly not the end of story. They will quickly bring in 60,000,000 immigrants through family chain, and augment US population to 400,000,000. And, the buffer will be quickly filled up with 30,000,000 new illegals. But even this is not the end of the story yet. The population growth in Africa outpaces any other continent, to triple from present 1 billion to 3 billions in the upcoming 30 years. That would serve as an unlimited supply chain of illegal immigrants for US...

So...

Now, let's do a math. After swallowing of 30,000,000 illegals, what would be the GDP per capita? Since US owes $30,000,000,000,000 to others, the present actual GDP per capita is something like $60,000. Thus, we obtain $45,000 per capita.

So... by one stroke, US would deteriorate into a tier-2 nation, which in turn could in theory further deteriorate into a third-world nation.

Now, suppose US intakes 30,000,000 legal immigrants instead, what would be the scenario? Each person could bring with $3,000,000 cashes, or equivalently her/his skill could make net profit of $3,000,000 within 30 years. That means $100,000,000,000,000 in total, 3 times of US concurrent debits. This is not a mission impossible, since US still has the upper hand in attracting world's young talents. Conversely, legalization of 30,000,000 illegals means US loses $100,000,000,000,000 money.

So...

And these 30,000,000 newly legalized citizens, plus half of the 60,000,000, grab jobs from concurrent Blacks, and Hispanics.
So...

God bless America
BIG SHOT?

Fauci credits himself for early move on vaccines, called out online
FOX NEWS PRIMETIME
Daily Caller reporter
witnesses 100
migrants cross
border: 'It was
shocking'

Slew of migrants
massive influx of illegals
terrorists may slip in

SELF-INDUCED CRISIS

CARAFANO: How America's adversaries view Biden border mess
quantum spin?

SPINNING A CRISIS

REP BANKS: Dems attempting PR stunts to deflect blame from disaster at border
spin 1/2 electron, or spin 1 photon?

STILL NO CRISIS, JOE?

Biden admin begs for government volunteers at the border amid surge
kneel + bow

STILL NO CRISIS, JOE?

Biden admin begs for government volunteers at the border amid surge
STILL NO CRISIS, JOE?

Biden admin begs for government volunteers at the border amid surge
night raid

STILL NO CRISIS, JOE?

Biden admin begs for government volunteers at the border amid surge
night + waterway

STILL NO CRISIS, JOE?

Biden admin begs for government volunteers at the border amid surge
Ted Cruz

'This is inhumane'

GOP senators reveal shocking new images of border crisis
war refugees

'THIS IS INHUMANE'

GOP senators reveal shocking new images of border crisis
POLITICS

Biden official asked GOP senators visiting border to delete photos from facilities
Democratic Coverup

Biden staffer blocks Cruz from taking video at migrant facility
Migrants from Central America and other nationalities, hoping to cross and request asylum in the U.S., hold banners and shout slogans to U.S. President Joe Biden at their campsite outside El Chaparral border crossing, in Tijuana, Mexico, Feb. 27, 2021. (REUTERS/Jorge Duenes)
The most radically partisan administration in US history

Mayorkas terminates 32 members of Homeland Security Advisory Council, says time to 'reconstitute'

- Mayorkas blames migrant surge on Trump administration
- TOM HOMAN: Our border is not closed or secure
- Mayorkas claims there's 'no' crisis at southern border
- Graham to Mayorkas, 'change course or change jobs'
- House Republicans call for answers from DHS
- Trump admin. dismantled 'safe' border policies: Mayorkas
The most hateful & divisive president in US history

Biden's DHS chief terminates 32 members of advisory council in the middle of the border crisis
Trump should slap Biden in the face.

Outrageous!

Trump blasts Biden claim that former president let migrant kids ‘starve’
Stephen Miller slams Biden for 'detestable lie' and 'smear' about Trump border policy
Coming from an Australian living in Australia... I still can't fathom the hate for Donald Trump who actually stopped your boarder crisis in comparison to the problem now... its no longer political now.. its now a collective mental disorder that voted Biden in.... nobody even likes Biden.... its the weirdest thing to watch play out... also terribly sad..

Reply 👍 1  👎
Trump ‘really concerned’ about crisis, may pay visit ‘soon,’ ex-aide says
Harris finds question over visit to border funny
That's great to hear. So glad you are recovering well and that... (b)(6)

Best
Tom

> On Aug 22, 2020, at 3:50 PM, Fauci, Anthony (NIH/NIAID) [E] <(b)(6) wrote:

> External Email - Use Caution

> Tom:
> Thank you for your kind note. It is much appreciated. I am recovering nicely. (b)(6)

> Best regards,
> Tony

> Anthony S. Fauci, MD
> Director
> National Institute of Allergy and Infectious Diseases
> Building 31, Room 7A-03
> 31 Center Drive, MSC 2520
> National Institutes of Health
> Bethesda, MD 20892-2520
> Phone: (b)(6)
> FAX: (b)(6)
> E-mail: (b)(6)

> The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

> -----Original Message-----
> From: Tom Inglesby <(b)(6)
> Sent: Saturday, August 22, 2020 3:43 PM
> To: Fauci, Anthony (NIH/NIAID) [E] <(b)(6)
> Subject: Wishing you a speedy recovery

> Hi Tony,
> I was sorry to hear you had to have... (b)(6) I hope you recover soon. You have been an incredible national leader on all things related to this pandemic and so will be great to see you back in the swing of things soon. We need you! Thanks for all your very hard work in really challenging conditions.

> All the best,
> Tom
Thanks for the follow up.

Jim
From: "LeDuc, James W."  
Date: Friday, April 27, 2018 at 1:47 PM  
To: "Feldmann, Heinrich (NIH/NIAID) [E]"  
"Allgood, Amanda (NIH/NIAID) [E]"  
"Kurilla, Michael (NIH/NCATS) [E]"  
"Mascola, John (NIH/VRC) [E]"  
Hugh Auchincloss  
"Tuma, Bonnie (NIH/OD) [E]"  
"King, Renee (NIH/OD) [E]"  
Cc: "Savage, Dana (NIH/NIAID) [E]"  
"Day, Vanessa (NIH/NIAID) [E]"  
"Faile, Laura (NIH/NIAID) [C]"
Subject: RE: Update on Director, IRF/DCR/NIAID Search and Request for Scheduling POC

I had exactly the same impression and I fully agree with Heinz’ suggestion

Jim

James W. Le DUC, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t)  
(f) 409-266-6310
(m) 

From: Feldmann, Heinrich (NIH/NIAID) [E]  
Sent: Friday, April 27, 2018 12:42 PM  
To: Allgood, Amanda (NIH/NIAID) [E]  
Kurilla, Michael (NIH/NCATS) [E]  
Mascola, John (NIH/VRC) [E]  
Holland, Steven (NIH/NIAID) [E]  
Auchincloss, Hugh (NIH/NIAID) [E]  
LeDuc, James W.  
Tuma, Bonnie (NIH/OD) [E]  
King, Renee (NIH/OD) [E]
Cc: Savage, Dana (NIH/NIAID) [E]  
Day, Vanessa (NIH/NIAID) [E]  
Faile, Laura (NIH/NIAID) [C]
Subject: RE: Update on Director, IRF/DCR/NIAID Search and Request for Scheduling POC

This is likely too late and not my business, but I think
From: Allgood, Amanda (NIH/NIAID) [E]
Sent: Thursday, April 26, 2018 6:46 AM
To: Kurilla, Michael (NIH/NCATS) [E] <[b][i]>Kurilla, Michael (NIH/NCATS) [E]</i></b> (b) (6) Mascola, John (NIH/VRC) [E] <[b][i]>Mascola, John (NIH/VRC) [E]</i></b> (b) (6) Hollander, Steven (NIH/NIAID) [E] <[b][i]>Hollander, Steven (NIH/NIAID) [E]</i></b> (b) (6) Auckinloss, Hugh (NIH/NIAID) [E] <[b][i]>Auckinloss, Hugh (NIH/NIAID) [E]</i></b> (b) (6) Feldman, Heinrich (NIH/NIAID) [E] <[b][i]>Feldman, Heinrich (NIH/NIAID) [E]</i></b> (b) (6) James Leduc <[b][i]>James Leduc</i></b> (b) (6) Tuma, Bonnie (NIH/OD) [E] <[b][i]>Tuma, Bonnie (NIH/OD) [E]</i></b> (b) (6) King, Renee (NIH/OD) [E] <[b][i]>King, Renee (NIH/OD) [E]</i></b> (b) (6) Savage, Dana (NIH/NIAID) [E] <[b][i]>Savage, Dana (NIH/NIAID) [E]</i></b> (b) (6) Day, Vanessa (NIH/NIAID) [E] <[b][i]>Day, Vanessa (NIH/NIAID) [E]</i></b> (b) (6) Faile, Laura (NIH/NIAID) [E] <[b][i]>Faile, Laura (NIH/NIAID) [E]</i></b> (b) (6) Allgood, Amanda (NIH/NIAID) [E] <[b][i]>Allgood, Amanda (NIH/NIAID) [E]</i></b> (b) (6) Subject: Update on Director, IRF/DCR/NIAID Search and Request for Scheduling POC

Dear Search Committee Member,

On behalf of Dr. Lane, thank you again for assisting with the selection process for the Director, Integrated Research Facility, Division of Clinical Research, NIAID and for your support of DCR/NIAID. The search process involves initially recruiting for the position as a Title 5 GS-15; if highly qualified candidates are not identified, then the position will be advertised as a Title 42 appointment.

The position is currently being advertised on a variety of scientific, diversity, and general outreach sites. For your reference, a copy of the ad is attached. The Title 5 GS vacancy announcement will open April 29, 2018 and close May 8, 2018. Therefore, we would like to schedule a one hour meeting in late-May/early-June for the committee to meet and review the applications. Would you please provide us with a point of contact to coordinate your availability?

The Executive Secretary team is available to answer any questions you may have about the process. Please let us know what we can do to assist.

Looking forward to working with you.

Best regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPAB
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b) (6)
From: Allgood, Amanda (NIH/NIAID) [E] /O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP /CN=RECIPIENTS/CN=1C3F99D2F024872985DA3CBB6FB4BE-PRATTAM
Sent: 8/23/2018 2:18:36 PM
To: Mascola, John (NIH/VRC) [E] /O=ExchangeLabs/OU=Exchange Administrative Group /CN=Recipients/CN=7f78b40a596b4ca4a2850a4529d1ae3f2-jmascola]; Holland, Steven (NIH/NIAID) [E] /O=ExchangeLabs/OU=Exchange Administrative Group /CN=Recipients/CN=98d92accc58924e5bb1eb32ff473475c-sholland]; Auchincloss, Hugh (NIH/NIAID) [E] /O=ExchangeLabs/OU=Exchange Administrative Group /CN=Recipients/CN=9304c753bb9e422c977ddeab54a924b-auchincloss]; James Leduc /O=ExchangeLabs/OU=Exchange Administrative Group /CN=Recipients/CN=89e5c6d10619a4d919065f18dd0cbea-jwleduc.utm]; Borio, Luciana L. EOP/NASC [E] /O=ExchangeLabs/OU=Exchange Administrative Group /CN=Recipients/CN=2ecc16d791e4844891f4e978b01288-kingor]; Davis, Deirdre (NIH/OD) [E] /O=ExchangeLabs/OU=Exchange Administrative Group /CN=Recipients/CN=b95d8e3aa54649349c7a0ae026e71-davisid1]; Austin, Sarah (NIH/NIAID) [E] /O=ExchangeLabs/OU=Exchange Administrative Group /CN=Recipients/CN=292fcb7609f4f199be343e08ef1781-austinjs]

Subject: IRF Director, DCR, NIAID, NIH Candidate Interviews
Location: 5601 Fishers Lane, Bethesda, MD 20892 / Room: TBD
Start: 9/6/2018 1:00:00 PM
End: 9/6/2018 5:00:00 PM
Show Time As: Tentative

Required: Mascola, John (NIH/VRC) [E]; Holland, Steven (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; James Leduc;
Attendees: Borio, Luciana L. EOP/NASC; King, Renee (NIH/OD) [E]; Davis, Deirdre (NIH/OD) [E]; Austin, Sarah (NIH/NIAID) [E]
Optional: Katz, Rebecca (NIH/NCATS) [E]; Suhana, Tina (NIH/VRC) [E]; Schmidt, Beth (NIH/NIAID) [E]; Savage, Dana (NIH/NIAID) [E]; Faile, Laura (NIH/NIAID) [C]; Salmon, Logan (NIH/NIAID) [E]; Guerra, Analilida [E]; Day, Vanessa (NIH/NIAID) [E]; Nashwinter, Nicole (NIH/NIAID) [E]
Attendees: [E]; [C]

Thank you in advance for your participation in interviewing the three candidates referred on the short list for the IRF, Director position. The purpose of this meeting is to conduct interviews to evaluate qualifications beyond a paper review. The three candidates applications will be sent to you in a separate email. An updated meeting maker request with room number and call-in information will be sent later as we are still working on the meeting logistics.
If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPAB
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (5) (6)
From: Algood, Amanda [NIH/NIAID] [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP/FYDIBOHF235PD/LT/cn=RECIPIENTS/cn=F1CF3F99DF02F48272985DA3CDBB6FB48E-PRATTAM]


Subject: IRF Director, DCR, NIAID, NIH Candidate Interviews
Attachments: 5601 Fishers Lane Directions and Parking.pdf
Location: 5601 Fishers Lane, Bethesda, MD 20882 / Room: LD10

Start: 9/6/2018 1:00:00 PM
End: 9/6/2018 4:30:00 PM
Show Time As: Tentative

Required: Mascola, John [NIH/VRC] [E]; Holland, Steven [NIH/NIAID] [E]; Auchincloss, Hugh [NIH/NIAID] [E]; James Leduc; Borio, Luciana L. EOP/NSC; King, Renee [NIH/OD] [E]; Davis, Deirdre [NIH/OD] [E]; Austin, Sarah [NIH/NIAID] [E]

Optional: Katz, Rebecca [NIH/NCATS] [E]; Suhana, Tina [NIH/VRC] [E]; Schmidt, Beth [NIH/NIAID] [E]; Savage, Dana [NIH/NIAID] [E]; Faile, Laura [NIH/NIAID] [C]; Salmon, Logan [NIH/NIAID] [E]; Guerra, Anallia [NIH/NIAID] [E]; Nashwinter, Nicole [NIH/NIAID] [E]; Michael [NIH/NCATS] Kurilla [E]

Good afternoon—This meeting maker is being updated to include the meeting location and conference call-in number. You should have received the agenda, candidate resumes and candidate evaluation form in an earlier email.

The IRF Director SSO interviews will be held at 5601 Fishers Lane, Rockville, MD 20852; Room LD10 from 9am – 12:30pm.
Parking
Visitor parking is located at 12721 Twinbrook Parkway, Rockville, MD 20852. Attached are directions including a parking map for your reference. I will provide parking validation stickers at the meeting.

Access to the Building at 5601 Fishers Lane
You will need your PIV badge to access the building. Please feel free to call me at (b)(6) once you arrive and I will meet you at the security desk to escort you to the meeting room.

If you have any questions, I am available at (b)(6)

Thank you,
Amanda Allgood

Thank you in advance for your participation in interviewing the three candidates referred on the short list for the IRF, Director position. The purpose of this meeting is to conduct interviews to evaluate qualifications beyond a paper review. The three candidates applications will be sent to you in a separate email. An updated meeting maker request with room number and call-in information will be sent later as we are still working on the meeting logistics.

If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPA3
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b)(6)
**Driving**

**From Baltimore and All Points North of Washington DC**
Take I-95 south toward Washington, DC. At I-495 (Capital Beltway), head west toward Silver Spring/Bethesda. From the Beltway (I-495), take Exit 34, which is Rt. 355 (Wisconsin Ave./Rockville Pike) and head north toward N/Rockville Pike. Merge onto MD-355 N/Rockville Pike. Turn right onto Twinbrook Pkwy. Turn right onto Fishers Ln. Destination will be on the left. 5601 Fishers Ln Rockville, MD 20852

**From I-495 (Capital Beltway) in Northern Virginia**
Take I-495 N and I-270 Spur N to Montrose Rd in North Bethesda. Take the Interstate 270/Montrose Rd exit from I-270 N. Continue on Montrose Rd. Turn left to merge onto MD-355 N/Rockville Pike. Turn right onto Twinbrook Pkwy. Turn right onto Fishers Ln. Destination will be on the left. 5601 Fishers Ln Rockville, MD 20852
Metro Map

Legend

Direction to NIAID Conference Center

From the Metrorail
- Take Metro's Red Line to the Twinbrook Station
- Exit Metro Station to the East Walking Underneath Train Tracks to the Parking Lot Towards Twinbrook Parkway and Fishers Lane
- Walk to Fishers Lane Heading East
- Continue East on Fishers Lane to 5601 Fishers Lane

Visitor Parking

Parking is at 12721 Twinbrook Parkway Rockville, MD 20852
Hours of Operation  Mon-Fri: 7am-8pm
Daily Rates: 1 Hour $4.00, 2 Hours $6.00 and $8.00 for the entire day. ACCEPTS CASH ONLY!

Walking Directions From Parking Garage Located Behind 5635 Fishers Lane:
- Exit Garage to Fishers Place (Unmarked)
- Walk South to Fishers Lane
- Turn Left and Walk East to 5601 Fishers Lane
Good afternoon—This meeting maker is being updated to include the meeting location and conference call-in number. You should have received the agenda, candidate resumes and candidate evaluation form in an earlier email.
The IRF Director SSO interviews will be held at **5601 Fishers Lane, Rockville, MD 20852; Room LD10 from 9am – 12:30pm.**

**Conference Call-in:** (b) (6)

**Participant Pick-Up:** (b) (6)

**Parking**
Visitor parking is located at 12721 Twinbrook Parkway, Rockville, MD 20852. Attached are directions including a parking map for your reference. I will provide parking validation stickers at the meeting.

**Access to the Building at 5601 Fishers Lane**
You will need your PIV badge to access the building. Please feel free to call me at (b) (6) once you arrive and I will meet you at the security desk to escort you to the meeting room.

If you have any questions, I am available at (b) (6)

Thank you,
Amanda Allgood

---

Thank you in advance for your participation in interviewing the three candidates referred on the short list for the IRF, Director position. The purpose of this meeting is to conduct interviews to evaluate qualifications beyond a paper review. The three candidates applications will be sent to you in a separate email. An updated meeting maker request with room number and call-in information will be sent later as we are still working on the meeting logistics.

If you have any questions please feel free to contact me directly and I will be happy to assist you.

**Warm regards,**
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPA3
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b) (6)
**Direction to NIAID Conference Center**

**Driving**

**From Baltimore and All Points North of Washington DC**
Take I-95 south toward Washington, DC. At I-495 (Capital Beltway), head west toward Silver Spring/Bethesda. From the Beltway (I-495), take Exit 34, which is Rt. 355 (Wisconsin Ave./Rockville Pike) and head north toward N/Rockville Pike. Merge onto MD-355 N/Rockville Pike. Turn right onto Twinbrook Pkwy. Turn right onto Fishers Ln. Destination will be on the left. 5601 Fishers Ln Rockville, MD 20852

**From I-495 (Capital Beltway) in Northern Virginia**
Take I-495 N and I-270 Spur N to Montrose Rd in North Bethesda. Take the Interstate 270/Montrose Rd exit from I-270 N. Continue on Montrose Rd. Turn left to merge onto MD-355 N/Rockville Pike. Turn right onto Twinbrook Pkwy. Turn right onto Fishers Ln. Destination will be on the left. 5601 Fishers Ln Rockville, MD 20852
NIAID Conference Center - Direction & Maps
5601 Fisher's Lane, Rockville, MD 20852

Metro Map

Direction to NIAID Conference Center

From the Metrorail
- Take Metro's Red Line to the Twinbrook Station
- Exit Metro Station to the East Walking Underneath Train Tracks to the Parking Lot Towards Twinbrook Parkway and Fishers Lane
- Walk to Fishers Lane Heading East
- Continue East on Fishers Lane to 5601 Fishers Lane

Visitor Parking

Parking is at 12721 Twinbrook Parkway Rockville, MD 20852

Hours of Operation Mon-Fri: 7am-8pm
Daily Rates: 1 Hour $4.00, 2 Hours $6.00 and $8.00 for the entire day. ACCEPTS CASH ONLY!

Walking Directions From Parking Garage Located Behind 5635 Fishers Lane:
- Exit Garage to Fishers Place (Unmarked)
- Walk South to Fishers Lane
- Turn Left and Walk East to 5601 Fishers Lane
Subject: Director, IRF/DCR/NIAID Search Committee Meeting
Attachments: 5601 Fishers Lane Directions and Parking.pdf; DCR IRF Director Search Agenda for 06-25-18.pdf
Location: 5601 Fisher’s Lane, Rockville, MD 20852; Room LD10
Start: 6/25/2018 3:00:00 PM
End: 6/25/2018 4:00:00 PM
Show Time As: Tentative

Required: Kurilla, Michael (NIH/NCATS) [E]; Mascola, John (NIH/VRC) [E]; Holland, Steven (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Borio, Luciana L. EOP/NSC [E]; James Leduc [E]; King, Renee (NIH/OD) [E]; Faie, Laura (NIH/NIAID) [C]; Tuma, Bonnie (NIH/OD) [E]; Day, Vanessa (NIH/NIAID) [E]; Bassett, James (NIH/OD) [E]; Davis, Deirdre (NIH/NIAID) [E]; Schultz, Beth (NIH/NIAID) [E]; Salmon, Logan (NIH/NIAID) [E]; Gross, Victoria (NIH/OD) [E]

Optional: Katz, Rebecca (NIH/NCATS) [E]; Suhana, Tina (NIH/VRC) [E]; Schmidt, Beth (NIH/NIAID) [E]; Suhana, Tina (NIH/OD) [E]; Davis, Deirdre (NIH/OD) [E]
Good afternoon—This meeting maker is being updated to include the meeting location, conference call-in number and agenda.

The IRF Director SSO meeting will be held at **5601 Fishers Lane, Rockville, MD 20852; Room LD10 from 11am – 12pm.**

**Conference Call-in:** (b) (6)  
**Participant Pick-Up:** (b) (6)  

**Parking**  
Visitor parking is located at 12721 Twinbrook Parkway, Rockville, MD 20852. Attached are directions including a parking map for your reference. I will provide parking validation stickers at the meeting.

**Access to the Building at 5601 Fishers Lane**  
You will need your PIV badge to access the building. Please feel free to call me at the number below once you arrive, and I will meet you at the security desk to escort you to the meeting room.

If you have any questions, I am available at (b) (6)  

I look forward to meeting you!

Best,  
Amanda Allgood  
Senior Program Specialist  
NIAID/DCR/PPAB  
Integrated Research Facility  
Fort Detrick  
8200 Research Plaza, Room 1A121D  
Frederick, MD 21702  
Phone: (b) (6)

---

On behalf of Dr. Lane, thank you in advance for your participation on the IRF, Director Search Committee. The purpose of this meeting is to review the applications that were referred by OHR. Additional information regarding the applications will be sent to you in a separate email. An updated meeting maker request with room number and call-in information will be sent later as we are still working on the meeting logistics.

If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,  
Amanda Allgood  
Senior Program Specialist  
NIAID/DCR/PPAB  
Integrated Research Facility  
Fort Detrick  
8200 Research Plaza, Room 1A121D  
Frederick, MD 21702  
Phone: (b) (6)
Driving

From Baltimore and All Points North of Washington DC
Take I-95 south toward Washington, DC. At I-495 (Capital Beltway), head west toward Silver Spring/Bethesda. From the Beltway (I-495), take Exit 34, which is Rt. 355 (Wisconsin Ave./Rockville Pike) and head north toward N/Rockville Pike. Merge onto MD-355 N/Rockville Pike. Turn right onto Twinbrook Pkwy. Turn right onto Fishers Ln. Destination will be on the left. 5601 Fishers Ln Rockville, MD 20852

From I-495 (Capital Beltway) in Northern Virginia
Take I-495 N and I-270 Spur N to Montrose Rd in North Bethesda. Take the Interstate 270/Montrose Rd exit from I-270 N. Continue on Montrose Rd. Turn left to merge onto MD-355 N/Rockville Pike. Turn right onto Twinbrook Pkwy. Turn right onto Fishers Ln. Destination will be on the left. 5601 Fishers Ln Rockville, MD 20852
NIAID Conference Center - Direction & Maps
5601 Fisher's Lane, Rockville, MD 20852

Metro Map

Direction to NIAID Conference Center

From the Metrorail
- Take Metro’s Red Line to the Twinbrook Station
- Exit Metro Station to the East Walking Underneath Train Tracks to the Parking Lot Towards Twinbrook Parkway and Fishers Lane
- Walk to Fishers Lane Heading East
- Continue East on Fishers Lane to 5601 Fishers Lane

Visitor Parking

Parking is at 12721 Twinbrook Parkway Rockville, MD 20852
Hours of Operation: Mon-Fri: 7am-8pm
Daily Rates: 1 Hour $4.00, 2 Hours $6.00 and $8.00 for the entire day. ACCEPTS CASH ONLY!

Walking Directions From Parking Garage Located Behind 5635 Fishers Lane:
- Exit Garage to Fishers Place (Unmarked)
- Walk South to Fishers Lane
- Turn Left and Walk East to 5601 Fishers Lane
DIRECTOR, INTEGRATED RESEARCH FACILITY, DCR, NIAID
SEARCH COMMITTEE MEETING AGENDA
June 25, 2018

Meeting Information
Date: Monday, June 25, 2018
Time: 11:00 am – 12:00 pm EST
Location: Fishers Lane, Room LD10 Conference Center
Teleconference Information: (b) / Enter Passcode: (b)

Agenda
1. Opening and Introductions by Dr. Mike Kurilla (Chair) and Committee Members
2. Charge by Dr. Cliff Lane
3. Review of Applications by Dr. Kurilla and Committee Members
4. Review of Action Items and Next Steps by Dr. Kurilla and Committee Members

Participants
Dr. Mike Kurilla Dr. John Mascola Dr. Steve Holland
Dr. Hugh Auchincloss Dr. Heinrich Feldmann Dr. Luciana Borio
Dr. James LeDuc Ms. Renee King Ms. Deirdre Davis
Ms. Laura Faile Ms. Nicole Nashwinter Ms. Dana Savage
Ms. Vanessa Day Ms. Amanda Allgood

For questions or assistance, please contact Amanda Allgood at (Office) (b), (Mobile) (b) or (b)
Subject: Canceled: Hold for Director, IRF/DRC/NIAID Search Committee Meeting - T42 Application Review
Location: 5601 Fisher’s Lane, Rockville, MD 20852; Room TBD
Start: 3/22/2019 5:00:00 PM
End: 3/22/2019 6:30:00 PM
Show Time As: Free
request with room number and call-in information will be sent later as we are still working on the meeting logistics.

If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPAB
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b) (b)
Subject: Hold for Director, IRF/DCR/NIAID Search Committee Meeting - T42 Application Review

Location: 5601 Fisher's Lane, Rockville, MD 20852; Room TBD

Start: 3/2/2019 5:00:00 PM
End: 3/2/2019 6:30:00 PM

The purpose of this meeting is to review applications submitted via the Title 42 mechanism. Additional information regarding the applications will be sent to you in a separate email. An updated meeting maker request with room number and call-in information will be sent later as we are still working on the meeting logistics.

If you have any questions please feel free to contact me directly and I will be happy to assist you.
Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPAB
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b) (6)
The purpose of this meeting is to review applications submitted via the Title 42 mechanism. Additional information regarding the applications will be sent to you in a separate email. An updated meeting maker request with room number and call-in information will be sent later as we are still working on the meeting logistics.
If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPAB
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b)(6)
The purpose of this meeting is to review applications submitted via the Title 42 mechanism. Additional information regarding the applications will be sent to you in a separate email. An updated meeting maker request with room number and call-in information will be sent later as we are still working on the meeting logistics.
If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPAB
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b) (b)
Subject: Canceled: Hold for Director, IRF/DCC/NIAID Search Committee Meeting - T42 Application Review
Location: 5601 Fisher's Lane, Rockville, MD 20852; Room TBD
Start: 3/22/2019 5:00:00 PM
End: 3/22/2019 6:30:00 PM
Show Time As: Free

Required: Kurilla, Michael (NIH/NCATS) [E]; Mascola, John (NIH/VRC) [E]; Holland, Steven (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; Feldman, Heinrich (NIH/NIAID) [E]; Borio, Luciana L. EOP/NSC [E]; Day, Vanessa (NIH/NIAID) [E]; Savage, Dana (NIH/NIAID) [E]; Chavez, Lizzie (NIH/VRC) [E]; Anderson, Nicole (NIH/NIAID) [E]; Guerra, Analia (NIH/NCATS) [E]; Lborio, Laura (NIH/NIAID) [E]; Rodela, Gloria (NIH/VRC) [E]

Optional: Katz, Rebecca (NIH/NCATS) [E]; Suhana, Tina (NIH/VRC) [E]; Schmidt, Beth (NIH/NIAID) [E]; Rodela, Gloria (NIH/VRC) [E]

The purpose of this meeting is to review applications submitted via the Title 42 mechanism. Additional information regarding the applications will be sent to you in a separate email. An updated meeting request with room number and call-in information will be sent later as we are still working on the meeting logistics.
If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPAB
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (301) 534-2762
Thank you in advance for your participation in interviewing the candidates for the IRF Director SSO position. The purpose of this two-day meeting is to conduct interviews to evaluate qualifications beyond a paper review. The applications of the candidates being interviewed will be sent to you in a separate email. An updated meeting maker request with room number and call-in information will be sent later as we are still working on the meeting logistics.
If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPAB
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b) (0)
Thank you in advance for your participation in interviewing the candidates for the IRF Director SSO position. The purpose of this two-day meeting is to conduct interviews to evaluate qualifications beyond a paper review. This is the first day of interviews. The second day is tentatively scheduled for May 29th. The applications of the candidates being interviewed will be sent to you in a separate email. An updated meeting request with room number and call-in information will be sent later as we are still working on the meeting logistics.
If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPAB
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b) (c)
From: (b) (6)
Sent: 8/12/2019 2:47:29 PM
To: Auchincloss, Hugh [NIH/NIAID] [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDL)/cn=Recipients/cn=9304c753bb9e422c977dddab54da924b-auchincloss]
Subject: chat with Dr. Auchincloss - discuss the GNL (Dr. Le Duc - please call (b) (6)
Start: 8/13/2019 3:00:00 PM
End: 8/13/2019 3:30:00 PM
Show Time As: Tentative

Recurrence: (none)
Good morning – This meeting maker is being updated to include the meeting location and conference call-in number. You will receive the agenda, candidate resumes and candidate evaluation form in an email this afternoon.

The IRF Director SSO interviews will be held at 5601 Fishers Lane, Rockville, MD 20852; Room 3LC4 from 12:30am – 4:30pm.
Conference Call-in: [Redacted]
Participant Pick-Up: (b) (6)

Parking
Visitor parking is located at 12721 Twinbrook Parkway, Rockville, MD 20852. Attached are directions including a parking map for your reference. I will provide parking validation stickers at the meeting.

Access to the Building at 5601 Fishers Lane
You will need your PIV badge to access the building. Please feel free to call me at (b) (6) once you arrive and I will meet you at the security desk to escort you to the meeting room.

If you have any questions, I am available at (b) (6)

Thank you,
Amanda Allgood

Thank you in advance for your participation in interviewing the candidates for the IRF Director SSO position. The purpose of this two-day meeting is to conduct interviews to evaluate qualifications beyond a paper review. The applications of the candidates being interviewed will be sent to you in a separate email. An updated meeting maker request with room number and call-in information will be sent later as we are still working on the meeting logistics.

If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPA3
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b) (6)
Thanks.

Jim

Both Tony and Cliff would be totally supportive. There is almost no one whom they admire more.

Hugh

Hi Hugh,

Any additional thoughts about [REDACTED] as a candidate for next GNL director? I have not followed up with him yet and don’t want to push it if you think it’s not a good idea.

Thanks, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) [REDACTED]
(f) [REDACTED]
(m) 409-789-2012
Subject: Director, IRF/DCR/NIAID Search Committee Meeting - T42 Application Review

Attachments: 5601 Fishers Lane Directions and Parking.pdf

Location: 5601 Fisher's Lane, Rockville, MD 20852; LD10

Start: 3/29/2019 5:00:00 PM
End: 3/29/2019 6:30:00 PM

Show Time As: Tentative

Required: Kurilla, Michael (NIH/NCATS) [E]; Mascola, John (NIH/VRC) [E]; Holland, Steven (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Borio, Luciana EOP/NSC [E]; Day, Vanessa (NIH/NIAID) [E]; Davis, Deirdre (NIH/OD) [E]; Leduc, James (NIH/NIAID) [E]; Savage, Dana (NIH/NIAID) [E]; Chavez, Lizzie (NIH/NIAID) [E]; Anderson, Nicole (NIH/NIAID) [E]; Faile, Laura (NIH/NIAID) [E]; Schmidt, Beth (NIH/NIAID) [E]; Suhana, Tina (NIH/VRC) [E]; Katz, Rebecca (NIH/NCATS) [E]; Guerra, Analilia [E]

Optional Attendees: Schmidt, Beth (NIH/NIAID) [E]; Suhana, Tina (NIH/VRC) [E]; Katz, Rebecca (NIH/NCATS) [E]; Guerra, Analilia [E]

Good morning –This meeting maker is being updated to include the meeting location and conference call-in number. I will send the documents for the meeting in a separate email.

The IRF Director SSO Search Committee meeting will be held at 5601 Fishers Lane, Rockville, MD 20852; Room LD10 from 1pm – 2:30pm.
Conference Call-in: (b) (6)
Participant Pick-Up: (b) (6)

Parking
Visitor parking is located at 12721 Twinbrook Parkway, Rockville, MD 20852. Attached are directions including a parking map for your reference. I will provide parking validation stickers at the meeting.

Access to the Building at 5601 Fishers Lane
You will need your PIV badge to access the building. Please feel free to call me at the number below once you arrive, and I will meet you at the security desk to escort you to the meeting room.

If you have any questions, I am available at (b) (6)

Best,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPA3
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b) (6)

The purpose of this meeting is to review applications submitted via the Title 42 mechanism. Additional information regarding the applications will be sent to you in a separate email. An updated meeting request with room number and call-in information will be sent later as we are still working on the meeting logistics.

If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPA3
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b) (6)
To Rockville

Twinbrook Station
Red line

Rock Creek Mill Rd

HHS Building

To Washington D.C.

To Washington D.C.

Directions to NIAID Conference Center

Driving

From Baltimore and All Points North of Washington DC
Take I-95 south toward Washington, DC. At I-495 (Capital Beltway), head west toward Silver Spring/Bethesda. From the Beltway (I-495), take Exit 34, which is Rt. 355 (Wisconsin Ave./Rockville Pike) and head north toward N/Rockville Pike. Merge onto MD-355 N/Rockville Pike. Turn right onto Twinbrook Pkwy. Turn right onto Fishers Ln. Destination will be on the left. 5601 Fishers Ln Rockville, MD 20852

From I-495 (Capital Beltway) in Northern Virginia
Take I-495 N and I-270 Spur N to Montrose Rd in North Bethesda. Take the Interstate 270/Montrose Rd exit from I-270 N. Continue on Montrose Rd. Turn left to merge onto MD-355 N/Rockville Pike. Turn right onto Twinbrook Pkwy. Turn right onto Fishers Ln. Destination will be on the left. 5601 Fishers Ln Rockville, MD 20852
**Direction to NIAID Conference Center**

**From the Metrorail**
- Take Metro’s Red Line to the Twinbrook Station
- Exit Metro Station to the East Walking Underneath Train Tracks to the Parking Lot Towards Twinbrook Parkway and Fishers Lane
- Walk to Fishers Lane Heading East
- Continue East on Fishers Lane to 5601 Fishers Lane

**Visitor Parking**

Parking is at 12721 Twinbrook Parkway Rockville, MD 20852
- Hours of Operation: Mon-Fri: 7am-8pm
- Daily Rates: 1 Hour $4.00, 2 Hours $6.00 and $8.00 for the entire day. ACCEPTS CASH ONLY!

**Walking Directions From Parking Garage Located Behind 5635 Fishers Lane:**
- Exit Garage to Fishers Place (Unmarked)
- Walk South to Fishers Lane
- Turn Left and Walk East to 5601 Fishers Lane

Subject: IRF Director, DCR, NIAID, NIH Candidate Interviews - Part 1 of 2
Attachments: 5601 Fishers Lane Directions and Parking.pdf
Location: 5601 Fishers Lane, Bethesda, MD 20892 / Room: 3LC4
Start: 5/9/2019 2:30:00 PM
End: 5/9/2019 5:30:00 PM
Show Time As: Tentative

Required: Kurilia, Michael (NIH/NCATS) [E]; Mascola, John (NIH/VRC) [E]; Holland, Steven (NIH/NIAID) [E]; Aucinhcloss, Hugh (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; James Leduc; Borio, Chavez, Lizzie (NIH/NIAID) [E]; Faile, Laura (NIH/NIAID) [C]; Day, Vanessa (NIH/NIAID) [E]; Savage, Dana (NIH/NIAID) [E]; Anderson, Nicole (NIH/NIAID) [E]; Davis, Deirdre (NIH/OD) [E]; Katz, Rebecca (NIH/NCATS) [E]; Guerra, Anailia; Suhana, Tina (NIH/VRC) [E]; Schmidt, Beth (NIH/NIAID) [E]

Attendees: Good afternoon —This meeting maker is being updated to include the meeting location and conference call-in number. You should have received the agenda, candidate resumes and candidate evaluation form in an earlier email.

The IRF Director SSO interviews will be held at 5601 Fishers Lane, Rockville, MD 20852; Room 3LC4 from 10:30am — 1:30pm.
Conference Call-in: (b) (6)
Participant Pick-Up: 

Parking
Visitor parking is located at 12721 Twinbrook Parkway, Rockville, MD 20852. Attached are directions including a parking map for your reference. I will provide parking validation stickers at the meeting.

Access to the Building at 5601 Fishers Lane
You will need your PIV badge to access the building. Please feel free to call me at (b) (6) once you arrive and I will meet you at the security desk to escort you to the meeting room.

If you have any questions, I am available at (b) (6)

Thank you,
Amanda Allgood

Thank you in advance for your participation in interviewing the candidates for the IRF Director SSO position. The purpose of this two-day meeting is to conduct interviews to evaluate qualifications beyond a paper review. This is the first day of interviews. The second day is tentatively scheduled for May 29th. The applications of the candidates being interviewed will be sent to you in a separate email. An updated meeting maker request with room number and call-in information will be sent later as we are still working on the meeting logistics.

If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPA3
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b) (6)
Vicinity Map

Direction to NIAID Conference Center

Driving

**From Baltimore and All Points North of Washington DC**
Take I-95 south toward Washington, DC. At I-495 (Capital Beltway), head west toward Silver Spring/Bethesda. From the Beltway (I-495), take Exit 34, which is Rt. 355 (Wisconsin Ave./Rockville Pike) and head north toward N/Rockville Pike. Merge onto MD-355 N/Rockville Pike. Turn right onto Twinbrook Pkwy. Turn right onto Fishers Ln. Destination will be on the left. 5601 Fishers Ln Rockville, MD 20852

**From I-495 (Capital Beltway) in Northern Virginia**
Take I-495 N and I-270 Spur N to Montrose Rd in North Bethesda. Take the Interstate 270/Montrose Rd exit from I-270 N. Continue on Montrose Rd. Turn left to merge onto MD-355 N/Rockville Pike. Turn right onto Twinbrook Pkwy. Turn right onto Fishers Ln. Destination will be on the left. 5601 Fishers Ln Rockville, MD 20852
From the Metrorail
- Take Metro’s Red Line to the Twinbrook Station
- Exit Metro Station to the East Walking Underneath Train Tracks to the Parking Lot Towards Twinbrook Parkway and Fishers Lane
- Walk to Fishers Lane Heading East
- Continue East on Fishers Lane to 5601 Fishers Lane

Visitor Parking

Parking is at 12721 Twinbrook Parkway Rockville, MD 20852
Hours of Operation    Mon-Fri: 7am-8pm
Daily Rates: 1 Hour $4.00, 2 Hours $6.00 and $8.00 for the entire day. ACCEPTS CASH ONLY!

Walking Directions From Parking Garage Located Behind 5635 Fishers Lane:
- Exit Garage to Fishers Place (Unmarked)
- Walk South to Fishers Lane
- Turn Left and Walk East to 5601 Fishers Lane
From: Allgood, Amanda (NIH/NIAID) [E] /o=EXCHANGELABS/ou=EXCHANGE ADMINISTRATIVE GROUP
(FYDIBOHF23SPDLT)/cn=Recipients/cn=F1C3F99D2F024872985DA3CDBB6FB4E-PRATTAM

Sent: 5/28/2019 8:18:19 PM

To: Kurilla, Michael (NIH/NCATS) [E] /o=Exchangelabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=recipients/cn=dc4e85061e3943b9b8ad3f426727861f-mkurilla]; Mascola, John (NIH/VRC) [E] /o=Exchangelabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=recipients/cn=7778b40a596b4ca4a2850a4291a3e3f2-jmascola]; Holland, Steven (NIH/NIAID) [E] /o=Exchangelabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=recipients/cn=98d92ac58924e5bb1eb32ff473475c-sholland]; Auchincloss, Hugh (NIH/NIAID) [E] /o=Exchangelabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=recipients/cn=930c753bb9e422e9777ddab54da924b-auchincloss]; Feldmann, Heinrich (NIH/NIAID) [E] /o=Exchangelabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=recipients/cn=7f4bacd16b7d4c22803a843ca5cc33312-feldmann]; James Leduc (NIH/NIAID) [C] /o=Exchangelabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=recipients/cn=89e5ce6106194c4d919065f18dd0cbea-jwleduc.utm]; L Borio (NIH/NIAID) [E] /o=Exchangelabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=recipients/cn=387e7b2ceaf4fb7b3c6dda20962c9bb-chavezzea]; Faile, Laura (NIH/NIAID) [C] /o=Exchangelabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=recipients/cn=d96a92c490e4151b5c719963216e907-failel]; Day, Vanessa (NIH/NIAID) [E] /o=Exchangelabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=recipients/cn=b4bcb9767174265a78746914e09c5ef-dayv]; Savage, Dana (NIH/NIAID) [E] /o=Exchangelabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=recipients/cn=9c498bf7e2d941eab2c0dadc469aaa7c-dsavage]; Anderson, Nicole (NIH/NIAID) [E] /o=Exchangelabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=recipients/cn=5175479651d4e46bb5ba4e70cbb1cd-nashwinton]; Davis, Deirdre (NIH/OD) [E] /o=Exchangelabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=recipients/cn=95b8e3a54649349f3c70a4e02b6e71-davisd1]

CC: Katz, Rebecca (NIH/NCATS) [E] /o=Exchangelabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=recipients/cn=8e21b174d9bf748e9a5ed901b4ca5a3d-katzrd]; Guerra, Analia (NIH/NIAID) [E] /o=Exchangelabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=recipients/cn=07e062bdf5a14748ba39f9bb3e468057-esuhana]; Schmidt, Beth (NIH/NIAID) [E] /o=Exchangelabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=recipients/cn=c94cef3b3ed242eb98ba7a34ee9100ad-bschmidt]

Subject: IRF Director, DCR, NIAID, NIH Candidate Interviews - Part 2 of 2
Attachments: 5601 Fishers Lane Directions and Parking.pdf
Location: 5601 Fishers Lane, Bethesda, MD 20892 / Room: 6H200AB

Start: 5/29/2019 4:30:00 PM
End: 5/29/2019 9:00:00 PM
Show Time As: Tentative

Good morning – This meeting maker is being updated to include the meeting location and conference call-in number. You will receive the agenda, candidate resumes and candidate evaluation form in an email this afternoon.

The IRF Director SSO interviews will be held at 5601 Fishers Lane, Rockville, MD 20852; Room 3LC4 from 12:30pm – 5pm.
Conference Call-in: (b) (6)
Participant Pick-Up: (b)

Parking
Visitor parking is located at 12721 Twinbrook Parkway, Rockville, MD 20852. Attached are directions including a parking map for your reference. I will provide parking validation stickers at the meeting.

Access to the Building at 5601 Fishers Lane
You will need your PIV badge to access the building. Please feel free to call me at (b) once you arrive and I will meet you at the security desk to escort you to the meeting room.

If you have any questions, I am available at (b)

Thank you,
Amanda Allgood

---

Thank you in advance for your participation in interviewing the candidates for the IRF Director SSO position. The purpose of this two-day meeting is to conduct interviews to evaluate qualifications beyond a paper review. The applications of the candidates being interviewed will be sent to you in a separate email. An updated meeting maker request with room number and call-in information will be sent later as we are still working on the meeting logistics.

If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPA3
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b)
Driving

**From Baltimore and All Points North of Washington DC**
Take I-95 south toward Washington, DC. At I-495 (Capital Beltway), head west toward Silver Spring/Bethesda. From the Beltway (I-495), take Exit 34, which is Rt. 355 (Wisconsin Ave./Rockville Pike) and head north toward N/Rockville Pike. Merge onto MD-355 N/Rockville Pike. Turn right onto Twinbrook Pkwy. Turn right onto Fishers Ln. Destination will be on the left. 5601 Fishers Ln Rockville, MD 20852

**From I-495 (Capital Beltway) in Northern Virginia**
Take I-495 N and I-270 Spur N to Montrose Rd in North Bethesda. Take the Interstate 270/Montrose Rd exit from I-270 N. Continue on Montrose Rd. Turn left to merge onto MD-355 N/Rockville Pike. Turn right onto Twinbrook Pkwy. Turn right onto Fishers Ln. Destination will be on the left. 5601 Fishers Ln Rockville, MD 20852
**NIAID Conference Center - Direction & Maps**
5601 Fisher’s Lane, Rockville, MD 20852

---

**Metro Map**

**Direction to NIAID Conference Center**

**From the Metrorail**
- Take Metro’s Red Line to the Twinbrook Station
- Exit Metro Station to the East Walking Underneath Train Tracks to the Parking Lot Towards Twinbrook Parkway and Fishers Lane
- Walk to Fishers Lane Heading East
- Continue East on Fishers Lane to 5601 Fishers Lane

**Visitor Parking**

Parking is at 12721 Twinbrook Parkway Rockville, MD 20852

Hours of Operation: Mon-Fri: 7am-8pm
Daily Rates: 1 Hour $4.00, 2 Hours $6.00 and $8.00 for the entire day. ACCEPTS CASH ONLY!

**Walking Directions From Parking Garage Located Behind 5635 Fishers Lane:**
- Exit Garage to Fishers Place (Unmarked)
- Walk South to Fishers Lane
- Turn Left and Walk East to 5601 Fishers Lane
Subject: Director, IRF/DCR/NIAID Search Committee Meeting

Location: TBD

Start: 6/25/2018 3:00:00 PM
End: 6/25/2018 4:00:00 PM
Show Time As: Busy

Required: Kurilla, Michael (NIH/NCATS) [E]; Mascola, John (NIH/VRC) [E]; Holland, Steven (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Borio, Luciana L. EOP/NSC <[redacted]>

Attendees: LeDuc, James W. <[redacted]>; King, Renee (NIH/OD) [E]; Faile, Laura (NIH/NIAID) [C]; Tuma, Bonnie (NIH/OD) [E]; Savage, Dana (NIH/NIAID) [E]; Schmidt, Beth (NIH/NIAID) [E]; Salmon, Logan (NIH/NIAID) [E]; Katz, Rebecca (NIH/NCATS) [E]; Suhana, Tina (NIH/VRC) [E]; Schmidt, Beth (NIH/NIAID) [E]; Salmon, Logan (NIH/NIAID) [E]; Suhana, Tina (NIH/VRC) [E]; Schmidt, Beth (NIH/NIAID) [E]
Subject: STPI Report/BSL4 Lab Meeting w/ Dr. LeDuc
Location: 317A03
Start: 3/14/2018 12:30:00 PM
End: 3/14/2018 1:30:00 PM
Show Time As: Busy

Required Attendees: Harper, Jill (NIH/NIAID) [E]; Boyd, Nancy (NIH/NIAID) [E]; LeDuc, James W.; Niesel, David W.; Guerra, Analilia
Subject: IRF Director, DCR, NIAID, NIH Candidate Interviews

Location: 5601 Fishers Lane, Bethesda, MD 20892 / Room: TBD

Start: 9/6/2018 1:00:00 PM
End: 9/6/2018 5:00:00 PM
Show Time As: Busy

Required: Mascola, John (NIH/VRC) [E]; Holland, Steven (NIH/NIAID) [E]; Aucincloss, Hugh (NIH/NIAID) [E]; James Leduc;
Attendees: Borio, Luciana L. ECP/NSC; King, Renee (NIH/OD) [E]; Davis, Deirdre (NIH/OD) [E]; Austin, Sarah (NIH/NIAID) [E]; Savage, Dana (NIH/NIAID) [E]; Katz, Rebecca (NIH/NCATS) [E]; Suhana, Tina (NIH/VRC) [E]; Schmidt, Beth (NIH/NIAID) [E]; Faile, Laura (NIH/NIAID) [C]; Salmon, Logan (NIH/NIAID) [E]; Guerra, Anallia [E]; Day, Vanessa (NIH/NIAID) [E]; Nashwinter, Nicole (NIH/NIAID) [E]; Kurilla, Michael (NIH/NCATS) [E]; [b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b][b]
Subject: Director, IRF/DCR/NIAID Search Committee Meeting
Location: TBD
Start: 6/25/2018 3:00:00 PM
End: 6/25/2018 4:00:00 PM
Show Time As: Busy
On behalf of Dr. Lane, thank you in advance for your participation on the IRF, Director Search Committee. The purpose of this meeting is to review the applications that were referred by OHR. Additional information regarding the applications will be sent to you in a separate email. An updated meeting maker request with room number and call-in information will be sent later as we are still working on the meeting logistics.

If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPA3
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b) (6)
Subject: Hold for Director, IRF/DCR/NIAID Search Committee Meeting - T42 Application Review
Location: 5601 Fisher’s Lane, Rockville, MD 20852; Room TBD
Start: 3/29/2019 5:00:00 PM
End: 3/29/2019 6:30:00 PM
Show Time As: Tentative

The purpose of this meeting is to review applications submitted via the Title 42 mechanism. Additional information regarding the applications will be sent to you in a separate email. An updated meeting maker
request with room number and call-in information will be sent later as we are still working on the meeting logistics.

If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPAB
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: [redacted] (b) (0)
Thank you in advance for your participation in interviewing the candidates for the IRF Director SSO position. The purpose of this two-day meeting is to conduct interviews to evaluate qualifications beyond a paper review. The applications of the candidates being interviewed will be sent to you in a separate email. An
updated meeting maker request with room number and call-in information will be sent later as we are still working on the meeting logistics.

If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPAB
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b) (6)
Subject: IRF Director, DCR, NIAID, NIH Candidate Interviews - Part 1 of 2
Attachments: 5601 Fishers Lane Directions and Parking.pdf
Location: 5601 Fishers Lane, Bethesda, MD 20892 / Room: 3LC4
Start: 5/9/2019 2:30:00 PM
End: 5/9/2019 5:30:00 PM
Show Time As: Tentative

Required Attendees: Kurilla, Michael (NIH/NCATS) [E]; Mascola, John (NIH/VRC) [E]; Holland, Steven (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; James Leduc; Chavez, Lizzie (NIH/NIAID) [E]; Faile, Laura (NIH/NIAID) [C]; Davis, Deirdre (NIH/OD) [E]; Katz, Rebecca (NIH/NCATS) [E]; Guerra, Analia [E]; Suhana, Tina (NIH/VRC) [E]; Schmidt, Beth (NIH/NIAID) [E]; Davis, Deirdre (NIH/OD) [E]; Katz, Rebecca (NIH/NCATS) [E]; Guerra, Analia; Suhana, Tina (NIH/VRC) [E]; Schmidt, Beth (NIH/NIAID) [E]

Good afternoon – This meeting maker is being updated to include the meeting location and conference call-in number. You should have received the agenda, candidate resumes and candidate evaluation form in an earlier email.

The IRF Director SSO interviews will be held at 5601 Fishers Lane, Rockville, MD 20852; Room 3LC4 from 10:30am – 1:30pm.
Conference Call-in: (b) (6)
Participant Pick-Up: (b) (6)

Parking
Visitor parking is located at 12721 Twinbrook Parkway, Rockville, MD 20852. Attached are directions including a parking map for your reference. I will provide parking validation stickers at the meeting.

Access to the Building at 5601 Fishers Lane
You will need your PIV badge to access the building. Please feel free to call me at (b) (6) once you arrive and I will meet you at the security desk to escort you to the meeting room.

If you have any questions, I am available at (b) (6)

Thank you,
Amanda Allgood

Thank you in advance for your participation in interviewing the candidates for the IRF Director SSO position. The purpose of this two-day meeting is to conduct interviews to evaluate qualifications beyond a paper review. This is the first day of interviews. The second day is tentatively scheduled for May 29th. The applications of the candidates being interviewed will be sent to you in a separate email. An updated meeting maker request with room number and call-in information will be sent later as we are still working on the meeting logistics.

If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPA3
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b) (6)
Driving

From Baltimore and All Points North of Washington DC
Take I-95 south toward Washington, DC. At I-495 (Capital Beltway), head west toward Silver Spring/Bethesda. From the Beltway (I-495), take Exit 34, which is Rt. 355 (Wisconsin Ave./Rockville Pike) and head north toward N/Rockville Pike. Merge onto MD-355 N/Rockville Pike. Turn right onto Twinbrook Pkwy. Turn right onto Fishers Ln. Destination will be on the left. 5601 Fishers Ln Rockville, MD 20852

From I-495 (Capital Beltway) in Northern Virginia
Take I-495 N and I-270 Spur N to Montrose Rd in North Bethesda. Take the Interstate 270/Montrose Rd exit from I-270 N. Continue on Montrose Rd. Turn left to merge onto MD-355 N/Rockville Pike. Turn right onto Twinbrook Pkwy. Turn right onto Fishers Ln. Destination will be on the left. 5601 Fishers Ln Rockville, MD 20852
Direction to NIAID Conference Center

From the Metrorail
- Take Metro's Red Line to the Twinbrook Station
- Exit Metro Station to the East Walking Underneath Train Tracks to the Parking Lot Towards Twinbrook Parkway and Fishers Lane
- Walk to Fishers Lane Heading East
- Continue East on Fishers Lane to 5601 Fishers Lane

Visitor Parking

Parking is at 12721 Twinbrook Parkway Rockville, MD 20852
Hours of Operation: Mon-Fri: 7am-8pm
Daily Rates: 1 Hour $4.00, 2 Hours $6.00 and $8.00 for the entire day. ACCEPTS CASH ONLY!

Walking Directions From Parking Garage Located Behind 5635 Fishers Lane:
- Exit Garage to Fishers Place (Unmarked)
- Walk South to Fishers Lane
- Turn Left and Walk East to 5601 Fishers Lane
Thank you in advance for your participation in interviewing the candidates for the IRF Director SSO position. The purpose of this two-day meeting is to conduct interviews to evaluate qualifications beyond a paper review. This is the first day of interviews. The second day is tentatively scheduled for May 29th. The applications of the candidates being interviewed will be sent to you in a separate email. An updated meeting maker request with room number and call-in information will be sent later as we are still working on the meeting logistics.

If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPAS
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: [phone number]
Good morning – This meeting maker is being updated to include the meeting location and conference call-in number. You will receive the agenda, candidate resumes and candidate evaluation form in an email this afternoon.

The IRF Director SSO interviews will be held at 5601 Fishers Lane, Rockville, MD 20852; Room 3LC4 from 12:30am – 4:30pm.
**Parking**
Visitor parking is located at 12721 Twinbrook Parkway, Rockville, MD 20852. Attached are directions including a parking map for your reference. I will provide parking validation stickers at the meeting.

**Access to the Building at 5601 Fishers Lane**
You will need your PIV badge to access the building. Please feel free to call me at (b) (6) once you arrive and I will meet you at the security desk to escort you to the meeting room.

If you have any questions, I am available at (b) (6)

Thank you,
Amanda Allgood

---

Thank you in advance for your participation in interviewing the candidates for the IRF Director SSO position. The purpose of this two-day meeting is to conduct interviews to evaluate qualifications beyond a paper review. The applications of the candidates being interviewed will be sent to you in a separate email. An updated meeting maker request with room number and call-in information will be sent later as we are still working on the meeting logistics.

If you have any questions please feel free to contact me directly and I will be happy to assist you.

Warm regards,
Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPA3
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b) (6)
From: LeDuc, James W. [redacted] (b) (6)
Sent: 8/12/2019 2:50:12 PM
To: LeDuc, James W. [redacted] (b) (6) Auchincloss, Hugh (NIH/NIAID) [E]
[redacted] ExchangeLabs/ou=Exchange Administrative Group [FYDIOH23SPDLT]/cn=Recipients/cn=9304c753bb9e422c977d954da924b-auchincloss]
Subject: chat with Dr. Auchincloss - discuss the GNL (Dr. Le Duc - please call (b) (6)
Start: 8/13/2019 3:00:00 PM
End: 8/13/2019 3:30:00 PM
Show Time As: Tentative
Recurrence: (none)
Ralph, I will get you a letter of intent from NIH by tomorrow. To whom would you like it addressed.

Hugh

Hugh Auchincloss, M.D.
Deputy Director, NIAID
National Institutes of Health
Bldg. 31 (7A/03), 31 Center Drive, MSC 2520
Bethesda, MD 20892
Phone: [redacted]

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.
Absolutely Jim. Tony would be happy to do this.

Hugh

Hi Hugh,

As we discussed earlier, the GNL will be celebrating 10 years of operation in November and to recognize the milestone we are hosting a gathering for our local Galveston partners and our own UTMB community. Our plans are for a luncheon for community VIPs, followed by a presentation on our accomplishments and talk in our large auditorium. We have invited Ian Crozier as our guest speaker and we anticipate a large turn-out. We will be inviting Emily Erbelding and our program officers, Nancy Boyd, Kim Taylor and Gary Zackowitz to represent NIAID in person.

I wonder if we could get a brief note of congratulations from Tony to recognize the important partnership that has been built between NIAID and the GNL/UTMB? We will have a program that will be given to all attendees and we are thinking that it would be nice to prominently display a “Message from Dr Fauci.”

Would you mind asking him if he would be willing to write a brief paragraph for this? I’m happy to ask him directly if you prefer. We would need it by mid-October to ensure that it is included in the program.

Thanks very much!

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(f) 409-266-6810
(m) (b) (6)
Discussion: GWS, BSL-3 and UNC

https://zoom.us/j/95020464838?pwd=qjVyUU1pbzFaOUJQXJwajJPWHFLZz09

6/5/2020 6:30:00 PM

End: 6/5/2020 7:00:00 PM

Show Time As: Busy

Required
- Dieffenbach, Carl (NIH/NIAID) [E]
- Auchtinloss, Hugh (NIH/NIAID) [E]
- Erbelding, Emily (NIH/NIAID) [E]
- Cohen, Myron [E]
- Baric, Ralph [E]
- Heise, Mark T [E]
- Damania, Blossom A [E]
- Magnuson, Terry R [E]
- Harper, Jill (NIH/NIAID) [E]
- Linde, Emily (NIH/NIAID) [E]

Optional
- Baric, Toni C [E]
From: Zackowitz, Gary (NIH/NIAID) [E] [O=EXCHANGE.LABS/CU=EXCHANGE ADMINISTRATIVE GROUP
(FYDIOBHF23SPDLTLT)/CN=RECIPIENTS/CN=8E46AB3F44D24A93B7907A328A87C23E-ZACKOWIG]
Sent: 3/17/2020 4:06:49 PM
To: Zackowitz, Gary (NIH/NIAID) [E] [O=Exchange.Labs/ou=Exchange Administrative Group
(FYDIOBHF23SPDLTLT)/cn=recipients/cn=846ab3f44d24a93b7907a328a87c23e-zackowig]; Auchincloss, Hugh
(NIH/NIAID) [E] [O=Exchange.Labs/ou=Exchange Administrative Group
(FYDIOBHF23SPDLTLT)/cn=recipients/cn=9304c753bb9e422c977dddb54a924b-auchincloss]; Erbelding, Emily
(NIH/NIAID) [E] [O=Exchange.Labs/ou=Exchange Administrative Group
(FYDIOBHF23SPDLTLT)/cn=recipients/cn=976eefb714124fb3c5c294eb334fe-erbelding]; James Leduc
[O=Exchange.Labs/ou=Exchange Administrative Group
(FYDIOBHF23SPDLTLT)/cn=recipients/cn=89e5cd6106194c4d919065f18dd0cbea-jwleduc.utm]; David Aliand
[O=Exchange.Labs/ou=Exchange Administrative Group
(FYDIOBHF23SPDLTLT)/cn=recipients/cn=d113d4eeb42341baa81e9468d209ac5-daviddouma];
Roy, Chad [O=Exchange.Labs/ou=Exchange Administrative Group
(FYDIOBHF23SPDLTLT)/cn=recipients/cn=8b7445d361dc4d088a77b0b23ca2e024-croy.tulane]; Missiakas, Dominique
[O=Exchange.Labs/ou=Exchange Administrative Group
(FYDIOBHF23SPDLTLT)/cn=recipients/cn=828ee6f9964fc2bec7badc5fc09cc69-dmissiak.bs]; Kenneth
[O=Exchange.Labs/ou=Exchange Administrative Group
(FYDIOBHF23SPDLTLT)/cn=recipients/cn=498400edb284bd2a7c92c0f6268ee41-bryantpr]; Taylor, Kimberly
(NIH/NIAID) [E] [O=Exchange.Labs/ou=Exchange Administrative Group
(FYDIOBHF23SPDLTLT)/cn=recipients/cn=40d070496154c54a9940a11c3a9c652-taylorkl]; Boyd, Nancy (NIH/NIAID)
[E] [O=Exchange.Labs/ou=Exchange Administrative Group
(FYDIOBHF23SPDLTLT)/cn=recipients/cn=78544d77c6ad49d826ac9b0b207fbc-nboyd]; Bloom, Marshall (NIH/NIAID)
[E] [O=Exchange.Labs/ou=Exchange Administrative Group
(FYDIOBHF23SPDLTLT)/cn=recipients/cn=3aaa49e371a4d4eb3c27babe9cd1308b-mbloom]; Ali Andalibi

(FYDIOBHF23SPDLTLT)/cn=recipients/cn=3398805168cd4cbb7320d2239909d09-d-gillessm]; Duprex, Paul
[O=Exchange.Labs/ou=Exchange Administrative Group
(FYDIOBHF23SPDLTLT)/cn=recipients/cn=3398805168cd4cbb7320d2239909d09-d-gillessm]; Harrod, Kevin
[O=Exchange.Labs/ou=Exchange Administrative Group
(FYDIOBHF23SPDLTLT)/cn=recipients/cn=3398805168cd4cbb7320d2239909d09-d-gillessm]; Roth, Justin
[O=Exchange.Labs/ou=Exchange Administrative Group
(FYDIOBHF23SPDLTLT)/cn=recipients/cn=3398805168cd4cbb7320d2239909d09-d-gillessm]; Petit, Chad
[O=Exchange.Labs/ou=Exchange Administrative Group
(FYDIOBHF23SPDLTLT)/cn=recipients/cn=3398805168cd4cbb7320d2239909d09-d-gillessm]

Subject: Coronavirus Roundtable - NBL/RBL Network Meeting
Location: Zoom Meeting--- https://oostonu.zoom.us/j
Start: 3/30/2020 7:00:00 PM
End: 3/30/2020 8:30:00 PM
Show Time As: Busy
-----Original Appointment-----
From: Zackowitz, Gary (NIH/NIAID) [E]
Sent: Thursday, March 12, 2020 10:48 AM
Subject: Coronavirus Roundtable - NBL/RBL Network Meeting
When: Monday, March 30, 2020 3:00 PM-4:30 PM (UTC-05:00) Eastern Time (US & Canada).
Where: Zoom Meeting--- https://bostonu.zoom.us/j/ (b) (6)

SCHEDULE UPDATE- Meeting Time Extended

Hi All — For those planning to join our discussion:
BU has provided a link below for the meeting via ZOOM.
I will put together a list of those who want time to share their screen for presentations. Please let me know if you have a topic or your current work that you want to present to the group. We will have a discussion leader to keep things moving!
Thanks-
Gary

Link to join by computer:
https://bostonu.zoom.us/j/ (b) (6)
- If multiple people join from the same room, they should join with a single computer to avoid audio feedback.
- If you’d like to try joining a Zoom meeting beforehand, use this link. You will enter a time-limited mock meeting that only includes yourself. This minute-long video explains the join process.
- If you are not able to download and run the prompted file, after opening the meeting link, click the option highlighted below. You’ll need to open the meeting link in Google Chrome or Microsoft Edge to use audio and video. Edge is Microsoft’s successor to Internet Explorer and is now on most Windows computers. The meeting can be opened in Firefox, but it would require also dialing in by phone to hear audio.

To only join by phone:
Dial (b) (6) and enter meeting passcode (b) (6)
Phone participants will be able to speak with those joining by computer, but will not be able to see anyone’s camera or shared screens.

Hi NBL/RBL Directors –
As you know our network meeting in Boston is cancelled for this year, however the planners think it is important to still have the session titled “Coronavirus Roundtable”. We ask that you keep the time this was originally scheduled [
Monday, March 30 at 3:00pm) available so you can participate in a virtual meeting. How this virtual meeting is best conducted is still being determined by BU, and we will send you updates on this as it develops.

As a reminder – this session was planned as an opportunity to share what work your lab is doing / capable of doing and get input from your network peers. Let us know if there is something you want to present and please forward this invitation to others in your lab that can contribute to this discussion.

Thanks
Gary
Subject: Informal Coronavirus Teleconference

Location: Salle B

Start: 7/8/2020 12:30:00 PM
End: 7/8/2020 1:30:00 PM
Show Time As: Busy

Recurrence: (none)
Join Zoom Meeting
https://who-e.zoom.us/j/[(b) (6)]

Meeting ID: [(b) (6)]
Password: [(b) (6)]

Dial by your location
+33 1 7095 0350 France
+33 1 8699 5831 France
+33 1 7037 2246 France
+33 1 7037 9729 France
+33 1 7095 0103 France
+41 43 210 71 08 Switzerland
+41 44 529 92 72 Switzerland
+41 22 591 00 05 Switzerland
+41 22 591 01 56 Switzerland
+41 31 528 09 88 Switzerland
+41 43 210 70 42 Switzerland

Meeting ID: [(b) (6)]
Password: [(b) (6)]
Find your local number: https://who-e.zoom.us/u/abV0EgHFND

Join by SIP
[(b) (6)]@zoomcrc.com
Informal Coronavirus Teleconference

Salle B

6/25/2020 12:30:00 PM

Busy

(none)
Join Zoom Meeting
https://who.zoom.us/j/ (b)(6)
Meeting ID: (b)(6)
Password: (b)(6)

Dial by your location
+41 22 591 00 05 Switzerland
0 800 002 622 Switzerland Toll-free
+1 720 928 9299 US
888 475 4499 US Toll-free
+33 1 7037 9729 France
+33 1 7095 0103 France
+33 1 7095 0350 France
+33 7 5678 4048 France
+33 1 7037 2246 France

Meeting ID: (b)(6)
Password: (b)(6)

Find your local number: https://who.zoom.us/u/aebBHqmWSS

Join by SIP
(b)(6)@zoomcrc.com
Subject: Informal Coronavirus Teleconference
Location: Salle A (Zoom link copied below)
Start: 5/28/2020 12:30:00 PM
End: 5/28/2020 1:30:00 PM
Show Time As: Busy
Recurrence: (none)

Join Zoom Meeting
https://who.zoom.us/
Meeting ID: 
Password: 

Dial by your location
+41 22 591 00 05 Switzerland
0 800 002 622 Switzerland Toll-free
+1 720 928 9299 US
888 475 4499 US Toll-free
+33 7 5678 4048 France
+33 1 7037 2246 France
+33 1 7037 9729 France
+33 1 7095 0103 France
+33 1 7095 0350 France

Meeting ID: 930 2016 3006
Password: ******

Find your local number: https://who.zoom.us/u/acedAgpbGI7

Join by SIP

(b) (6)@zoomcrc.com
Subject: Informal Coronavirus Teleconference

Location: Salle A

Start: 7/22/2020 12:30:00 PM
End: 7/22/2020 1:30:00 PM

Recurrence: (none)
Join Zoom Meeting
https://who-e.zoom.us/j/ (b) (6)

Meeting ID: (b) (6)
Passcode: (b) (6)

Dial by your location
   +41 22 591 00 05 Switzerland
   +1 929 205 6099 US (New York)
   +33 1 7095 0103 France
Meeting ID: (b) (6)
Passcode: (b) (6)
Find your local number: https://who-e.zoom.us/u/6adH7QZ4Nnlm?

Join by SIP
(6)@zoomerc.com
Perfect, thanks very much. I am copying my assistant Imelda Mendoza and she can work with your office to see if we can find a time to chat. I will be in DC the first part of next week for a meeting at the National Academy of Sciences, so it will probably be later in the week before we can talk.

Thanks, Jim

Hi Jim,

Thanks for your message.

Given the time that the NBL and RBL staff have put into the STPI project and the data you all have provided, we do want to make sure that you have access to the results.

We will discuss with STPI the appropriate person to present at the NBL-RBL annual meeting as well as how best to present the results. I understand that some of the labs have expressed concern about budget and other data being shared and we want to be sensitive to that while ensuring that the presentation is informative to you all.

I’d be happy to discuss further. Can we find a mutually agreeable time next week to chat?

Regards,
Jill

Jill R. Harper, Ph.D.
Director, Office of Biodefense Research and Surety, and
Associate Director for Science Management
Office of Science Management and Operations (OSMO)
NIAID/NIH/DHHS
Bldg. 31, Room 7A-18, MSC 2520
Bethesda, MD 20892-2520
Phone: (b) (6)
Fax: 301/496-9082 (b) (6)
Dear Dr Harper,

As I believe you know, I have been working with Nancy Boyd and the team organizing the upcoming National and Regional biocontainment laboratory annual meeting for 2017. We will be hosting this year’s meeting at the Galveston National Laboratory on 30 April to 2 May and I would like to explore with you the possibility of having someone from either NIH and/or STPI to give an update to the network members on the findings of the STPI project to document the cost of operations for biocontainment laboratories. As you know, many individuals from the RBL-NBL network have been interviewed by the STPI team and they are eager to learn about progress on the study. I initially discussed having a presentation on the report with Dr Auchincloss and also with Dr Simon (both copied here), but then learned from Nancy that you are the primary point of contact for the study and thus my reason for writing to you.

I understand that the study is still underway but that some preliminary results are to be shared with NIH in the coming months. It would be of great interest to the RBL-NBL network members to learn of the progress that has been made so far, even if next steps are still undefined. I hope that you or someone from the STPI project can join us!

Thank you for your consideration of our request. I would be pleased to discuss details further at your convenience.

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) (b)(6)
(f) 409-266-6810
(m) (b)(6)
Dear Dr Harper,

As I believe you know, I have been working with Nancy Boyd and the team organizing the upcoming National and Regional biocontainment laboratory annual meeting for 2017. We will be hosting this year’s meeting at the Galveston National Laboratory on 30 April to 2 May and I would like to explore with you the possibility of having someone from either NIH and/or STPI to give an update to the network members on the findings of the STPI project to document the cost of operations for biocontainment laboratories. As you know, many individuals from the RBL-NBL network have been interviewed by the STPI team and they are eager to learn about progress on the study. I initially discussed having a presentation on the report with Dr Auchincloss and also with Dr Simon (both copied here), but then learned from Nancy that you are the primary point of contact for the study and thus my reason for writing to you.

I understand that the study is still underway but that some preliminary results are to be shared with NIH in the coming months. It would be of great interest to the RBL-NBL network members to learn of the progress that has been made so far, even if next steps are still undefined. I hope that you or someone from the STPI project can join us!

Thank you for your consideration of our request. I would be pleased to discuss details further at your convenience.

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) (b) (6)
(f) 409-266-6810
(m) (b) (6)
Amanda, please see my comments for the candidates interviewed today.

Thanks, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610

From: Allgood, Amanda (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, May 08, 2019 11:24 AM
To: Kurilla, Michael (NIH/NCATS) [E] (b) (6) Mascola, John (NIH/VRC) [E] (b) (6)
Holland, Steven (NIH/NIAID) [E] (b) (6) Auchincloss, Hugh (NIH/NIAID) [E] (b) (6)
Feldmann, Heinrich (NIH/NIAID) [E] (b) (6) LeDuc, James W. (b) (6)
L. Borio (b) (6) Chavez, Lizzie (NIH/NIAID) [E] (b) (6) Falle, Laura (NIH/NIAID) [C] (b) (6)
Day, Vanessa (NIH/NIAID) [E] (b) (6) Savage, Dana (NIH/NIAID) [E] (b) (6)
Anderson, Nicole (NIH/NIAID) [E] (b) (6) Davis, Deirdre (NIH/OD) [E] (b) (6)
Katz, Rebecca (NIH/NCATS) [E] (b) (6) Schmidt, Beth (NIH/NIAID) [E] (b) (6)
Guerra, Analii (b) (6) Suhana, Tina (NIH/VRC) [E] (b) (6) Anderson, Nicole (NIH/NIAID) [E] (b) (6)

Subject: Documents for IRF Director SSO, DCR, NIAID, NIH Candidate Interviews scheduled on 5/9/19

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good afternoon,

We are looking forward to your participation in the three IRF Director interviews scheduled for tomorrow May 9th beginning at 10:30am and ending at 1:30pm. This will be the first of two phases scheduled for interviews. In preparation for tomorrow, please see the attached documents. The documents will be printed and provided for those attending in person.

- Interview Meeting Agenda
- Candidate Resumes for
- Candidate Evaluation form. We kindly ask that those participating in person complete the evaluation form and hand it in at the conclusion of the interviews, while those joining by phone email the document to me by COB 5/9, so that we can collate all feedback and send to Dr. Lane.
Assigned Interview Questions

Working with Drs. Lane and Kurilla we have finalized the list of interview questions, and have identified an interview question for each committee member to ask of the respective candidates. The assigned interview questions are attached.

Lastly, if haven’t done so already, please let me know as soon as possible if you will be joining in person or by phone so that we may plan accordingly.

Thank you again for your time and support.

Amanda Allgood
Senior Program Specialist
NIAID/DCR/PPAB
Integrated Research Facility
Fort Detrick
8200 Research Plaza, Room 1A121D
Frederick, MD 21702
Phone: (b)(6)
Candidate Interview Evaluation Form, 9 May 2019

Director, Integrated Research Facility, DCR
Candidate Interview Evaluation Form, 9 May 2019

Director, Integrated Research Facility, DCR
Dear Tony and Hugh,

I wanted to share with you both that I have begun discussions with UTMB leadership for me to start a glide path towards retirement. We are currently preparing a job description for the Director, GNL, and it will be posted in the next month or two with the goal of having a candidate selected by the end of this calendar year or early next year. This would allow a period of overlap during which the person could gain a complete understanding of the program. My target date for stepping down is August 2020.

We plan to conduct a national search and we would welcome your suggestions of highly qualified candidates. Before a final decision is made, I know that our university leadership would like to have your input.

I hope to remain associated with UTMB, and I will continue to be involved in emerging infectious diseases and high-risk pathogens.

Let me take this opportunity to sincerely thank you both for your unwavering support as we have developed this new model of partnership between NIH and academia. I am extremely proud of the work we have done together to bring the GNL to full operational status and of the many scientific contributions that were made possible by having access to the unique resource that we have created. Together, we have made your vision of nearly two decades ago a reality; together, we have built one of the premier biocontainment laboratories in the world. Thank you for allowing me to be a part of this exciting initiative.

I look forward to working with you through this transition.

With my very best wishes,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) [redacted] (b) (6)
(f) 409-266-6810
(m) [redacted] (9) (6)
See below regarding changes in top leadership underway at UTMB. This was announced earlier today and came as a surprise to most of us. No clear understudy here on campus so I suspect that a national search will start very soon. Too soon to say what, if any, impact will be on the GNL. Dr Callender has always been a strong supporter of us.

Thanks, Jim

At today’s Town Hall meeting, I announced that my last day to serve as UTMB’s president will be August 31, 2019. Effective September 1, I will join the Memorial Hermann Health System in Houston as its President and Chief Executive Officer. The University of Texas System will soon name an interim president to lead UTMB while the national search for a new president progresses.

I want to assure you that the university remains in the highly capable hands of Executive Vice Presidents Dr. Charles Mouton and Dr. Tim Harlin; Chief Financial Officer Cheryl Sadro; Deans Dr. David Brown, Dr. Deborah Jones and Dr. David Niesel; and Senior Vice Presidents Carrie King, Becky Korenek and Dr. Ben Raimer. In addition, UT System Chancellor J.B. Milliken and Executive Vice Chancellor for Health Affairs ad interim Amy Shaw Thomas have pledged their assistance and support for UTMB during this transition period.

Serving as your president for the past 12 years has been an extraordinary privilege. During phases of great opportunity as well as cycles of significant challenge, UTMB has continued to grow and prosper because of the dedication and commitment of this UTMB family. I am incredibly proud of this institution, its people, its remarkable history and the impressive slate of achievements you’ve made possible during my tenure here.

UTMB is one of the most well-positioned academic health institutions in the country in terms of its mission, people, programs and demonstrated strength to survive and thrive. You have been and will continue to be the foundation of this organization’s impact and success. What started as a clever tag line—working together to work wonders—now captures the indelible spirit of this university and all who
make it great. You truly have worked wonders at UTMB, and I am confident you’ll continue to help shape the future of academic health care in all three mission areas: education, patient care and research.

I will always cherish my time working with you to advance this beloved organization. Thank you for challenging and supporting me during these past dozen years and know that you will always have my strong support and encouragement.

Dr. David L. Callender
President
Hi Tony,

It was nice to see you at ASM and to hear your reassuring comments about the new administration.

I wanted to give you a heads up that we had the Discovery Channel here on Thursday and Friday to film a segment about Ebola. They interviewed Tom Ksiazek and Tom Geisbert and apparently got some great footage of folks working in the BSL4. I bring this to your attention as I understand that they will be interviewing you next week for the same segment.

Best wishes,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) (b) (6)
(f) 409-266-6810
(m) (b) (6)
Have fun! It's an interesting part of the world! Safe travels. Let's chat when you're back in town.

Jim

sent from my iPhone

> On Sep 12, 2019, at 9:51 AM, Auchincloss, Hugh (NIH/NIAID) [E] <[Redacted]> wrote:
> Would love to talk but I'm in the Balkans for another week.
> sent from my iPad
> >> On Sep 12, 2019, at 1:10 PM, LeDuc, James W. <[Redacted]> wrote:
> >> Hi Hugh
> >> Are you around for a brief call sometime tomorrow, Friday? I'd like to discuss the new OSTP RFI on
> >> the bioeconomy. Just heard about this at briefing yesterday and I want to explore opportunities for the
> >> biocontainment lab network as critical infrastructure.
> >> >> Thanks. Jim
> >> >> Sent from my iPhone
Hi Hugh,

Any additional thoughts about [REDACTED] as a candidate for next GNL director? I have not followed up with him yet and don’t want to push it if you think it’s not a good idea.

Thanks, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) [REDACTED]
(f) 409-266-6810
(m) [REDACTED]
Hi Hugh,

I hope the New Year is off to a good start for you. I tried to call but missed you so let me summarize briefly here and we can chat next week if needed.

Since the construction of the NBL-RBL laboratories we have held annual meetings of the network members, alternating locations between UTBM and Boston. The next meeting will be held 30 April-2 May here at the GNL and we are now in the process of organizing the sessions. As many of the labs were interviewed by the STPI team regarding operations costs, I’m wondering if it would be appropriate for you or someone from STPI to make a presentation during the network meeting about findings and next steps. Clearly there is a lot of interest in the subject and I know that the network members are eager to learn more about the study findings and how the information might be used going forward. I’m happy to invite Ian Simon from STPI but didn’t want to start that dialogue before checking with you.

BTW, we invited Emily Erbelding to participate in the meeting as well, but I have yet to hear back from her. Mike K indicated that she was receptive to an invitation and this would certainly be a good opportunity for her to efficiently meet an important component of the DMID portfolio. I hope that she can make it.

With all good wishes for the New Year. It’s going to be interesting!

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) (b) (6)
(f) 409-266-6810
(m) (b) (6)
Are you around for a call sometime tomorrow (Friday)? Just a couple of issues I would like to discuss.

Thanks. Jim

sent from my iPhone
Hi Hugh

Are you around for a brief call sometime tomorrow, Friday? I'd like to discuss the new OSTP RFI on the bioeconomy. Just heard about this at briefing yesterday and I want to explore opportunities for the biocontainment lab network as critical infrastructure.

Thanks. Jim

Sent from my iPhone
Hi Hugh,

Thanks very much for the prompt and complete responses. Attached please find a copy of the draft job description. If you could get Tony’s blessing (or suggestions for change), that would be very helpful! Thank you!

I’ll keep you posted on the OSTP RFI.

Thanks, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) (b) (6)
(f) 409-266-6810
(m) (b) (6)

Jim regarding some of the issues pending:

1) You are going to send me the job description for Tony’s blessing. Any time.
2) Regarding the OSTP RFI, we think your response is fine and obviously raises an appropriate issue. I’m also going to continue having conversations around here about a workshop to address the biocontainment issues.
3) You’re right that the RFP for operational support is on the horizon. I’m told that there is no plan to alter the current level of funding.
4) Regarding the STPI data, Jill Harper tells me that when the data was solicited it was with the promise that it would only be used internally or with the consortium members. As a result, we’re reluctant to have you show the STPI slides per se. However, I’m sure you can identify your institution within the data set and it would be fine to say that those numbers are similar to other BSL-4 facilities. Similarly, I think it would be fine to talk about the BSL 3 facilities with a generalization that they cost about 20% as much. In other words I have no problem with your sharing the big picture STPI conclusions without the actual detailed slides (which are probably more detailed than you want anyway).

Let me know if I’ve missed any of the pending issues.
Hugh

Hugh Auchincloss, M.D.
Deputy Director, NIAID
National Institutes of Health
Bldg. 31 (7A/03), 31 Center Drive, MSC 2520
Bethesda, MD 20892
Phone: (b) (b)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.
Job Summary: Director, Galveston National Laboratory

Function:
The University of Texas Medical Branch (UTMB), a national and international leader in high biocontainment infectious disease research, is seeking an outstanding leader as Director of the Galveston National Laboratory (GNL). The state-of-the-art GNL is located on the main UTMB campus in Galveston, Texas. The GNL works closely with the National Institute of Allergy and Infectious Diseases (NIAID) and other federal and commercial partners in conducting investigator-initiated and contract research addressing basic science to translational research at Biosafety Level (BSL)-2, BSL-3, and BSL-4 levels. This position will provide direction, leadership, and vision for the GNL and will understand and support research in infectious disease, emerging infections, and biodefense.

Infectious disease research is a major strength at UTMB and provides the largest component of National Institutes of Health (NIH) funding to the university. Facilities and research programs that contribute to and support this research are extensive, involve multiple departments, centers, and core laboratories, and encompass more than 120 investigators. The mission of the GNL is to assist the NIAID and the nation in developing improved mechanisms for the prevention, diagnosis, and treatment of potentially life-threatening diseases caused by naturally emerging and purposefully disseminated infectious agents.

Scope:
The Director oversees a complex scientific and educational program encompassing a diverse set of research areas. The incumbent is responsible for developing and articulating GNL research strategies, educational mission, goals, and priorities within a landscape that continually evolves due to new, emerging, and reemerging threats, changing regulatory environments, and shifting funding opportunities. The Director analyzes and interprets current and new legislation for its effect on GNL activities and establishes new or modified operational procedures as required.

Essential Job Functions:
- Ensures the safe and secure operations of the GNL;
- Demonstrated scientific leadership ability;
- Active or recently active in research with academic or equivalent experience;
- Strong communication skills and an ability to work effectively with independent scientists in an academic setting;
- Provides strong leadership in working with diverse UTMB research leaders to facilitate state-of-the-art research that stimulates basic science, translational studies, and advanced product development initiatives;
- Develops effective measures to support regulated studies which generate data for possible submission to the Food and Drug Administration (FDA) in support of product development;
- Coordinates initiatives to direct and manage GNL operations, including identification of resources to meet existing and anticipated staffing, equipment, instrumentation, and infrastructure requirements;
- Continually develops, refines, and executes the GNL's strategic plan with a primary focus on fostering collaborative relationships with government agencies, other academic centers, industry partners, and on basic research;
- Sustains research and educational programs that directly align with national priorities and goals for infectious diseases and biodefense research;
- Ensures that research involving laboratory animals is conducted in a manner that is consistent with the highest ethical standards and complies with all regulations governing animal use in biomedical research;
- Provides efficient, comprehensive fiscal management of the GNL;
- Ensures equitable access to and efficient use of GNL biocontainment, laboratory, and office space;
- Facilitates the educational mission of UTMB.

**Required Qualifications:**

**Terminal degree and**
- Successful administration of biomedical research programs and management of a complex, multifaceted research portfolio that addresses high priority pathogens;
- International stature in biodefense and/or emerging infectious disease research;
- Experience in high containment facilities and understanding of the associated regulatory and compliance environment.

**Preferred Qualifications:**
- Ability to maintain strong, supportive relationship with community leaders;
- Ability to successfully balance interests of external sponsors with academic responsibilities of independent faculty and the needs of trainees;
- Leadership experience in directing a biocontainment laboratory and coordinating a range of individuals engaged in multifaceted, complex scientific programs;
- Established and maintained productive collaborative interactions with national and international scientists in related scientific fields;
- Experience successfully competing for national external research funding, preferably both grants and contracts;
- Effective negotiation skills and experience interacting with federal funding agencies; existing relationships with leadership at the NIH, Department of Defense, or Centers for Disease Control and Prevention preferable;
- Serves as an ambassador and diplomat at the national and international levels for infectious disease and high biocontainment research and contributes to health policy and biocontainment policy nationally and internationally;

**Supervision:**

*Received:* Provost, UTMB  
*Given:* Direct reports

**Budget Responsibility:**

*Direct:* Management of extramural awards provided for the operations of the GNL; management of grants and contracts where incumbent serves as principal investigator.

*Indirect:

**Decision-Making Responsibility:**
Responsible for the safe, secure, and efficient operations of the GNL; responsible for the equitable and transparent distribution of resources to ensure optimum laboratory utilization and productivity.

**Equipment:**
Standard office equipment; oversight responsibility for sophisticated biocontainment infrastructure and state-of-the-art instrumentation.

**Working Environment/Location of Position:**
Standard office environment within the GNL on the UTMB main campus. May require travel nationally and internationally.

**Other:**
None
Great, I'll call about 2 pm ET/1 pm CT. I'm free at 3 ET also if something comes up.

Thanks, Jim

-----Original Message-----
From: Auchincloss, Hugh (NIH/NIAID) [E] < [(b)(6)]
Sent: Thursday, September 26, 2019 5:00 PM
To: LeDuc, James W. < [(b)(6)]
Subject: Re: Call?

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Absolutely. I'm free 11, 12, 3PM.

sent from my ipad

> On Sep 26, 2019, at 5:05 PM, LeDuc, James W. < [(b)(6)] wrote:
> Are you around for a call sometime tomorrow (Friday)? Just a couple of issues I would like to discuss.
> Thanks. Jim
> Sent from my iPhone
Hugh,

Perfect, thanks. I will relay the message and I’m sure that our administration will be satisfied. The important message is that UTMB values the partnership with NIAID greatly and we want to be fully transparent in our recruitment of the next GNL director.

Thanks again,

Jim
Hugh, thanks for making time to talk today. As discussed, please see attached copy of the OSTP RFI on the bioeconomy and a draft response that I wrote. If we agree that this or something similar should be sent, I would probably seek the support of all the RBL directors and Boston NBL prior to submission, but I want to make sure that you all are supportive before sharing further. I would really appreciate your thoughts.

Thanks, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) (b) (6)
(f) 409-266-6810
(m) (b) (6)
pursuant to an Order of the Commission or the presiding officer. If you do not have an NRC-issued digital ID certificate as described above, click "Cancel" when the link requests certificates and you will be automatically directed to the NRC's electronic hearing dockets where you will be able to access any publicly available documents in a particular hearing docket. Participants are requested not to include personal privacy information, such as social security numbers, home addresses, or personal phone numbers in their filings, unless an NRC regulation or other law requires submission of such information. For example, in some instances, individuals provide home addresses in order to demonstrate proximity to a facility or site. With respect to copyrighted works, except for limited uses to serve the purpose of the adjudication filings and would constitute a Fair Use application, participants are requested not to include copyrighted materials in their submission.

The Commission will issue a notice or Order granting or denying a hearing request or intervention petition, designating the issues for any hearing that will be held and designating the Presiding Officer. A notice granting a hearing will be published in the Federal Register and served on the parties to the hearing.

If a person (other than Justin Roberts) requests a hearing, that person shall set forth with particularity the manner in which his interest is adversely affected by this Order and shall address the criteria set forth in 10 CFR 2.300(d) and (f).

If a hearing is requested by a person whose interest is adversely affected, the Commission will issue an Order designating the time and place of any hearings. If a hearing is held, the issue to be considered at such hearing shall be whether this Order should be sustained. In the absence of any request for hearing, or written approval of an extension of time in which to request a hearing, the provisions specified in Section IV above shall be final thirty (30) calendar days from the date of issuance of this Order without further order or proceeding. If an extension of time for requesting a hearing has been approved, the provisions specified in Section IV shall be final when the extension expires if a hearing request has not been received.

For the Nuclear Regulatory Commission,

George A. Wilson,
Director, Office of Enforcement.

Dated this 5th day of September, 2019.

[FR Doc. 2019–15536 Filed 9–9–19; 8:45 am]

BILLING CODE 7550·01·P

OFFICE OF SCIENCE AND TECHNOLOGY POLICY

Request for Information on the Bioeconomy

AGENCY: Office of Science and Technology Policy (OSTP).

ACTION: Notice of request for information (RFI) for Bioeconomy.

SUMMARY: The Office of Science and Technology Policy (OSTP) requests input from all interested parties on the U.S. Bioeconomy. The Bioeconomy represents the infrastructure, innovation, products, technology, and data derived from biologically-related processes and science that drive economic growth, promote health, and increase public benefit. Through this Request for Information (RFI), OSTP seeks input from the public, including those with capital investments, performing innovative research, or developing enabling platforms and applications in the field of biological sciences, including healthcare, medicine, pharmaceuticals, biotechnology, manufacturing, energy production, and agriculture. This RFI will inform notables gaps, vulnerabilities, and areas to promote and protect in the U.S. Bioeconomy that may benefit from Federal government attention. The information can include suggestions on those areas of greatest priority within the Bioeconomy, as well as past or future Federal government efforts to build, promote, and sustain the U.S. Bioeconomy. The public input provided in response to this RFI will inform the Executive Office of the President as well as private sector, academia, non-governmental entities, and other stakeholders with interest in and expertise relating to the promotion of a Bioeconomy ecosystem encompassing shared values and core American principles.

DATES: Interested persons are invited to submit comments on or before 11:59 p.m. (ET) on October 22, 2019.

ADDRESSES: Comments submitted in response to this notice may be submitted online to:

MBX.OSTP.WHIBioeconomy@ostp.eop.gov. Email submissions should be machine-readable [pdf, word] and not be copy-protected. Submissions should include “RFI Response: Bioeconomy” in the subject line of the message.

Instructions: Response to this RFI is voluntary. Each individual or institution is requested to submit only one response. Submission must not exceed 10 pages in 12 point or larger font, with a page number provided on each page. Responses should include the name of the person(s) or organization(s) filing the comment. Comments containing references, studies, research, and other empirical data that are not widely published should include copies or electronic links of the referenced materials. Comments containing profanity, vulgarity, threats, or other inappropriate language or content will not be considered.

Comments submitted in response to this notice are subject to FOIA.

Responses to this RFI may also be posted, without change, on a Federal website. Therefore, we request that no business proprietary information, copyrighted information, or personally identifiable information be submitted in response to this RFI.

In accordance with FAR 15.202(3), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Additionally, the U.S. Government will not pay for responses prepared or for the use of any information contained in the response.

FOR FURTHER INFORMATION CONTACT:

Paige Waterman at MBX.OSTP.WHIBioeconomy@ostp.eop.gov

SUPPLEMENTARY INFORMATION:

A prosperous bioeconomy provides a host of opportunities for the current and future growth of all sectors of the U.S. economy. Today, the Bioeconomy ecosystem in the United States is a rapidly changing technological and economic environment. Data rights, analysis, use, storage and security are all critical components of biotechnology, healthcare, medicine, public health, data science, energy, environment, and agriculture. Ongoing research and innovation in these areas provide the foundation for solving the problems of today and the potentially unforeseen issues of tomorrow. To that end, stimulating the research enterprise, developing and sustaining workforce talent, and supporting the infrastructure for the manufacturing of products remain critical components to any Bioeconomy objective.

To inform the Federal government’s decision-making and establish the Nation’s guiding values and principles in the promotion and protection of the U.S. Bioeconomy, OSTP seeks public input on how U.S. Government action regarding the Bioeconomy can support
scientific discovery, the development of technological advances, and increase the impact of a vibrant Bioeconomy on the nation's vitality and our citizens' lives. To that end, respondents are specifically requested to answer one or more of the following questions in their submissions. Consortia responses are also encouraged.

1. What specific actions could the U.S. Government take to reinforce a values-based ecosystem that will guide the transformation and expansion of the U.S. Bioeconomy, in both the short- and long-term? Please consider:
   a. Policy or regulatory opportunities and gaps throughout the continuum of basic science translation, product development and commercialization;
   b. Scientific areas where research funding could be strategically targeted to stimulate discovery;
   c. Novel public-private partnership mechanisms;
   d. International opportunities;
   e. Challenges to taking identified actions or implementing change.

2. In what ways can the U.S. Government partner with the private sector, industry, professional organizations, and academia to ensure the training and continued development of a skilled workforce to support the growth of the Bioeconomy? Please consider:
   a. Potential needs and solutions at the skilled technical, undergraduate, professional master's program or graduate level;
   b. Specific needs within basic science, translational research, product development, and commercialization;
   c. Approaches for the development of non-traditional, multi-disciplinary educational backgrounds that address the convergent nature of emerging technologies and integrate core values including safety and security;
   d. Effective geographic distribution of workforce and talent development across the United States;
   e. The development of a public and private ecosystem that will attract and retain domestic and foreign talent within the United States at all skill levels.

3. In what ways can the U.S. Government partner with the private sector, industry, professional organizations, and academia to establish a more robust and efficient Bioeconomy infrastructure? Please consider:
   a. Current infrastructure—from databases to world-class technology and manufacturing capabilities;
   b. Geographic distribution of manufacturing capabilities compared to future manufacturing needs;
   c. Leveraging existing public-private partnerships and identifying trusted information sharing mechanisms to accelerate innovation and facilitate fruitful, equitable domestic and international collaborations;
   d. Institutional models for achieving translation of basic science discoveries to application and/or entry into the marketplace.

4. Across the spectrum, from basic discovery to practical application, what data policies, information-sharing mechanisms, and safeguards will be necessary for a prosperous U.S. Bioeconomy? Please consider:
   a. Scientific, regulatory, manufacturing standards and/or benchmarks and/or best practices around data that should be developed to best accelerate Bioeconomy growth;
   b. Possible safeguards for technology, data, and emergent products, such as patent/intellectual property protection, data quality and provenance validation, and privacy and security assurances.

Sean Bonyun,
Chief of Staff, Office of Science and Technology Policy.

[FR Doc. 2019-19479 Filed 9-9-19; 8:45 am]

BILLING CODE 3270-F9-P

SECURITIES AND EXCHANGE COMMISSION

[Investment Company Act Release No. 33616; File No. 812-14988]

Diamond Hill Funds and Diamond Hill Capital Management, Inc.

September 4, 2019.

AGENCY: Securities and Exchange Commission (“Commission”).

ACTION: Notice.

Notice of an application for an order pursuant to: (a) Section 6(c) of the Investment Company Act of 1940 (“Act”); granting an exemption from sections 18(f) and 21(b) of the Act; (b) section 21(d)(1)(B) of the Act granting an exemption from section 21(d)(1) of the Act; (c) sections 6(c) and 17(b) of the Act granting an exemption from sections 17(a)(1), 17(a)(2) and 17(a)(3) of the Act; and (d) section 17(d) of the Act and rule 17(d)-1 under the Act to permit certain joint arrangements and transactions. Applicants request an order that would permit certain registered open-end management investment companies to participate in a joint lending and borrowing facility.

APPLICANTS: Diamond Hill Funds, established as a business trust under the laws of Ohio and registered under the Act as an open-end management investment company with multiple series, and Diamond Hill Capital Management, Inc. (the “Adviser”), an Ohio corporation registered as an investment adviser under the Investment Advisers Act of 1940.

FILING DATES: The application was filed on December 19, 2018, and amended on May 17, 2019.

HEARING OR NOTIFICATION OF HEARING: An order granting the requested relief will be issued unless the Commission orders a hearing. Interested persons may request a hearing by writing to the Commission’s Secretary and serving applicants with a copy of the request, personally or by mail. Hearing requests should be received by the Commission by 5:30 p.m. on September 30, 2019 and should be accompanied by proof of service on the applicants, in the form of an affidavit, or, for lawyers, a certificate of service. Pursuant to Rule 0-11 under the Act, hearing requests should state the nature of the writer’s interest, any facts bearing upon the desirability of a hearing on the matter, the reason for the request, and the issues contested. Persons who wish to be notified of a hearing may request notification by writing to the Commission’s Secretary.


FOR FURTHER INFORMATION CONTACT: Kieran G. Brown, Senior Counsel, at 202-551-6773, or David J. Markus, Branch Chief, at (202) 551-6821 (Division of Investment Management, Chief Counsel’s Office).

SUPPLEMENTARY INFORMATION: The following is a summary of the application. The complete application may be obtained via the Commission’s website by searching for the file number, or an applicant using the Company name box, at http://www.sec.gov/search/search.htm or by calling (202) 551-8090.

Summary of the Application

1. Applicants request an order that would permit the applicants to participate in an interfund lending facility where each Fund could lend money directly to and borrow money directly from other Funds to cover anticipated cash shortfalls, such as anticipated redemptions or trade fails. The Funds will not borrow under

1 Applicants request that the order apply to the applicants and to any other registered open-end management investment company or series thereof (such, a “Fund” and collectively, the “Funds”) for which the Adviser or any successor-in-interest thereto or an investment adviser controlling.
Hi Hugh,

I was invited to present during a WHO work group on global biocontainment laboratories in November. Specifically, they asked that I speak about the cost of operations of biocontainment labs and I’m wondering if it would be all right with you (NIH) if I used some of the slides presented by STPI during our annual meeting here in Galveston in 2017. A copy of the slides they presented is attached for your information. I asked STPI (Ian Simon) and he deferred to you as owners of the study results. I don’t think that there is anything sensitive in their findings and since their data includes information (under code) from several RBLs and both NBLs, it would allow a much more relevant summary of costs for this international audience.

Thanks, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) (b)(6)
(f) 409-266-6810
(m) (b)(6)
Functional Analysis of NBL/RBL Costs

Annual NBL-RBL Network Meeting

Dr. Oren Grad
Dr. Judith Hautaia
Dr. Ian Simon
Dr. Brian Zuckerma

May 2, 2017
Agenda

- Introduction
- Functional Approach to Cost Analysis
- BSL-3 Cost Analysis Results
- BSL-4 Cost Analysis Results
IDA Science and Technology Policy Institute

- Federally-funded research and development center (FFRDC) chartered by Congress and operated by the Institute For Defense Analyses
- Conducts rigorous, independent research and analysis in support of the White House Office of Science and Technology Policy as well as the executive branch departments and agencies that conduct scientific research
- Findings inform policy formulation and program management
Key Study Objective

What are the infrastructure costs for operating BSL-3 and BSL-4 laboratories that were constructed with NIAID support?
- What costs are distinctive to BSL-4 laboratories compared to BSL-3 laboratories?
- What factors account for any variations in cost across laboratories?
- What patterns can be discerned and insights derived that may be of value to NIAID and to the laboratories?
Important Definitions

• "Infrastructure costs" refers to the fixed costs of personnel, equipment, services, etc. needed for a laboratory to conduct BSL-3 or BSL-4 research
  – Includes utility costs and costs for animal caretaking and housing but not the cost of animal procedures
  – Excludes the variable costs of personnel, equipment, services, etc. associated with conducting individual research projects
  – Excludes the cost of specialized research services such as aerobiology, imaging, etc.

• "Costs" refers to the actual total costs independent of how those costs are funded
  – Costs that are explicitly in the expense budget for the laboratory
  – Costs that are incurred by the host institution without a direct transfer of funds to the laboratory budget
  – Costs that are offset in whole or in part by per diems, contracts or other sources of revenue
Extramural Laboratories Included in the Assessment

**BSL-3 Regional Biocontainment Laboratories**
- Rutgers University
- University of Pittsburgh
- George Mason University
- Duke University Medical Center
- Tulane National Primate Research Center
- Colorado State University

**BSL-4 National Biocontainment Laboratories**
- University of Texas Medical Branch, Galveston National Laboratory (GNL)
- Boston University Medical Center, National Emerging Infectious Diseases Laboratory (NEIDL)
Functional Approach to Cost Analysis
Analytical Challenge

- Understanding factors that account for variations in costs requires an analytic framework that enables apples-to-apples comparisons across laboratories
- Existing budget structures aren’t well suited to the task
  - Budgets generally developed according to organizational units rather than functions
  - Each laboratory hosted by a parent institution with its own conventions for budgeting and cost accounting
  - Existing laboratory budgets may not include costs for certain functions because they are covered by institutional budgets or other in-kind contributions
Functional Approach to Cost Analysis

- Identify a set of distinct, generic functions that define the operating capabilities of the organizations included in the analysis
- Map each organization’s costs to these defined functional categories
- Use this common function cost mapping to identify
  - Similarities and differences in cost structure across organizations
  - Factors driving total cost differences across organizations
  - Primary cost drivers for different organizations
  - Areas of cost efficiency or cost inefficiency for various organizations as a guide to future improvements
Functional Cost Categories

- General Administration
- Operational Services
  - Facility Operations and Maintenance
  - Utilities
  - Information Technology
  - Physical Security
  - Environmental Health/Regulatory/Training
- Animal/Insectary Services

Other Research Support Services are idiosyncratically present in different labs but are varied in character and scope and, in the BSL-3 labs, account for a small portion of overall costs
Cost Allocation within Functional Categories

- Labor
  - FTE/% time
  - Salary/wage cost
  - Fringe benefit cost

- Other Direct Costs
  - Consultants
  - Equipment
  - Maintenance/Service Contracts
  - Consumable Supplies
  - Travel
  - Other

For each functional category, we examined these direct costs; indirect costs are excluded.
Data Collection

- Collected preliminary budget data from each laboratory
- Performed preliminary mapping to functional cost categories
- Conducted laboratory site visits
  - Clarified budgetary data submitted
  - Identified infrastructure costs that do not appear in the standard laboratory budget
  - Identified income streams used to cover infrastructure costs
  - Identified laboratory specific factors that affect costs
  - Gathered information on capacity and current project portfolio
- Updated mapping based on information gathered during site visits
- Addressed remaining data gaps through follow-up exchanges with each laboratory

[If not already said: thank the participating labs for all of their special efforts to help us obtain data that they do not normally use in their day-to-day management]
Data Analysis Challenges

- Extracting function-specific costs from budget data submitted in more aggregated form
- Identifying costs for BSL-2 activities conducted in support of BSL-3 or BSL-4 activities
- Distinguishing BSL-4 or BSL-3 costs when activities are performed in a building with other unrelated laboratory activities
- Determining an appropriate annual equipment replacement budget
  - Small equipment replacement not generally included in budgets
  - Most labs do not have a capital equipment replacement plan based on estimated cost and useful life
Cross-Laboratory Analysis Challenges

- Heterogeneity in operating structure
  - Geographic location
  - Character of host institution
  - Integration of laboratory with host institution
  - Physical capacity (e.g. square footage, number of distinct lab modules, number of investigators and animals that can be accommodated)
  - Degree of access to budgetary information beyond the specific laboratory budget

- Heterogeneity in project activity
  - Nature of projects (e.g. NHPs versus small animals)
  - Range of project types (e.g., grant versus contract studies, response activities)
  - Number of distinct projects and/or investigators
  - Mix of internal versus external investigators
  - Nature of specialized research support services
  - Dollar value of research enabled by access to containment laboratory
BSL-3 Cost Analysis Results

As we head into our findings, just a heads-up about how we will be presenting. For purposes of this presentation, to preserve confidentiality of the detailed information shared with us, names have been redacted from the data that we will be showing. Also, we use different sets of substitute labels in different parts of the presentation, so elements from one slide cannot be linked with elements from others to reconstruct a complete picture that might identify a specific lab.

We know that cost intensity - for example, measures such as cost per square foot - is a topic of considerable interest. Those data turn out to be very complex and we're still analyzing them, so we won't be talking about that here today.
To give a sense of the order of magnitude that we are talking about, here is the range of estimated total direct operating costs for the RBLs that we examined. Note that this varies by a factor of two across the group.

Please note that these numbers will not be a direct match to what the labs would normally identify as their annual budget. These are our best estimates of total operating costs for each lab, incorporating both explicitly budgeted items and other costs that are incurred but which are not part of the annual budget associated with the RBL as an organizational unit.

What do these differences mean? Are they a simple function of scale or scope? The short answer is no, but stay tuned as the picture unfolds.

[Make point that they’re different sizes]
Here are a couple of slides to introduce one of our most striking findings: the RBL's that we examined vary radically in their functional cost mix.

Not to worry – we'll be showing a different version with a legend in a moment – the point of this slide is just to drive home qualitatively the extent of variation.
Same point, except that this one shows variation in labor effort, which abstracts away from differences in wages and salaries.
Distribution of RBL Infrastructure Cost by Functional Area

Here's another version of the operating cost distribution with a legend that allows you to see what the pieces are.
And again, the labor distribution, with the legend this time.

In the next slides, we'll unpack some of these functional categories, with an emphasis on those that contribute most to the observed variation across the labs.
This category encompasses not just the director and his executive assistant, but also various associate directors, financial managers, etc.

One needs to tread very carefully in interpreting the variation in this area. The RBLs vary in how senior the leadership team is; to what extent leadership wears multiple hats and thus attributes only fractional time to the RBL; the host organization's salary structure, and the extent to which administrative assistants and other support staff are allowed.
We see substantial variation in facility operations and maintenance as well. Keep in mind that you wouldn't expect FTE to necessarily track exactly with total costs, both because wage levels vary geographically and ODCs also vary independently.

It appears that some of this variation reflects the extent to which the RBL is embedded in its host organization - how is the RBL facility physically situated, how much incremental labor effort and other direct cost is incurred when some resources can be shared with other parts of the host organization.

We're not going to show a chart for IT. Those numbers turned out to be pretty small for the RBLs. What we could call routine IT infrastructure - things like desktop computers and office productivity software, the university network - are funded out of general overhead and have been excluded from our analysis. Computers and software that come in the form of integrated solutions for functions such as building controls and security systems have been included in those functional areas. Computers and software that are dedicated to specialized scientific tasks are generally not considered part of the core lab infrastructure.
There is large variation as well in costs for physical security. Yes, those are zeroes for labs one and two; I'll have more to say about that in a moment.

Many factors influence this category. The labs are located in different locations, some in the middle of dense urban zones and others in more peripheral settings. In these varied locations they face different risks and threat profiles. Some are the sole tenants of freestanding buildings; some of these buildings are situated within a larger campus while others are more isolated. On the other hand, some of the RBLs are components in larger buildings.

Different judgments are plainly being made about possible threat scenarios and the mix of staffing, physical barriers and screening and surveillance resources that are warranted to sufficiently mitigate any risks posed by those scenarios at the different laboratories.

I want to be clear that the two labs that are showing zeroes do not have zero security. Each is embedded within a larger facility, and the zeroes reflect judgments that the incremental cost to secure the RBL facility, over and above whatever provisions are already in effect for the campus and building as a whole, is such a small portion of the overall institutional investment in physical security as to be de minimis and virtually impossible to estimate.
There is huge variation in absolute expenditure on animal services.

It appears that some of this variation as well reflects the extent to which an RBL is free-standing as opposed to embedded in an organization that conducts substantial non-RBL BSL-3 animal research and has a high volume of animal research more generally. Embedded facilities often have the ability to share animal services staff, which can allow fractional attribution to the RBL as well as some flexibility in shifting FTE in and out with the ebb and flow of project work. The conduct of NHP studies would also be expected to increase costs. However, that is clearly not the whole story, and we are continuing to try to understand the basis for these differences.
What's included in this utilities cost measure is basically electricity, steam and water.

The observed variation in cost is affected by variation in both utilization and unit charges. Key factors responsible for variation in utilization include differences in the size and configuration of the buildings, the efficiency of their building systems, and the weather and climate in the respective regions. Unit charges vary with the rate structures of regional utilities and the mix between self-generated and externally-provided utilities.

As an illustration, electricity rates paid by the RBLs vary from 5.4 cents per kilowatt-hour to 10.9 cents per kilowatt-hour.
Equipment Costs

- Equipment categories considered as RBL infrastructure
  - Containment (e.g., autoclaves, safety cabinets, disinfection units)
  - Animal caretaking (e.g., caging, cage washers)
  - Building systems that are likely more extensive for a containment laboratory (e.g., HVAC, exhaust and emergency power systems)
  - Physical security (e.g. cameras, access control systems)
- Current status of data on annualized costs
  - Containment equipment costs are $100-250K annualized
  - Animal caretaking equipment costs are $50-150K annualized
  - Building systems cost data provided to date not sufficiently complete to permit comparisons
  - Physical security equipment costs currently incomplete but appear to be minimal

Equipment costs include both capital and non-capital equipment. Annualized equipment costs are based on estimated purchase price and useful life either provided by the labs or if not provided assumed to be 8 years for non-capital equipment and 20 years for capital equipment.
BSL-4 Cost Analysis Results
BSL-4 Cost Analysis Observations

- NBLs are substantially larger in size and have higher total infrastructure costs
- With the exception of general administration, resources ($ and FTE) devoted to each functional area are materially higher than for the corresponding areas in any of the RBLs

The NBLs operate at substantially larger scale than the RBLs, and their costs reflect that – with the exception of general administration, the absolute level of resources devoted to each functional area is substantially higher than for the corresponding areas in any of the RBLs.

Let's look at some details. To facilitate comparison, we've added the NBLs to the RBL charts that you've already seen.
Total Direct Annual Infrastructure Costs

- RBL 1: $0
- RBL 2: $2,000,000
- RBL 3: $4,000,000
- RBL 4: $6,000,000
- RBL 5: $8,000,000
- RBL 6: $10,000,000
- NBL 1: $12,000,000
- NBL 2: $14,000,000

IDA SCIENCE AND TECHNOLOGY POLICY INSTITUTE
Distribution of Infrastructure Cost by Functional Area

- General Admin
- Fac/Maint
- Utilities
- IT
- Phys Security
- Env Hlth/Reg/Train
- Animal/insect
Facility Operations and Maintenance Cost and Labor

Total cost

FTE

IDA SCIENCE AND TECHNOLOGY POLICY INSTITUTE
Physical Security Cost and Labor

Total cost

FTE

$3,000,000
$2,500,000
$2,000,000
$1,500,000
$1,000,000
$500,000
$0

RBL RBL RBL RBL RBL NBL NBL
i ii iii iv v vi i ii

30.00
25.00
20.00
15.00
10.00
5.00
0.00

RBL RBL RBL RBL RBL NBL NBL
i ii iii iv v vi i ii
Animal Services Cost and Labor

Total cost

FTE

IDA

SCIENCE AND TECHNOLOGY POLICY INSTITUTE
Utilities Cost

$1,400,000
$1,200,000
$1,000,000
$800,000
$600,000
$400,000
$200,000
$0

RBL α, RBL β, RBL γ, RBL δ, RBL ε, RBL ζ, NBL α, NBL β
Thanks Hugh,

I trust you got home safely from NC in spite of the bad weather.

Would it be alright for me to extend an invitation to Ian Simon (STPI project lead) and ask for a presentation on their overall findings? I certainly understand about steering clear from a discussion of next steps, but their findings would be of interest to all the labs I'm sure. It would be good to get the dates on his/your calendar and we can then adapt the presentation to whatever seems appropriate at the time of the meeting.

Thanks, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) (b) (f) 409-266-6810
(m) (b) (6)

Dear Jim, sorry to miss your call. I was on my way to North Carolina for a late Christmas gathering over a cold weekend.

I have not yet seen the STPI report which seems to have been forever in the making. However, I think your idea of having its findings presented and discussed at your annual meeting is an excellent one. I'm not sure that I'm the right person to do the presentation but I would be interested in attending some of your meeting in order to hear the discussion. I doubt I'll be able to tell you specifically about next steps – recall that the STPI report was commissioned in order to provide the data for the debate about next steps – but I would be interested in hearing the perspective of you and the other network members.

Regards,

Hugh
Hi Hugh,

I hope the New Year is off to a good start for you. I tried to call but missed you so let me summarize briefly here and we can chat next week if needed.

Since the construction of the NBL-RBL laboratories we have held annual meetings of the network members, alternating locations between UTBM and Boston. The next meeting will be held 30 April-2 May here at the GNL and we are now in the process of organizing the sessions. As many of the labs were interviewed by the STPI team regarding operations costs, I’m wondering if it would be appropriate for you or someone from STPI to make a presentation during the network meeting about findings and next steps. Clearly there is a lot of interest in the subject and I know that the network members are eager to learn more about the study findings and how the information might be used going forward. I’m happy to invite Ian Simon from STPI but didn’t want to start that dialogue before checking with you.

BTW, we invited Emily Erbelding to participate in the meeting as well, but I have yet to hear back from her. Mike K indicated that she was receptive to an invitation and this would certainly be a good opportunity for her to efficiently meet an important component of the DMID portfolio. I hope that she can make it.

With all good wishes for the New Year. It’s going to be interesting!

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) (b) (6)
(f) 409-266-6810
(m) (b) (6)
From: LeDuc, James W.  
Sent: 12/9/2019 10:45:45 PM  
To: Auchincloss, Hugh [NIH/NIAID] [E]  
Subject: RE: Response Requested: Hill Briefing Opportunity

How about 4:00 pm ET/3:00 pm CT. I’m available from about 2:00 pm CT on so let me know if another time is better for you. My direct line is (b)(6)

Thanks, Jim

James W. Le Duc, Ph.D.  
Director  
Galveston National Laboratory  
University of Texas Medical Branch  
Galveston, TX 77555-0610  
(t) (b)(6)  
(f) 409-266-6810  
(m) (b)(6)

From: Auchincloss, Hugh [NIH/NIAID] [E]  
Sent: Monday, December 09, 2019 4:30 PM  
To: LeDuc, James W.  
Subject: Re: Response Requested: Hill Briefing Opportunity

WARNING: This email originated from outside of UTMB’s email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Let’s talk. I’m free after 3pm my time tomorrow. Give me a time and I’ll call you.

Sent from my iPad

On Dec 9, 2019, at 4:59 PM, LeDuc, James W. (b)(6) wrote:

Hi Hugh,

I just called but missed you, so let me share with you the email string below dealing with use of NHP in research. Specifically, ASM is considering a Hill briefing to discuss the importance of NHP in research as described in the note below. At the very bottom of the string is Congressional language dealing specifically with NIH intramural use of NHP. ASM has scheduled a brief conference call for Thursday for the committee to discuss the pros and cons of participating in a Hill briefing and I wanted to touch base with you first to see if you have any concerns and to ensure that my discussion points are consistent with NIH’s position. I of course will not mention NIH’s intramural work, but the GNL clearly does a lot of NHP work under NIH sponsorship and this work is absolutely critical to the product development successes we have enjoyed. I am happy to try to make the case, but I want to be sure that our messaging is consistent with NIH. I’m tied up all morning both tomorrow and Wednesday, but free in the afternoons if you’d like to chat.
Dear PSAC,

We hope you had a great Thanksgiving. This is the first of a few emails you will be receiving this week. We will also be sending travel information for the 2/26 PSAC meeting and Mary Lee will be sending you an email regarding an RFI from OSTP. Please be on the lookout for those.

We’ve been in approached by the Society for Neuroscience asking ASM to co-sponsor a Hill briefing on the role of nonhuman primates in biomedical research. This has taken on some added urgency because of report language (below) accompanying the Labor/HHS appropriations bill. While the primary focus of the language is on pain studies, as you can see it goes beyond pain to look at all research involving NHPs.

To their credit, SFN recognizes the value in highlighting infectious disease studies as part of the briefing, rather than focusing exclusively on neuroscience. The question is whether ASM should cosponsor the briefing with them and provide a speaker.

We have money in the budget for such events and plan to do several briefings next year. The downside of doing this briefing is that it’s potentially controversial, and risks exposing ASM on an issue area where we have not traditionally engaged. However, if efforts like these – driven by Congress, not the scientific community – are successful, then we may be forced into playing a more active role. The question comes down to how proactive we want to be right now.

This does get to one of the issues we have on the agenda for February, which is determining the appropriate decision-making process for issues/opportunities as they arise. In this case, I think the process is pretty straightforward. However, if the committee would like to have that discussion before moving forward with this briefing, that’s fine.

Let us know what you think.
Intramural Non-Human Primate Research.—The Committee has expressed concern since 2015 about the NIH’s intramural use of nonhuman primates in biomedical research. The Committee is especially concerned by a nearly 50 percent increase in NIH’s use of nonhuman primates in research involving pain and distress since fiscal year 2014. The Committee is encouraged, however, by the NIH’s January 2019 letter to Congress expressing support for the retirement of primates no longer needed for research. The Committee urges the NIH to accelerate efforts to reduce and replace the use of nonhuman primates with alternative research models and directs the NIH to provide a report to the Committee no later than 180 days after enactment that includes: (1) an overview of current NIH nonhuman primate use, including a table with summaries of all active projects, USDA pain categories, and their cost; (2) a detailed explanation of current NIH efforts to reduce and replace the use of primates in research with alternative methods; (3) an assessment of existing research technology not already in use by NIH to reduce and replace primate research and the feasibility of employing it to meet current and future research needs; (4) an assessment of areas where alternatives to primate research may not yet be available; (5) a detailed strategy and timeline for the reduction and replacement of NIH primate research with alternative research methods; and (6) standard operating procedures for the retirement of nonhuman primates no longer needed in research to suitable sanctuaries.

Allen D. Segal | Director, Public Policy and Advocacy
American Society for Microbiology
1752 N Street, NW | Washington, DC 20036

Have you joined or renewed as an ASM Member for 2019?

Your membership in the Society supports the science of microbiology, and provides you access to and discounts for the resources that will help you to advance your career, grow your professional network, and further your education.

Join ASM:  http://www.asm.org/join
Renew with ASM:  http://www.asm.org/renew

This transmission is intended by the sender and proper recipient to be confidential and is intended only for the proper recipient. If you are not the intended recipient, you are notified that the dissemination, distribution or copying of this message is strictly prohibited. If you receive this message in error or are not the proper recipient, please notify the sender at the e-mail address above and delete this e-mail from your computer.
Hugh, Nancy,

We worked with members of the RBL/NBL network to develop the attached response to the OSTP RFI on the bioeconomy. The attached response was submitted on Friday to OSTP, before tomorrow’s deadline. We will let you know if we hear anything in response.

Thanks, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) [removed] (b)(6)
(f) 409-266-6810
(m) [removed] (b)(6)
RFI Response: Bioeconomy

A unique and critical component of the national bioeconomy is that which deals with biodefense and the risk to national health and security arising from especially dangerous emerging infectious diseases due to pathogens such as Ebola virus and antibiotic resistant microbes. An essential element in our critical national infrastructure required to safely and securely address these dangerous threats is the existing national network of biocontainment laboratories, which were constructed over a decade ago. Herein we express our support for the value of these labs to medical research, as well as our concerns about the sustainability of the network of academic biocontainment laboratories developed by NIH.

Especially Dangerous Pathogens. In the United States, dangerous pathogens are grouped by the severity of the diseases they cause, their ease of transmission and the availability of vaccines to prevent infection and therapeutics to treat those who become infected. Pathogens are classified as biological safety level risk groups (BSL) 2, 3 or 4, with BSL4 reserved for the most dangerous pathogens where we have no effective treatment or vaccines. BSL4 laboratories are specially constructed to protect the welfare of the workforce involved in research and development, and to ensure the safety of the surrounding community and environment against possible release due to a breach in containment. BSL3 laboratories have only slightly less rigorous infrastructure requirements and handle pathogens such as plague and anthrax, among many others. The safety and security of the entire dangerous pathogen research and development enterprise is overseen by the U.S. Centers for Disease Control and Prevention/Division of Select Agent and Toxins under the Federal Select Agent Program (FSAP), mandated by federal law. Those pathogens that are of agricultural importance are managed by the Department of Agriculture Animal and Plant Health Inspection Service/Agriculture Select Agent Services, and microbes that may cause disease in both humans and animals are jointly managed by both CDC and USDA.

Critical National Infrastructure. The critical national infrastructure established to support research on especially dangerous pathogens currently includes 8 BSL4 biocontainment laboratories in the United States, plus others now under construction. Historically, the few biocontainment laboratories in operation were located only in the federal sector; however, following the 9/11 attacks and the anthrax mailings, NIH, working in partnership with states, invested approximately $1 billion for the construction of 12 regional BSL3 biocontainment laboratories and two national maximum containment facilities (BSL4) on academic campuses across the nation (see Table 1 below). The goal was to harness the strengths of the academic sector for basic and applied research by providing selected academic centers with the critical infrastructure required to safely and securely investigate the most dangerous pathogens. In addition to the network of academic biocontainment laboratories, today there are five BSL4 laboratories managed by the U.S. government, one by a private foundation, and one BSL4 agriculture laboratory is under construction (see Table 2 below). A large number of BSL3 laboratories have also been independently constructed by both the commercial and academic sectors, usually without significant federal governmental investment.
**Personnel.** Personnel handling select agents in biocontainment laboratories undergo background checks by the Department of Justice, must be enrolled in an Occupational Health Program, and require extensive training in biosafety and biosecurity prior to gaining access to the laboratory. They may work in various aspects of research and development, from basic discovery research to advanced product preclinical testing and evaluation. Basic and applied research often depends on having access to highly specialized equipment, instrumentation and continuously evolving technology. Similarly, the need for comprehensive documentation, record keeping and complete external audit of records that is required by the Food and Drug Administration makes the conduct of well-documented studies to demonstrate the efficacy of candidate vaccines and therapeutics in laboratory animals both challenging and expensive from a study design and personnel standpoint. Successful operations of biocontainment laboratories require skilled building engineers and safety officers adept at managing the unique requirements of these complex facilities. Veterinarians and animal care staff also require extensive training prior to working in a high containment laboratory. Collectively, the workforce that exists today within the biocontainment laboratory network is uniquely skilled and represents a major investment by universities that are home to this critical national infrastructure.

**Demonstrated Success.** Over the past decade, the network of academic biocontainment laboratories has repeatedly proven its value to the nation and the world through scientific advances in our understanding of the most dangerous pathogens and development of products needed for their prevention and control. For example, the academic network of BSL4 laboratories contributed to the development of the vaccines, therapeutics and diagnostics now in use to diagnose, treat and prevent Ebola virus infections among healthcare workers and exposed persons in the Democratic Republic of Congo. Similarly, network scientists rapidly worked to understand the devastating disease seen among pregnant women following infection with Zika virus and helped lead the effort to advance a vaccine for this terrible disease. Many other success stories exist involving globally important diseases and biodefense threats, such as tuberculosis, anthrax, plague, influenza, West Nile, Eastern Equine Encephalitis and infections due to antimicrobial resistant microbes.

**Sustaining the Investments for Preparedness and Response.** We write on behalf of the network of academic regional and national biocontainment laboratories (the NIAID Biodefense Laboratory Network) to express our grave concern about the need for Federal support to ensure the sustainability of this critical national infrastructure. The network is threatened by high operating costs that cannot be met through traditional facilities and administrative costs typically associated with extramural research grants and contracts, the increasing regulatory burden associated with the Federal Select Agent Program, and the demands for a highly trained workforce. The business model originally envisioned to sustain the network through facilities and administrative costs associated with extramurally funded research and development projects has simply failed to meet the extraordinary operations costs of these unique facilities. Further, several biocontainment laboratories are currently being built or contemplated around the world, many in countries that lack the rigorous oversight, the specially trained workforce or the engineering controls. The NIAID network of BSL3 and BSL4 laboratories on U.S. academic campuses has the infrastructure and experience that positions our facilities and their personnel as
resources for global collaborators who are less experienced with the critical operation and best practices of these labs, reducing the potential for accidental release of dangerous pathogens and misuse by nefarious actors interested in developing biological weapons. We expand briefly on each of these issues below:

- **Operations Costs.** The safety and security of modern biocontainment laboratories rests on a complex foundation of facility infrastructure and physical security. Physical security is provided by police and guards, restrictive card key and biometric access, and tech-based surveillance systems, leading to controlled access to ensure that only approved, appropriately trained individuals are allowed entry to the facilities. Mechanical systems include sophisticated air handling to create directional airflow within the facilities and ensure that exhaust from all BSL4 and many BSL3 containment labs is filtered and free of pathogens. Solid and liquid wastes are treated prior to leaving the facility, with solid wastes disposed of through specialized incineration. Because air flow is directional, with higher air changes than ordinary laboratory environments, single pass, filtered, and requires redundant systems, energy costs greatly exceed those of a traditional research laboratory. In addition, the network labs have been in operations for over a decade and essential equipment is reaching end of life and requires replacement as technology advances.

The costs of maintaining these laboratories greatly exceed the financial support provided by research sponsors for facilities and administrative cost recovery, resulting in a significant financial burden on the universities where these facilities are located. While the two national biocontainment laboratories housing BSL4 capabilities receive limited federal support to help offset their BSL4 operational costs, the BSL3 laboratories at both the national and regional facilities receive none. An independent assessment funded by NIAID in 2017 found that annual operational costs for biocontainment laboratories were approximately 5-8% of the original multi-million dollar construction costs of the facilities. The current approach to financing this important national resource network is insufficient to meet operational needs.

- **Regulatory Burden.** Oversight of biocontainment laboratories handling select agents is mandated in federal law and provide by the Centers for Disease Control and Prevention and by the Department of Agriculture through the Federal Select Agent Program. Certain pathogens are further designated as Tier One agents and require additional special documentation, enhanced access control to laboratory spaces where they are handled, and additional personnel monitoring. Federal oversight includes documentation that all individuals having access to select agents have undergone a background check by the Department of Justice, have been enrolled in an entity-specific Occupational Health Program and are appropriately trained for their duties. Files that document training must be maintained for each individual involved in work with select agents or others who must enter select agent spaces (e.g. maintenance personnel) and all records must be maintained for 3 years. Facilities are approved to handle and store specific select agents and although these microbes can be easily grown at any time, FSAP nonetheless requires an
accurate inventory of individual vials containing each registered pathogen, thereby adding a significant accounting burden for investigators. Inter-entity transfer of select agents requires prior approval from FSAP and the shipping permit is only valid for 30 days. All shipments must be documented by both the sending and receiving entities, and records maintained for a minimum of 3 years. BSL4 laboratories are inspected annually during which pathogen inventories, personnel training files, pathogen transfer records, building maintenance records, and other items are reviewed. BSL3 facilities are inspected at least every three years and often with an unannounced inspection in between. All audits are to the same level of detail.

The compliance burden placed on universities to meet the FSAP requirements is substantial and growing. Each select agent inspection requires preparation by all staff handling select agents prior to the visit, then time spent with inspectors to review records and document inventories during the inspections. The accounting burden of documenting the use of each vial of a pathogen used in an experiment or the increase in the number of vials when new stocks are grown is substantial. Documentation requirements for the removal of specimens from biocontainment are likewise burdensome. Communications with the select agent program before, during and after each site visit is time consuming, and failure to meet any requirements may force the removal of an individual from the laboratory, closure of a specific program, or removal of select agent registration approval for the entire entity.

As the select agent program continues to evolve, more of the administrative burden is placed on the regulated entities. There is no program in place to allow universities to recoup the expenses of maintaining compliance with the select agent program; consequently, universities are forced to sustain the costs of this mandatory program using already limited institutional funds.

- **Skilled Labor Force.** Personnel working in biocontainment are uniquely trained and represent a wide diversity of technical skills. Entities managing biocontainment laboratories are required to maintain extensive records that document not only formal educational degrees, but also specialized training in biosafety and biosecurity appropriate for the work their employees undertake. Requirements for independent entry to biocontainment are not standardized across the nation, but rather are established by each individual entity. In addition to formal university training and advanced degrees providing the essential skills needed to conduct their individual research or development project, each individual is usually required to have some level of general and specific training to work at the level of biocontainment appropriate for their duties. This often includes a period of formal mentorship at the side of a more experienced individual and represents a significant training path. Maintenance personnel and those involved in ensuring the safe and secure operations of the facility may have different specific training requirements, but nonetheless must complete demanding and time consuming biocontainment-specific training and orientation. Support personnel, particularly those
from equipment suppliers involved in providing equipment and instrumentation installation, calibration, service and repairs often are not willing to enter into biocontainment spaces, leaving programs with few options to sustain these essential resources. For personnel safety, there are few options for biosafety training by commercial vendors or partner universities, thus most universities of the national network maintain their own independent training programs. This represents yet another unfunded mandate assumed by the universities to sustain this critical national infrastructure.

- **International Engagement.** The United States has always been a global leader in research and development involving especially dangerous pathogens. We were among the first to construct dedicated biocontainment facilities and we pioneered the development of biosafety and biosecurity equipment and programs required to ensure the safety of our workforce and the surrounding community. Our preeminence in the field is, however, dwindling. Today there are more than 50 BSL4 laboratories in operation or under construction around the world. In the past we were able to offer new facilities assistance to establish best practices for safe and secure operations of their facilities. Unfortunately, funding for such activities is no longer available, leaving a massive gap in global security as more and more biocontainment facilities obtain dangerous pathogens and begin their own independent investigations, often times without the benefit of adequate training or the experience and good counsel that U.S. experts traditionally provided. The risk of accidental releases or purposeful misuse of dangerous pathogens is greater without meaningful engagement between U.S. labs and our colleagues working in biocontainment around the world.

**The U.S. Government should consider the following specific actions:** These will help sustain the bioeconomy’s critical national infrastructure that deals with biodefense and the risk to national health and security arising from especially dangerous emerging infections.

- **Strategically Targeted Research Funding:** We must create a sustained funding mechanism for maintenance and operations costs of the critical national infrastructure that exists in the network of academic BSL3 and BSL4 biocontainment laboratories.

- **Policy and Regulatory Opportunities:** We should explore ways to reduce the regulatory burden on entities handling select agents. (1) Entities should be held accountable for the dangerous pathogens under their control; however, they should not be wasting time and effort accounting for individual vials of replicating agents. (2) Experienced individuals should be able to easily transfer between biocontainment facilities to make efficient use of unique resources and to enhance opportunities for collaborations. (3) Scientific progress requires efficient specimen transport and sharing between entities. The regulatory burden placed on entities and the commercial transportation sector should be reviewed, recognizing the critical role they play in facilitating research on especially dangerous pathogens.
• **Training and Continued Development of a Skilled Workforce:** We need to invest in ways to sustain and enhance the uniquely trained workforce critical to the successful operations of biocontainment laboratories and the implementation of cutting edge research. Development of coordinated training programs for both domestic and foreign talent working in biocontainment should be explored. Academia has a proven track record of success in providing such training for national and international partners; however, funding to support this critical endeavor has eroded.

• **International Opportunities:** We should establish a formal program to support international engagement with foreign biocontainment laboratories to ensure their safety and security by (1) providing training in best practices in biosafety and biosecurity, and (2) conducting collaborative research activities to enhance transparency and reduce the risk of intentional misuse of dangerous pathogens.

**Table 1. The network of academic biocontainment laboratories.**

National Biocontainment Laboratories (BSL3 and BSL4 capabilities)

- Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX
- National Emerging Infectious Diseases Laboratory, Boston University, Boston, MA

Regional Biocontainment Laboratories (BSL3 capabilities only)

- Colorado State University, Fort Collins, CO
- Duke University, Raleigh-Durham, NC
- George Mason University, Fairfax, VA
- Rutgers University, New Brunswick, NJ
- Tufts University, Boston, MA
- Tulane University, New Orleans, LA
- University of Alabama, Birmingham, AL
- University of Chicago, Chicago, IL
- University of Louisville, Louisville, KY
- University of Missouri, Columbia, MO
- University of Pittsburg, Pittsburg, PA
- University of Tennessee, Memphis, TN

**Table 2. Federal and foundation BSL4 biocontainment laboratories (affiliation)**

- Centers for Disease Control and Prevention, Atlanta, GA (includes new laboratory planned for construction; DHHS/CDC)
• United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD (includes new laboratory under construction; DOD)
• Integrated Research Facility, Fort Detrick, Frederick, MD (DHHS/NIH)
• National Biodefense Analysis and Countermeasures Center, Fort Detrick, Frederick, MD (DHS)
• Rocky Mountain Laboratory, Hamilton, MT (DHHS/NIH)
• Texas Biomedical Research Institute, San Antonio, TX (Private Foundation)
• National Bio- and Agro-defense Facility, Manhattan, KS (Agriculture Facility under construction; DHS/USDA; to be turned over solely to USDA)
Hi Hugh,

I just called but missed you, so let me share with you the email string below dealing with use of NHP in research. Specifically, ASM is considering a Hill briefing to discuss the importance of NHP in research as described in the note below. At the very bottom of the string is Congressional language dealing specifically with NIH intramural use of NHP. ASM has scheduled a brief conference call for Thursday for the committee to discuss the pros and cons of participating in a Hill briefing and I wanted to touch base with you first to see if you have any concerns and to ensure that my discussion points are consistent with NIH’s position. I of course will not mention NIH’s intramural work, but the GNL clearly does a lot of NHP work under NIH sponsorship and this work is absolutely critical to the product development successes we have enjoyed. I am happy to try to make the case, but I want to be sure that our messaging is consistent with NIH. I’m tied up all morning both tomorrow and Wednesday, but free in the afternoons if you’d like to chat.

Thanks, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) [b][l](f) 409-266-6810
(m) [b][l]

From: Segal, Allen <[b][l]>
Sent: Tuesday, December 03, 2019 10:34 AM
Cc: Watts, Mary Lee <[b][l]>
Subject: Response Requested: Hill Briefing Opportunity

**WARNING:** This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear PSAC,

We hope you had a great Thanksgiving. This is the first of a few emails you will be receiving this week. We will also be sending travel information for the 2/26 PSAC meeting and Mary Lee will be sending you an email regarding an RFI from OSTP. Please be on the lookout for those.

We’ve been in approached by the Society for Neuroscience asking ASM to co-sponsor a Hill briefing on the role of nonhuman primates in biomedical research. This has taken on some added urgency because of report language (below)
accompanying the Labor/HHS appropriations bill. While the primary focus of the language is on pain studies, as you can see it goes beyond pain to look at all research involving NHPs.

To their credit, SfN recognizes the value in highlighting infectious disease studies as part of the briefing, rather than focusing exclusively on neuroscience. The question is whether ASM should cosponsor the briefing with them and provide a speaker.

We have money in the budget for such events and plan to do several briefings next year. The downside of doing this briefing is that it's potentially controversial, and risks exposing ASM on an issue area where we have not traditionally engaged. However, if efforts like these – driven by Congress, not the scientific community -- are successful, then we may be forced into playing a more active role. The question comes down to how proactive we want to be right now.

This does get to one of the issues we have on the agenda for February, which is determining the appropriate decision-making process for issues/opportunities as they arise. In this case, I think the process is pretty straightforward. However, if the committee would like to have that discussion before moving forward with this briefing, that’s fine.

Let us know what you think.

Thanks!
Allen

_Intramural Non-Human Primate Research._—The Committee has expressed concern since 2015 about the NIH's intramural use of nonhuman primates in biomedical research. The Committee is especially concerned by a nearly 50 percent increase in NIH's use of nonhuman primates in research involving pain and distress since fiscal year 2014. The Committee is encouraged, however, by the NIH's January 2019 letter to Congress expressing support for the retirement of primates no longer needed for research. The Committee urges the NIH to accelerate efforts to reduce and replace the use of nonhuman primates with alternative research models and directs the NIH to provide a report to the Committee no later than 180 days after enactment that includes: (1) an overview of current NIH nonhuman primate use, including a table with summaries of all active projects, USDA pain categories, and their cost; (2) a detailed explanation of current NIH efforts to reduce and replace the use of primates in research with alternative methods; (3) an assessment of existing research technology not already in use by NIH to reduce and replace primate research and the feasibility of employing it to meet current and future research needs; (4) an assessment of areas where alternatives to primate research may not yet be available; (5) a detailed strategy and timeline for the reduction and replacement of NIH primate research with alternative research methods; and (6) standard operating procedures for the retirement of nonhuman primates no longer needed in research to suitable sanctuaries.

Allen D. Segal | Director, Public Policy and Advocacy
American Society for Microbiology
1752 N Street, NW | Washington, DC 20036

(b)(6) direct | (b)(6) main
Have you joined or renewed as an ASM Member for 2019?

Your membership in the Society supports the science of microbiology, and provides you access to and discounts for the resources that will help you to advance your career, grow your professional network, and further your education.

Join ASM: http://www.asm.org/join
Renew with ASM: http://www.asm.org/renew

This transmission is intended by the sender and proper recipient to be confidential and is intended only for the proper recipient. If you are not the intended recipient, you are notified that the dissemination, distribution or copying of this message is strictly prohibited. If you receive this message in error or are not the proper recipient, please notify the sender at the e-mail address above and delete this e-mail from your computer.
Hi Hugh,

I hope the new year is off to a good start for you. I wanted to let you know that I will be in DC next week for the NSABB meeting, arriving on Wednesday, 22 Jan evening and leaving Friday evening. Unfortunately, the meeting is at the Hyatt Regency in Bethesda and not on NIH campus. We start at 9:30 am on Thursday morning. Let me know if you’d like to get together for coffee first thing Thursday morning—I should be able to get to main campus and back in time for our start. I don’t have anything special to discuss, but I didn’t want to miss an opportunity to catch up a bit.

Thanks, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) (b)(6)
(f) 409-266-6810
(m) (b)(6)

---

Dear NSABB Members,

We are looking forward to seeing many of you in Bethesda in a couple weeks for the meeting of the National Science Advisory Board for Biosecurity. We are also extremely pleased to welcome Dr. Gerald Parker as the new NSABB Chair! An updated roster for the committee will be shared soon.

In preparation for the meeting we wanted to provide you with the meeting agenda (attached). Please note this document is still draft and there may be a few additional changes. We will provide any updated information closer to the meeting date. Also attached is the agenda for the member orientation that will immediately precede the meeting on Jan 23. Please note that the orientation will begin at 9:30 am. This will be a closed administrative session for members only.
If you haven’t already, we request that you provide us with a short (half page) biography for inclusion in the meeting materials as soon as possible (and by 1/14/2020, if at all possible).

If you have any questions, please let us know. We very much look forward to seeing (or hearing) many of you soon!

Best,

Jessica

Jessica Tucker, Ph.D.
Director, Division of Biosafety, Biosecurity, and Emerging Biotechnology Policy
Office of Science Policy
National Institutes of Health

OSP Blog: Under the Poliscope
Twitter: @CWolinetzNIH
AGENDA - JANUARY 23

12:30 PM – 12:45 PM  Welcome and Introduction of NSABB Members
                      Gerald W. Parker, Jr., DVM, PhD

SESSION I: POLICY UPDATES AND CHARGE TO THE NSABB
Provide a historical overview of issues related to GOF research, update on relevant USG policies, and deliver the charge to the NSABB.

                    Potential Pandemic Pathogens (PPP) – the Gain-of-Function
                    Deliberative Process
                    Carrie D. Wolinetz, PhD

1:15 PM – 1:45 PM  HHS Framework for Guiding Funding Decisions about Proposed
                   Research Involving Enhanced PPP and Public Transparency
                   regarding Funded Projects
                   David C. Hassell, PhD

1:45 PM – 2:00 PM  Charge to the NSABB
                   Lawrence A. Tabak, DDS, PhD

2:00 PM – 2:15 PM  BREAK

SESSION II: TRANSPARENCY AND SECURITY IN RESEARCH – POLICIES & PERSPECTIVES
Discuss relevant policies and ethical issues that should be considered regarding the appropriate balance between security and public transparency and hear perspectives from the scientific, public health, and biosecurity communities.

2:15 PM – 3:00 PM  Balancing Transparency and Security – Ethical and Policy
                   Considerations
                   David Resnik, JD, PhD and Gigi Gronvall, PhD
3:00 PM – 4:30 PM  Perspectives on Transparency and Security regarding Enhanced PPP Research

Moderator:  Carrie D. Wolinetz, PhD

Panelists:  Thomas Inglesby, MD
           Vincent Racaniello, PhD
           Jessica Belser, PhD
           Marc Lipsitch, PhD
           Luciana Borio, MD

4:30 PM – 5:00 PM  NSABB Discussion
Gerald W. Parker, Jr., DVM, PhD

5:00 PM  Adjournment
Gerald W. Parker, Jr., DVM, PhD

AGENDA – JANUARY 24

9:00 AM – 9:05 AM  Opening Remarks
Gerald W. Parker, Jr., DVM, PhD

SESSION III: TRANSPARENCY, SECURITY & CONFIDENTIALITY – PROCEDURES & PRACTICES

Discuss the balance of openness and confidentiality in peer review process; explore approaches to balancing transparency and security for research involving high-consequence pathogens; and learn about the experiences of information sharing and engagement between research institutions and local communities.

9:05 AM – 9:35 AM  Scientific Peer Review
Jodi Black, PhD and Theresa Good, PhD, MSc

9:35 AM – 10:00 AM  Balancing Security and Transparency for Research involving Biological Select Agents and Toxins
Samuel Edwin, PhD

10:00 AM – 11:30 AM  Community Engagement on Pathogen Research

Moderator:  James LeDuc, PhD

Panelists:  Ann Masel, CPA
           Caree Vander Linden, BS
           Rebecca Moritz MS, CBSP, SM(NRCM)
           Shannon Benjamin, MS, MBA, RBP, CBSP, SM(NRCM)
11:30AM – 12:30 PM LUNCH BREAK

SESSION IV: RESPONSIBLE ENGAGEMENT/COMMUNICATION FOR ENHANCED PPP RESEARCH – CONSIDERATIONS AND STRATEGIES

Discuss principles, considerations, and practical issues associated with public communication of and engagement regarding risks and benefits in the face of uncertainty; responsible communication of dual use research of concern; and practical communication and engagement experiences of public health officials.

12:30 PM – 2:00 PM  
Responsible Public Communication/Engagement – Risk, Benefit, and Uncertainty

Moderator:  Joseph Kanabrocki, PhD, CBSP

Panelists:  Baruch Fischhoff, PhD  
Jo Husbands, PhD  
Sam Lipson, MS, REHS  
Carole Baskin, DVM, MSc, CPIA

2:00 PM – 2:15 PM  
PUBLIC COMMENT

2:15 PM – 2:30 PM  
NSABB Discussion and Next Steps  
Gerald W. Parker, Jr., DVM, PhD and Carrie D. Wolinetz, PhD

2:30 PM  
Closing Remarks and Adjournment  
Gerald W. Parker, Jr., DVM, PhD
Administrative Orientation Agenda

Hyatt Regency Bethesda
January 23, 2020

9:30 AM  Welcoming of NSABB Members and Introductions

Jessica Tucker, PhD
Director, Division of Biosafety, Biosecurity, and Emerging Biotechnology Policy,
NIH Office of Science Policy

9:45 AM  Roles and Responsibilities of Federal Advisory Committees

Claire Harris
Director, Office of Federal Advisory Committee Policy, NIH

10:05 AM  Ethics Overview

Kevette Burwell
Senior Ethics Specialist, NIH Ethics Office, NIH

10:35 AM  OSP and NSABB Overview

Jessica Tucker, PhD
Director, Division of Biosafety, Biosecurity, and Emerging Biotechnology Policy,
NIH Office of Science Policy

11:05 AM  Questions

11:30 AM  Adjourn
From: Guerra, Anallia (b) (6)
Sent: 1/15/2020 9:32:08 PM
To: Auchincloss, Hugh [NIH/NIAID] [E] [/c=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23_SPDLT)/cn=Recipients/cn=9304c753bb9e422c977dddab54da924b-auchincloss]

Subject: Accepted: James LeDuc
Location: Daily Grill Bethesda

Start: 1/23/2020 1:00:00 PM
End: 1/23/2020 2:00:00 PM
Show Time As: Busy

Recurrence: (none)
Hugh

Thanks for making arrangements to meet with Tony and for the personalized transport. I enjoyed catching up. I have been in communications with [b][6] about sharing isolates and I think we are making progress. We may hear more later today but as you can imagine this is a touchy issue. I also had a telecom yesterday afternoon with Bob Kadlec and his team and encouraged him to speak directly with George Gao RE the public health response coordination.

Given all that's going on we canceled our trip to Hawaii so I'll be in the office.

Thanks again. Jim

Sent from my iPhone
Sounds perfect—thanks very much! Let me know if there are specific issues he’s like to discuss.

Enjoy the long weekend,

Jim

When Tony heard that you would be in town he asked if we could arrange to have you drop by to see him for a few minutes. How about I pick you up at the Hyatt at 7:45 and bring you to the NIH to see him. He has another meeting at 8:30. At that point you and I could go back to the Hyatt for a bite to eat and some coffee.

Hugh

Hugh Auchincloss, M.D.
Deputy Director, NIAID
National Institutes of Health
Bldg. 31 (7A/03), 31 Center Drive, MSC 2520
Bethesda, MD 20892
Phone:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.
From: LeDuc, James W. [b](b) [6]
Sent: 1/22/2020 1:48:48 PM
To: Auchincloss, Hugh [NIH/NIAID] [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=9304c753bb9e422c977dddab54da924b-auchincloss]
Subject: U.S.-China relationship, good news with the bad amid public health response to new virus outbreak [Opinion] - HoustonChronicle.com


Sent from my iPhone
Perfect! I’ll see you about 8:00 am at the Daily Grill on Thursday, 23 Jan.

Jim

Absolutely, let’s get together. I could make a reservation for the 23rd at the Daily Grill which is attached to the Hyatt and has breakfast, coffee etc. I can be there at 8 or any time after that works for you.

Hugh

Hi Hugh,

I hope the new year is off to a good start for you. I wanted to let you know that I will be in DC next week for the NSABB meeting, arriving on Wednesday, 22 Jan evening and leaving Friday evening. Unfortunately, the meeting is at the Hyatt Regency in Bethesda and not on NIH campus. We start at 9:30 am on Thursday morning. Let me know if you’d like to get together for coffee first thing Thursday morning—I should be able to get to main campus and back in time for our start. I don’t have anything special to discuss, but I didn’t want to miss an opportunity to catch up a bit.

Thanks, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) (b) (6)
(f) 409-266-6810
(m) (b) (6)
Dear NSABB Members,

We are looking forward to seeing many of you in Bethesda in a couple weeks for the meeting of the National Science Advisory Board for Biosecurity. We are also extremely pleased to welcome Dr. Gerald Parker as the new NSABB Chair! An updated roster for the committee will be shared soon.

In preparation for the meeting we wanted to provide you with the meeting agenda (attached). Please note this document is still draft and there may be a few additional changes. We will provide any updated information closer to the meeting date. Also attached is the agenda for the member orientation that will immediately precede the meeting on Jan 23. Please note that the orientation will begin at 9:30 am. This will be a closed administrative session for members only.

If you haven’t already, we request that you provide us with a short (half page) biography for inclusion in the meeting materials as soon as possible (and by 1/14/2020, if at all possible).

If you have any questions, please let us know. We very much look forward to seeing (or hearing) many of you soon!

Best,

Jessica

Jessica Tucker, Ph.D.
Director, Division of Biosafety, Biosecurity, and Emerging Biotechnology Policy
Office of Science Policy
National Institutes of Health

OSP Blog: Under the Poliscope
Twitter: @CWolinetzNIH
Hi Hugh,

I'm looking forward to seeing you and hopefully Tony on Thursday. I should be arriving late evening on Wednesday and will be ready early Thursday morning. I suspect that things are hectic at NIAID now with the new coronavirus (as they are here) and I will understand if you need to cancel. It also occurs to me that I will need to go through NIH security so let me know by email or call if it is more convenient for me to just take the metro and walk over to your offices. I'll look for you around 7:30-7:45 at the Hyatt unless I hear otherwise.

Thanks, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-6610
(t) (b)(6)
(f) 409-266-6810
(m) (b)(6)
Hugh, Carole

It was great to see both of you yesterday at the universal influenza vaccine meeting. Thank you again for inviting me to attend. Great talks and a really important problem. I’m glad to see NIAID making this a priority focus.

One observation: I was struck by the absence of anyone from the agriculture sector. Clearly avian influenza is an important piece of the larger problem and the agriculture folks would certainly be interested in a universal vaccine if the cost made its use feasible. Seeking their input is certainly consistent with the One Health initiative that is becoming well accepted.

Hugh, in follow up to our brief discussions on how many BSL4 labs are needed, I wanted to remind you that Homeland Security is constructing the new NBAF BSL4 agriculture lab in Kansas. This is the massive $1.2B investment being build adjacent to Kansas State University and it will have BSL4 capabilities, to include for large domestic animals. It should come on line sometime around 2022 I think. How this capacity is used in the future remains to be seen, especially given that there are very, very few BSL4 pathogens of agricultural health significance. DHS has also announced in the President’s budget that they will be closing the NBACC BSL4 lab at Fort Detrick. Talk of reverse engineering the shutdown has been publicized and while I personally doubt that they will actually follow through, it does send a disconcerting message. Finally, the new USAMRIID 1 M sq. ft. lab is set to open in the relatively near future—maybe next year. This facility has additional BSL4 space. To the best of my knowledge, no decision has been made about the future use of the existing USAMRIID BSL4 facility. Collectively, there may be adequate BSL4 capacity in place or on the near horizon. The question is how to most efficiently utilize this capacity across government agencies to meet existing and future demands for basic and translational/product development research. Let me know if I can help.

With best regards,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) (b) (6)
(f) 409-266-6810
(m) (b) (6)
From: LeDuc, James W. (b) (6)
Sent: 2/5/2020 5:25:07 PM
To: Auchincloss, Hugh [NIH/NIAID] (E) [/c=ExchangeLabs/ou=Exchange Administrative Group (FYDI)BOHF23SPDLT/cn=Recipients/cn=9304c753bb9e422c977ddab54da924b-auchincloss]
Subject: FW: I contacted Heinz Feldmann about a technical issue yesterday

From: Ksiazek, Thomas G. (b) (6)
Sent: Wednesday, February 05, 2020 10:55 AM
To: Rollin, P (b) (6) < (b) (6) Nichol, S(b) (6) (b) (6) (b) (6)
LeDuc, James W. (b) (6)
Cc: Bente, Dennis A. (b) (6)
Subject: I contacted Heinz Feldmann about a technical issue yesterday

He was in Mali, but he replied and added that Frank Plummer died yesterday while on vacation in Kenya.

Tom Ksiazek
Diagnostics capacity may become a major limitation if the new virus gets going in the US. We have already begun work with the Texas State health lab to provide surge diagnostic testing if needed (as we did in 2009 H1N1). Should we consider approaching the RBL network to explore if they might help in diagnostics?

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) (b)(6)
(f) 409-266-6810
(m) (b)(6)
Nancy, Emily,

As we approach the renewal for the UC7 and given the current nCoV crisis as a real-world example, I’m wondering if there is a need for NIH to include a statement in the next UC7 agreement that would allow, with prior approval from NIAID, the use of UC7 funds to initiate limited emergency response activities. Such a clause would be fully consistent with the mission of the NBLs and it would give us greater flexibility in responding to time sensitive events. I am not suggesting additional funding, only in flexibility to use existing resources. I suggested this during a brief meeting with Tony and Hugh prior to the NSABB meeting last week and they seemed to think it was a good idea, but we certainly did not talk in detail.

I would like to explore this further with you now in hopes that we can insert some language along these lines in the next 5 year award. Such an arrangement could also provide an option for rapid supplement to allow specific tasks that might require bioccontainment to be undertaken quickly. The request is consistent with our mission: “...the NBLs must be prepared and available to provide facilities and support to first-line responders in the event of a public health emergency.” Perhaps this flexibility already exists under “specialized research support services” which is also stated in the opening Purpose section.

Thanks, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) (b)(6)
(f) 409-266-6810
(m) (b)(6)
From: LeDuc, James W. [b] (6)
Sent: 1/24/2020 1:01:19 PM
To: Kadlec, Robert (OS/ASPR/IO) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYD/BOHF23SPDLT)/cn=Recipients/cn=7f23b72e23e047e98fb6f136e865d60a-Robert.Kad]; Auchincloss, Hugh (NIH/NIAID) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYD/BOHF23SPDLT)/cn=Recipients/cn=9304c753bb9e422c977ddab54da924b-auchincloss]
CC: Pei yong. Shi [/o=ExchangeLabs/ou=Exchange Administrative Group (FYD/BOHF23SPDLT)/cn=Recipients/cn=3cf21b1e8f4e425180f0da03f3261b6-peshi.UTMB.]
Subject: Fwd: No Snakes?

See text at bottom for more on sequence analysis.

Thanks. Jim

Sent from my iPhone

Begin forwarded message:

From: "Ksiazek, Thomas G." [b] (6)
Date: January 24, 2020 at 2:33:14 AM EST
Subject: Fwd: No Snakes?

Tom Ksiazek
Sent from a portable device

Begin forwarded message:

From: Dean Erdman [b] (6)
Date: January 23, 2020 at 22:29:42 CST
To: "Ksiazek, Thomas G." [b] (6)
Subject: No Snakes?

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

nCoV's relationship to bat coronaviruses & recombination signals (no snakes)
With Xiaowei Jiang at XJTLU we’ve carried out a preliminary evolutionary analysis to characterise the evolutionary origins of the Wuhan virus, nCoV. Focus of our analysis is on the Wuhan-Hu-1 virus (accession no. MN908947, released on GenBank by Shanghai Public Health Clinical Center and School of Public Health, Fudan University, Shanghai, China) as all nCoV cluster together so will share the same evolutionary ancestry. It’s clear from phylogenetic analysis the new human virus is most closely related to bat coronaviruses in the Betacoronaviruses genera. While this is apparent from both the previously reported BLAST and full-genome phylogenetic analysis the closest related bat viruses (CoVZC45 and CoVZXC21) are in fact recombinants with shared breakpoints either side of ORF1b:
The phylogenetic clustering of the Wuhan-Hu-1 virus is consistently as a sister group to the SARS-related bat coronaviruses. Interestingly, a third bat coronavirus (Longquan_140) is a recombinant involving the Wuhan virus lineage in part of ORF1a.
This analysis has detected three bat coronavirus recombinants (two with shared breakpoints) involving the nCoV lineage indicating greater diversity in the Chinese Sarbecovirus group than previously appreciated. The clustering of the related Sarbecovirus viruses from Kenya and Europe suggest the Wuhan virus is still part of the Sabecovirus sub-genre, and these recombination events probably occurred in bats. Although, given the propensity of coronaviruses to switch hosts, involvement of another species cannot be discounted. There is also a very good chance that a non-bat intermediate species is responsible for the beginning of the current outbreak in Wuhan. Given the tight clustering of the nCoV viruses in phylogenetic trees it seems most likely one event has occurred.
Several of these bat coronaviruses have been previously detected to be recombinant under-scoring the importance of doing appropriate analysis when analysing these viruses using phylogenetic methods. Recombination, in this case between divergent coronaviruses circulating in bats, violates our assumption of a single evolutionary tree and so needs to be considered carefully when inferring coronavirus evolution from complete genome alignments. We’re looking into the patterns of breakpoints to see if there’s any clues to the significance (or not) of these recombination events.

We’d like to thank the researchers and health professionals for making the nCoV data available. Credit also needs to be given to the surveillance projects for generating the data that is now available for comparison and to the software developers for making the tools we’ve used freely available: FigTree, available at: http://tree.bio.ed.ac.uk/software/figtree/; 27 GARD, available at http://www.hyphy.org/15; MAFFT, available at https://mafft.cbrc.jp/alignment/software/; 7 PhyML, available at http://www.atgc-montpellier.fr/phyml/; 9 and RDP4, available at http://www.atgc-montpellier.fr/phyml/ 17.

- created

1d

- last reply

9h

- 13

replies
Just to be clear Spike is at positions 21717 to 25693 in our diversity plot and recombination analysis so to the right of the recombination breakpoint in the bat viruses CoVZC45 and CoVZXC21. In a Spike phylogeny nCoV clusters with these bat viruses. There is no evidence of snakes being involved as incorrectly reported here https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25682189!
Hi David
Thanks for sharing this. Interesting dive into the hidden world of these viruses in their reservoir (presumably). I guess there will be insufficient sampling of bat viruses do dabble at when this may have occurred?

Would also like to hear your opinion on the "snake" paper. I see it criticised but am not familiar enough with the specific analyses to make a real assessment.

Marion
Any word on engaging the RBL/NBL network?

Thanks, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) (b)(6)
(f) 409-266-6810
(m) (b)(6)
Thanks Hugh. We are developing a white paper that I will forward later for your review. It describes how a nationwide surveillance system might be structured. I spoke to Bob Kadlec yesterday on a conference call and his office is pushing the concept by trying to engage the major diagnostic testing companies and also the RBL/NBL network, NETEC, and other clinical medical centers with the goal of 100K tests/day nationwide. We are working out the technical details and hopefully can create a network that does not require human use clearance or CLIA certified labs. Next steps will include reaching out to lab directors to explore their interests in joining the network. **Do you mind if I reach out to the RBL/NBL lab directors to see if they are interested?** Those that are, we will then determine capabilities and define the population they might serve.

Thanks, Jim

---

Jim, I finally got a chance to catch up a bit with Tony. but so far we’re standing by.

Happy to discuss further, especially if you know more than I do about where this is going.

Hugh

Hugh Auchincloss, M.D.
Deputy Director, NIAID
National Institutes of Health
Bldg. 31 (7A/03), 31 Center Drive, MSC 2520
Bethesda, MD 20892
Phone: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.
Colleagues,

You are all aware of the growing COVID-19 epidemic raging in China and threatening the rest of the world. The DHHS Office of the Assistant Secretary of Preparedness and Response is exploring the possibility of rapidly establishing diagnostic screening for COVID-19 focused on influenza-like illness patients seen across the country with the goal of testing 100,000 clinical specimens per day nation-wide. To accomplish this, they are seeking collaborations with the Regional Biocontainment Labs to assist in conducting the tests along with labs associated with the NETEC network and other academic centers and the larger commercial testing facilities. Tests would likely be done for surveillance purposes only and would not involve patient identification. Results would not be added to patients medical records and the testing should not require human use approval or CLIA certified laboratory conditions. (Nonetheless, please let us know if your laboratory is CLIA certified or if you are interested in obtaining CLIA certification.) We propose to us a standard PCR-based assay across all testing centers—this is still under discussion. Our goal will be to establish an overarching EUA that is flexible enough to take into account that various testing platforms and equipment are in use among the laboratories, but will use standardized reagents, control panels and SOPs. Assays would be locally validated and appropriate controls included in each run. Results will be reported daily to a central hub and positive findings would be immediately reported to the source healthcare facility and state and local health officials. We are exploring if duplicate sample aliquots could be made to allow positive samples to be rapidly transported to a reference facility for confirmatory testing.

Funding will be provided to cover anticipated costs of consumable supplies and personnel time and other associated expenses. It is unclear if equipment purchases will be allowed.

With this brief (and evolving) background, please let me know if you are interested in participating in this emergency response. Please indicate your ability conduct diagnostic PCR testing as proposed, the patient population from which you would likely draw samples, and an approximation of the maximum number of specimens you could test per day once your system is validated and reagents/consumables are secured.

This is an excellent opportunity for the RBL network to demonstrate it value to the nation in addressing a critical emerging infectious disease.

Thanks, Jim

James W. Le Duc, Ph.D.
James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) ... (b)(6)
(f) 409-266-6810
(m) ... (b)(6)

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.